CONTENTS 目錄
2 Corporate Information ʮ̡༟ࣘ
4 Management Discussion and Analysis ၍ଣᄴীሞʿʱؓ
19 Corporate Governance Highlights
Άุ၍طࠅ
21 Other Information
Չ˼༟ࣘ
33 Condensed Consolidated Statement of Profit or Loss ᔊၝΥฦूڌ
35 Condensed Consolidated Statement of Financial Position ᔊၝΥৌਕًرڌ
37 Condensed Consolidated Statement of Changes in Equity ᔊၝΥᛆूᜊਗڌ
38 Condensed Consolidated Statement of Cash Flows ᔊၝΥତږݴඎڌ
40 Notes to the Condensed
Consolidated Interim Financial
Statements ᔊၝΥʕಂৌਕజڌڝൗ
34 Condensed Consolidated Statement of Comprehensive Income ᔊၝΥΌࠦϗɝڌ
67 Glossary ൚ค
Corporate Information | |
公司資料 | |
BOARD OF DIRECTORS | 董事會 |
Executive Directors | 執行董事 |
Dr. Sun Yiu Kwong (Chairman and Chief Executive Officer) | ᘴϪᔼ͛€˴ࢩࡒБ݁ᐼ |
Ms. Kwok Cheuk Kwan, Jacquen (Managing Director) | ெՙёɾɻ€ԫᐼଣ |
Mr. Tsang On Yip, Patrick | ಀτุ͛ |
Dr. Sun Man Kin, Michael | ˖ᔼ͛ |
Mr. Lee Kar Chung, Felix | ҽᑋ͛ |
Dr. Lee Pak Cheung, Patrick | ҽݡୂᔼ͛ |
Independent Non-executive Directors | 獨立非執行董事 |
Mr. Lee Luen Wai, John BBS JP | ҽᑌਃ͛€ზഓঠd˄̻ɻ |
Dr. Li Kwok Tung, Donald SBS JP | ҽಊᔼ͛€ვഓঠd˄̻ɻ |
Mr. Yeung Wing Sun, Mike | เ⮹͛ |
AUDIT COMMITTEE | 審核委員會 |
Mr. Lee Luen Wai, John BBS JP (Chairman) | ҽᑌਃ͛€ზഓঠd˄̻ɻ€ ˴ࢩ |
Dr. Li Kwok Tung, Donald SBS JP | ҽಊᔼ͛€ვഓঠd˄̻ɻ |
Mr. Yeung Wing Sun, Mike | เ⮹͛ |
REMUNERATION COMMITTEE | 薪酬委員會 |
Dr. Li Kwok Tung, Donald SBS JP (Chairman) | ҽಊᔼ͛€ვഓঠd˄̻ɻ€ ˴ࢩ |
Mr. Yeung Wing Sun, Mike | เ⮹͛ |
Mr. Tsang On Yip, Patrick | ಀτุ͛ |
NOMINATION COMMITTEE | 提名委員會 |
Dr. Sun Yiu Kwong (Chairman) | ᘴϪᔼ͛€˴ࢩ |
Mr. Lee Luen Wai, John BBS JP | ҽᑌਃ͛€ზഓঠd˄̻ɻ |
Dr. Li Kwok Tung, Donald SBS JP | ҽಊᔼ͛€ვഓঠd˄̻ɻ |
AUTHORISED REPRESENTATIVES | 授權代表 |
Mr. Lee Kar Chung, Felix | ҽᑋ͛ |
Ms. Ma Hoi Wan | ৵௱ථɾɻ |
COMPANY SECRETARY | 公司秘書 |
Ms. Ma Hoi Wan | ৵௱ථɾɻ |
HEADQUARTERS AND PRINCIPAL PLACE | 總部及主要營業地點 |
OF BUSINESS | |
Room 1404-1408, 14th Floor | ࠰ಥ |
Wing On House | ʕᐑᅃႾ༸ʕ71 |
71 Des Voeux Road Central | ͑τණྠɽข |
Hong Kong | 14ᅽ1404-1408܃ |
Corporate Information 公司資料
REGISTERED OFFICE | 註冊辦事處 |
Cricket Square | Cricket Square |
Hutchins Drive | Hutchins Drive |
PO Box 2681 | PO Box 2681 |
Grand Cayman KY1-1111 | Grand Cayman KY1-1111 |
Cayman Islands | Cayman Islands |
PRINCIPAL SHARE REGISTRAR AND TRANSFER | 開曼群島主要股份過戶登記處 |
OFFICE IN THE CAYMAN ISLANDS | |
Conyers Trust Company (Cayman) Limited | Conyers Trust Company (Cayman) Limited |
Cricket Square | Cricket Square |
Hutchins Drive | Hutchins Drive |
PO Box 2681 | PO Box 2681 |
Grand Cayman KY1-1111 | Grand Cayman KY1-1111 |
Cayman Islands | Cayman Islands |
HONG KONG BRANCH SHARE REGISTRAR | 香港股份過戶登記分處 |
Tricor Investor Services Limited | ՙԳᗇՎ೮াϞࠢʮ̡ |
Level 54 | ࠰ಥ |
Hopewell Centre | ެΧɽ༸؇183 |
183 Queen's Road East | Υձʕː |
Hong Kong | 54ᅽ |
AUDITOR | 核數師 |
KPMG | ଭ৵۾ึࠇࢪԫਕה |
Public Interested Entity Auditor registered in | ৌਕිజ҅ૢԷ'ɨٙ |
accordance with the Financial Reporting Council Ordinance | ൗ̅ʮлूྼࣨᅰࢪ |
8th Floor, Prince's Building | ࠰ಥʕᐑ |
10 Charter Road | ቈ͂༸ɤ |
Central, Hong Kong | ˄ɿɽขɞᅽ |
LEGAL ADVISER | 法律顧問 |
Allen & Overy | τଣყܛࢪԫਕה |
9th Floor, Three Exchange Square | ࠰ಥʕᐑ |
Central, Hong Kong | ʹᄿఙɧࢭɘᅽ |
PRINCIPAL BANKER | 主要往來銀行 |
Hang Seng Bank Limited | 㛬͛ვБϞࠢʮ̡ |
20th Floor | ࠰ಥ |
83 Des Voeux Road Central | ʕᐑᅃႾ༸ʕ83 |
Hong Kong | 20ᅽ |
STOCK CODE | 股份代號 |
722 | 722 |
COMPANY WEBSITE | 公司網站 |
www.ump.com.hk | www.ump.com.hk |
BUSINESS OVERVIEW AND OUTLOOK
Healthcare is not only a cornerstone to the overall well-being of citizens but it is also the foundation of economic and social development. In the last six months, COVID-19 continued to pose unprecedented risks and opportunities for our Group. As the third and fourth waves of COVID-19 hit the shores of Hong Kong, widespread fear of the contagion as well as sustained economic volatility ensued. Against this backdrop, however, our Group continued to record steady revenue performance in the six months ended 31 December 2020, which testified to our reputation as one of the premier medical service providers in Hong Kong. Further, the perceptible shock of COVID-19 and the resulting social distancing protocols validated our continued investment in technology. We believe COVID-19 has expedited public reception toward medical technology and we are poised to use it as an enabler to enhance our service quality and reach.
業務回顧及展望
ᔼᐕڭʔఊ݊ɛ͏၅߀ٙᇂͩdՉһ݊ ʿٟึ೯࢝ٙਿͩfཀ̘ʬࡈ˜dอۨڿ ًषݭᘱᚃމ͉ණྠ੭Ըۃה͊ԈٙΚၾ ዚfᎇഹ࠰ಥᖑ೯ୋɧʿୋ̬تอۨڿًष ݭޥઋd࿁ޥઋٙࢵฑίٟึᇶַdՉ ਗᐗ͵౨ʘʔ̘f್ϾdίνϤѢྤʕd͉ ණྠ࿚Ї 2020ϋ12˜31 ˚˟ʬࡈ˜ᘱᚃ ᖢٙϗɝุᐶdᗇ͉ණྠᆽ݊࠰ಥ ᎴӸٙᔼᐕਕԶᏐ٫ʘɓfϤ̮dอۨڿ ًषݭה੭ԸٙቤᐗʿΪϤྼ݄ٟٙਜཞᕎ ણ݄dΙᗇҢࡁܵᚃҳ༟߅ҦϞଣfҢࡁ ڦdอۨڿًषݭʊ৷౷ᖯɽ࿁ᔼᐕҦ ஔٙટաܓdϾҢࡁ͵௪˸ϤʺҢࡁ ٙਕሯ९ʿᓒɽ̹ఙf
In Hong Kong, despite the impact of the contagion, we were able to capitalize on our extensive business network to provide uninterrupted offline clinical services to outpatients as well as policyholders of corporates and insurance companies at the primary care entry level. Our commitment to communal healthcare extended to provide year-round, all-encompassing medical services in areas such as general and specialist services, regular health check-ups, medical imaging and laboratory services, dental services, physiotherapy clinics and cosmetic dermatology centre. We firmly believe that our core strength in Hong Kong lies in our dynamic, full-service ecosystem that can fulfill our clients' shifting demand.
࠰ಥdኋ၍աՑޥઋᅂᚤdઓҢࡁʥঐл ͜ҢࡁٙᄿɽุਕၣഖdΣژൢषɛ˸ʿΆ ุձڭᎈʮ̡ٙڭఊܵϞɛԶೌගᓙٙ ᇞɨਿᄴᔼᐕژൢਕfҢࡁ࿁Ό͏ᔼᐕٙ וፕʊᓒ࢝ЇΌϋೌ;ٙΌ˙ࠦᔼᐕਕd Էν౷ஷ߅ձਖ਼߅ਕe֛ಂੰᏨݟeᔼ ኪᅂ྅ʿʷ᜕ਕe˫߅ਕeيଣطᐕൢ הʿߕ࢙ͤᇮ߅ʕːfҢࡁଉڦdҢࡁ࠰ ಥٙࣨːᎴැίঐတԑ܄˒ʔᓙᜊʷც ӋeਗɢတޮϾႊΌ˙Зਕٙ͛࿒ਸ਼f
Our competitive differentiation shone through in the time of COVID-19. When social distancing in Hong Kong became commonplace, our clients and their employees relied more than ever on our continuous, innovative corporate healthcare solutions and tailor-made third-party administration services such as 24/7 customer care hotline to address their rising needs. Our agile business models also gave us the flexibility to seize online business opportunities while contributing to the containment of the COVID-19 impact as a socially responsible healthcare group. As concerns over the rising COVID-19 rose to an alarming level, we expanded our online products offering to include same-day-delivery of COVID-19 screening test kits. We believe our swift response and expansion in time of crisis are testament to our professionalism and our belief in the growth prospects within the region.
ίอۨڿًषݭޥઋಂගdҢࡁჯΝٙ ᘩنᎴැᜑᚣೌ፲fٟʹ൷ᕎણ݄ʊϓމ ࠰ಥٟึ੬࿒ʘࣛdҢࡁٙ܄˒ʿՉࡰʈ ༰˸ֻОࣛගɰһԱࠠҢࡁʔᓙ௴อٙΆ ุᔼᐕ༆Ӕ˙ࣩձ֛Փٙୋɧ˙၍ଣਕd νீཀ24ʃࣛ܄˒ਕਖ਼ᇞတԑ˼ࡁʔᓙᄣ ̋ٙცࠅfᏐԫԘઽุٙਕᅼόɰᜫҢࡁᜳ ݺҪᇞɪਠዚdΝࣛЪމɓගɢБٟึப ٙᔼᐕණྠdމ༿ՓอۨڿًषݭᅂᚤЪ ্̈ᘠfอۨڿًषݭޥઋһᒈᘌࢡʘყd ɽᅊᙰᗭеdϞԈʿϤdҢࡁᓒɽəᇞɪ ପۜٙᇍᖚdܼ̍у˚อۨڿًषݭጜ ݟ༊̍fҢࡁΚዚʘʕዚͭᓙԨᓒɽ ᅼdڦʊԑᗇҢࡁٙਖ਼ุၚग़ʿ࿁ਜʫ ೯࢝ۃ౻ٙڦːf
In the last six months, while our offline clinics uncharacteristically dropped in patient volume during the COVID-19 outbreak, our online consultation services have garnered significant interest from our existing and new customers as Hong Kong citizens became wary of going to public places. The abrupt shift in market sentiment justifies our timely decision to augment our offline network with an expanding online presence. To further improve our digital footprint, our information technology teams in Hong Kong and China have been working around the clock to refine our web-and-app-based telemedicine platforms in both regions. As an indication to our adaptability to the evolving needs of our customers, during the peak of the COVID-19 pandemic, we leveraged on technology to overcome the barriers of social distancing and provide cutting-edge, web-based teleconsultation to multiple Hong Kong-based conglomerates, reputable insurance companies and private clients.
ཀ̘ʬࡈ˜d͟࠰ಥ͏ᒒеۃֻʮఙ הdҢࡁٙྼൢהอۨڿًषݭᖑ೯ಂ ගٙઃ٫ఱൢɛϣΪϾಯˇdઋرၾཀ̘ࠕ ್ʔΝdШҢࡁٙᇞɪᏐൢਕۆՑତϞ ʿอ܄˒ٙڡຕfࠦ࿁̹ఙઋၫᒓᜊdҢࡁ ͵ΪࣛՓ֝Ъ̈Ӕ֛d˸ʔᓙѯɽٙᇞɪุ ਕԸᄣ੶ᇞɨၣഖfމəආɓӉʺҢࡁٙ ᇞɪุਕوྡdҢࡁ࠰ಥʿʕٙ༟ৃ߅ Ҧྠඟɓٜ˚˸ᘱցʈЪd˸ҁഛவՇࡈή ਜٙჃᔼᐕၣഖʿᏐ̨̻͜fҢࡁ༶͜߅ Ҧ͂ॎٟึ൷ᕎણ݄ிϓٙཞჟdΣ࠰ಥε ගၝΥΆุeڦᚑԄλٙ࠰ಥڭᎈʮ̡ձӷ ɛ܄˒Զ࿃อٙၣɪჃᏐൢਕdΙᗇ ҢࡁঐቇᏐʔᓙᜊʷٙ܄˒ცӋf
We believe the future delivery of healthcare is hinged upon finding an optimal balance between online and offline service platforms. In the coming future, we will continue to invest in technology to connect patients to the most appropriate care medium to make healthcare more accessible and affordable to the general public. Capitalizing on our vast customer base, in-house medical teams, and proprietary technology, we will continue to deepen the integration between online and offline healthcare services.
Ңࡁڦd͊Ըٙᔼᐕਕ՟Ӕᇞɪၾᇞ ɨਕ̨̻ʘගٙ௰Գ̻ፅfҢࡁ˚ܝਗ਼ᘱ ᚃҳ༟߅Ҧdމઃ٫ҬՑ௰Υቇٙਕద ʧdᜫ౷ᖯɽᐏһ̙ʿ˲̙ࠋዄٙᔼᐕ ਕfԱቦᕼɽٙ܄˒໊eʫᔼᐕྠඟʿ ਖ਼ϞҦஔdҢࡁਗ਼ᘱᚃଉʷᇞɪၾᇞɨᔼᐕ ਕፄΥf
Our focus on providing quality health services expands beyond the borders of Hong Kong. Currently, our Greater China network boasts more than 800 self-owned and affiliated medical service points across Hong Kong, Macau, Beijing, Tianjin, Shanghai, as well as other major cities in the GBA including Guangzhou, Shenzhen, Zhuhai, Zhongshan, Dongguan and Foshan. Further, our remote consultation platform in China serves as a crucial portal to connect family doctors to deliver on-demand, face-to-face online consultations to insured policyholders.
Ңࡁਖ਼ءԶᎴሯᔼᐕਕdԨן࢝Ї ࠰ಥ˸̮fͦۃdҢࡁٙɽʕശਜၣഖѬኹ ൴ཀ 800 ࡈІᐄʿڝ᙮ᔼᐕਕᓃdཁ̺࠰ ಥeዦ ژȅ ԯe˂ ݵeɪ ऎd˸ ʿ ᄿ ψe ଉέeमऎeʕʆe؇୷ʿНʆഃɽᝄਜՉ ˼˴ࠅ̹۬fϤ̮dҢࡁʕٙჃᏐൢ ̨̻ɗஹટࢬᔼ͛ٙࠠࠅژ˒d˸ܲცࠅ މڭఊܵϞɛԶࠦ࿁ࠦٙᇞɪᏐൢf
In recent years, consistent with the Chinese government's emphasis on improving the quality of primary care, the Group has broadened the breadth and depth of our family doctor and nurse training through our revered GOLDTM training and GOLDTM-EN training programmes, respectively. Despite the restrictions placed upon cross-border traveling during COVID-19, we continued to administer a combination of online and offline trainings to our students in the Mainland to optimum effect.
ڐϋdމৣΥʕִ݁ءࠠ৷ਿᄴᔼᐕ ਕሯ९d͉ණྠʱйீཀ௪աႩ̙ٙGOLD™ ږሙʿGOLD™-ENږᚐɻሙ dᓒɽࢬᔼ͛ʿᚐɻሙٙᄿܓʿ ଉܓfኋ၍༨ྤ༷ࣚอۨڿًषݭໍ߿ಂ ගաՑࠢՓdઓҢࡁᘱᚃމʫήኪࡰԶᇞ ɪᇞɨԨБٙd˸༺Ց௰Գࣖ؈f
We undertook the mission of fostering efficient collaboration between well-trained doctors and patients in a bid to build a scalable but agile medical service platform. Our unique GOLDTM and GOLDTM-EN programmes have delivered trainings to almost 1,000 doctors and nurses cumulatively in Mainland China, with a focus on GBA. Our clinic network with various regional and local governments consists of 45 established PPP with over 40 others scheduled to be built. Our expansion even in the time of global economic uncertainty made us one of the largest outpatient clinic networks in the GBA. We will deploy more GOLDTM-trained doctors and GOLDTM-EN-trained nurses to our existing and new PPP or to our virtual care platform down the road to enhance the standard and reach of medical services in GBA.
Innovation is the key to sustained success especially in a vast and growing market such as Mainland China. Our Group has made tremendous headway in being a market-leading trendsetter. In August 2020, we have officially launched our Internet hospital business. As the only Hong Kong-based healthcare platform with an Internet hospital license, we will continue to provide patients and Mainland residents with licensed telemedicine services through our network of highly qualified doctors and the development of strategic partnerships with new and existing specialist group.
ҢࡁٙԴն݊ᅃஔԨᎴٙᔼ͛ၾઃ٫ʘග ܔͭ৷ࣖΥЪd͂ிɓࡈ̙ᓒ࢝˲ᜳݺٙᔼ ᐕਕ̨̻fҢࡁዹतٙGOLD™ږሙ ʿGOLD™-ENږᚐɻሙၳೊɽᝄ ਜdЇʦʊଢ଼ࠇމڐɷΤʕʫήᔼ͛ձᚐ ɻԶfҢࡁၾήਜʿή˙ִ݁ΥЪ කணٙൢהၣഖ͟45ࡈତʊܔϓٙPPP̋ɪ ̤̮གྷ40ࡈࠇྌጳܔٙPPPଡ଼ϓfኋ၍Όଢ ᐑྤʔࣦdШҢࡁ͵ೌ৾ɨᓒੵӉͽd ԨʊϓމɽᝄਜՉʕɓࡈ௰ɽژൢၣഖfҢ ࡁ͊Ըਗ਼һεGOLD™ږሙ ʿGOLD™-ENږᚐɻሙٙաᔼ͛ ʿᚐɻତϞʿอணٙPPPൢהאൈᏝᔼᐕ̻ ̨d˸৷ɽᝄਜٙᔼᐕਕ˥̻ʿᓒɽ̹ ఙf ܵᚃϓ̌ٙᗫᒟί௴อdतй݊ίʕʫ ήவছᕼɽձʔᓙᄣڗ̹ٙఙf͉ණྠԐί ۃضdˏჯ̹ఙࠬΣf2020ϋ8˜dҢࡁ͍ όක࢝ʝᑌၣᔼ৫ุਕfЪމਬɓᐏ೯ʝ ᑌၣᔼ৫ٙ࠰ಥᔼᐕڭ̨̻dҢࡁਗ਼ ீཀɨٙԄᔼၣഖ˸ʿၾอආձତϞਖ਼߅ ᔼ͛ණྠ೯࢝ٙଫྫМᗫڷdᘱᚃމઃ٫ ձʫή֢͏ԶΥجٙჃᔼᐕਕf
The technique of making use of the right time to introduce the right business decision for the future is the essence of the art of management. This is what we meant by: " ༶ᘪ੯ℭdӔ௷ɷԢ (Devising strategies within a command post that will assure victory a thousand miles away)". Contrary to widespread pessimism in the economic outlook, we have confidence in the growth engine of China especially in the field of healthcare. Our stable cashflow position enabled us to ramp up our expansion plan to open a new headquarter in the central business district of Shenzhen with a total floor space of approximately 11,000 sq. feet to facilitate the administration of GOLDTM and GOLDTM-EN trainings as well as the capturing of potential GBA-based business opportunities.
ၚࣅ࣌ࣛዚdᘱϾપ͍̈ᆽٙਠุӔഄٙ Ҧ̷d̙ፗ၍ଣᖵஔٙၚהίd͵у˜༶ᘪ ੯ℭdӔ௷ɷԢ™fତʦٟึ࿁ۃ౻Ꮞ ဘేᝈઋၫdҢࡁۍˀՉ༸ϾБd࿁ʕ ٙᄣڗਗɢ̂တڦːdʕˈ˸ᔼᐕჯਹ މ್fҢࡁᖢ֛ٙତږݴًرᜫҢࡁ̙˸̋ ɽᓒੵࠇྌdίଉέٙਠุʕːਜਹணͭᐼ ᅽࠦ٤ගߒމ11,000 ̻˙ъٙอᐼd͜ GOLD™ږሙʿGOLD™-ENږᚐ ɻሙٙ၍ଣʈЪd˸ʿࣉ࣍ɽᝄਜٙ ᆑίਠዚf
Our unwavering commitment in GBA will also bring synergy to the heart of our Hong Kong business. Spurred on by our service excellence and increasing brand presence in the GBA, once traveling resumes, Mainland travelers will be gravitated towards our existing primary care network, growing specialist services scope and differentiated healthcare solutions in Hong Kong. We are poised to strengthen our self-reinforcing business flywheel by capturing the flows of talent and business opportunities between the two regions.
Ңࡁ࿁ɽᝄਜ֛ٙוፕɰਗ਼މ࠰ಥࣨːุ ਕ੭ԸΝࣖूfίҢࡁɽᝄਜٙՙ൳ ਕձᑊᚑ˚ඤٙۜࣖूપਗɨdɓ͇ʫή ၾ࠰ಥܨూ͍੬ֻ༷ࣚԸdʫήࣚ܄ਗ਼މҢ ࡁତϞٙਿᄴᔼᐕၣഖeʔᓙᄣڗٙਖ਼߅ ਕᇍఖձ࠰ಥჯΝٙᔼᐕ༆Ӕ˙ࣩהі ˏfҢࡁਗ਼ஷཀҪՇήʘගٙɛʑʿਠዚ ݴਗd̋੶ණྠ͉ԒʔᓙІҢᄣ੶ุٙਕ ӻf
Our goal is to build on our existing business practice that exemplifies our corporate vision, which is "to give everyone access to trusted and affordable care so that everyone can freely pursue their dreams without worrying about their health." Such vision and our development trajectory are intertwined. We firmly believe that we can maximize our growth potential while continuing to be a pioneer of change in the healthcare space.
Ңࡁٙͦᅺ݊ίତϞุਕྼስɪΎટΎᄒd ତҢࡁٙΆุᗴ౻d˜ᜫהϞɛᐏ̙ڦ ʿ̙ࠋዄٙਕdϾίʔ͜ዄːੰٙϽ ᅇɨdӋІʉٙྫྷซ™fவࡈᗴ౻ၾҢࡁٙ ೯࢝༩ࢰʝԑʿࠠᛌfҢࡁڦҢࡁঐ း࢝ᄣڗᆑɢdԨᘱᚃίᔼᐕڭჯਹዄ ᜊࠧٙᚨf
OUR BUSINESS
UMP's business scope consists of the following business lines:
我們的業務
ᑌΥᔼਕุٙਕᇍᖚܼ̍˸ɨุਕᇞj
1.
Hong Kong & Macau Corporate Healthcare Solution Services
UMP provides corporate healthcare solutions through the design and administration of tailored healthcare benefits plans for its Contract Customers. The extension of Third Party Administration service to our insurance company clients since last year enriched UMP's corporate healthcare solutions scope. UMP aims to provide convenient, reliable, coordinated, comprehensive and affordable healthcare services through our well-established and multi-specialties UMP Network. As at 31 December 2020, the UMP Network comprises more than 800 points of services located across Hong Kong and Macau.
The Group's Contract Customers comprise (i) insurance companies, who enter into contracts with the Group for healthcare services for their policyholders or employees of their policyholders and (ii) corporations, who enter into contracts with the Group for healthcare services for their employees and/or their dependants. When designing healthcare benefits plans, the Group collaborates closely with the Contract Customers and designs and refines corporate healthcare benefits plans, with each plan tailored to each customer's needs based on factors such as industry or occupational health-related concerns, scope of healthcare benefits desired, employee demographic as well as their budget.
1.
香港及澳門企業醫療保健解決方案 服務 ᑌΥᔼਕஷཀணࠇʿ၍ଣ০࿁ՉΥߒ܄ ˒ܓԒ֛Ⴁٙᔼᐕڭ၅лࠇྌdԶ Άุᔼᐕڭ༆Ӕ˙ࣩfІ̘ϋৎd͉ ණྠਗ਼ୋɧ˙၍ଣਕן࢝ЇҢࡁڭᎈ ʮ̡܄˒dᓒɽᑌΥᔼਕٙΆุᔼᐕڭ ༆Ӕ˙ࣩᇍఖfᑌΥᔼਕϙίஷཀҁ ഛʿεࡈʔΝਖ਼߅ٙUMPၣഖdԶک ઠe̙ቦeሜeΌࠦʿྼٙᔼᐕڭ ਕf 2020ϋ12˜31˚dUMPၣ ഖܼ̍൴ཀ800ࡈЗ࠰ಥʿዦژٙ ਕᓃf ͉ණྠٙΥߒ܄˒ܼ̍(i)ڭᎈʮ̡dމ ־ഃڭఊܵϞɛאڭఊܵϞɛٙ྇ࡰఱ ᔼᐕڭਕၾ͉ණྠࠈͭΥߒiʿ(ii) Άุdމ־ഃ྇ࡰʿŊא־ഃʘաቮɛ ఱᔼᐕڭਕၾ͉ණྠࠈͭΥߒfί ணࠇᔼᐕڭ၅лࠇྌࣛd͉ණྠၾΥ ߒ܄˒ʲΥЪdணࠇʿᎴʷΆุᔼᐕ ڭ၅лࠇྌd࣬ኽБุאϞᗫٙᔖุ ੰਪᕚeהცᔼᐕ၅лٙᇍఖe྇ࡰ तᅄʿՉཫၑක˕ഃΪ९d০࿁ӊɓ܄ ˒ٙცӋԶܓԒ֛Ⴁٙࠇྌf
2. Hong Kong & Macau Clinical Healthcare Services
UMP provides medical, dental and auxiliary services to Self-paid Patients. For medical services, UMP provides (i) general practice services, which serves as the first point of contact for the patients and (ii) specialist services covering more than 16 different specialties. For dental services, UMP provides both primary dental care and secondary dental care such as dental implants. For auxiliary services, UMP provides services such as medical imaging and laboratory services, physiotherapy and vision care.
2. 香港及澳門臨床醫療保健服務
ᑌΥᔼਕΣІ൬ઃ٫Զᔼᐕe˫߅ʿ
Ⴞпਕfᔼᐕਕ˙ࠦdᑌΥᔼਕ
Զ(i)Ό߅ᔼᐕਕdމઃ٫ٙࡈટᙃ
ᓃiʿ(ii)ਖ਼߅ਕdᔧႊ൴ཀ16ࡈʔΝ
ਖ਼߅f˫߅ਕ˙ࠦdᑌΥᔼਕԶਿ
͉˫߅ᚐଣʿୋɚᄴ˫߅ᚐଣ€Էνಔ
˫fႾпਕ˙ࠦdᑌΥᔼਕԶᔼ
ኪᅂ྅ʿʷ᜕ਕeيଣطᐕ˸ʿ߅
ᚐଣഃਕf
3. PRC Healthcare Business
Our PRC Healthcare Business currently consists of (i) health check-up business; (ii) corporate healthcare solutions business for contract customers; (iii) selected outpatient services such as family medicine within the clinics we own and operate; (iv) provision of online tele-consultation service and (v) provision of professional training to doctors and nurses under our GOLD™ training programme. Our current focus is on the development of our PRC Healthcare Business in Beijing, Shanghai, Guangzhou, Shenzhen and other GBA , through both building a sizeable offline PPP network and an online presence through our tele-consultation platform.
BUSINESS LINES ANALYSIS
Hong Kong & Macau Corporate Healthcare Solution Services
Revenue for this business line has decreased 5.9% from HK$129.9 million to HK$122.3 million (before inter-segment elimination) due to a general decrease in patient visits.
3. 中國保健業務
Ңࡁٙʕڭุਕͦۃܼ̍(i)Ꮸุ
ਕi(ii)ਕΥߒ܄˒ٙΆุᔼᐕڭ༆
Ӕ˙ุࣩਕi(iii)ίҢࡁኹϞʿᐄ༶ٙൢ
הʫԶ፯֛ژൢਕ€νࢬᔼኪi
(iv) ԶίᇞჃᔼᐕਕiʿ (v) ࣬ኽ
ҢࡁٙGOLD™ږሙΣᔼ͛ʿ
ᚐɻԶਖ਼ุfҢࡁͦۃٙࠠᓃ݊
Νࣛீཀ͂ிՈᅼٙྼPPPၣഖ˸
ʿீཀҢࡁٙჃᔼᐕਕ̨̻Զٙ
ၣɪਕdί̏ԯeɪऎeᄿψeଉέ
ʿɽᝄਜʫٙՉ˼ήਜ೯࢝ʕڭุ
ਕf
業務線分析 香港及澳門企業醫療保健解決方案服務
ԸІϤุਕᇞٙϗɝ͟ 129.9 ϵຬಥʩಯˇ 5.9%Ї122.3 ϵຬಥʩ€ʱගתቖۃdɗ ͟ఱൢɛϣɨࠥf
Hong Kong & Macau Clinical Healthcare Services
Revenue for this business line has increased approximately 5.7% from HK$201.6 million to HK$213.1 million (before inter-segment elimination) due to a general increase in number of health check-ups and average spending per visit.
香港及澳門臨床醫療保健服務
ԸІϤุਕᇞٙϗɝ͟201.6ϵຬಥʩᄣ̋ߒ 5.7%Ї213.1 ϵຬಥʩ€ʱගתቖۃdɗ ͟ԶٙᏨϣᅰʿ̻ѩൢ൬ᄣ̋f
Our business lines in Hong Kong and Macau are mature and continue to generate profit and operating cash flows for investment in new growth areas.
Ңࡁί࠰ಥձዦژุٙਕᇞʊ೯࢝ϓᆞd Ԩܵᚃପ͛лᆗձᐄତږݴϾ̙͜ҳ༟ อٙᄣڗჯਹf
PRC Healthcare Business
Revenue for this business line has decreased approximately 26.3% from HK$27.7 million to HK$20.4 million (before inter-segment elimination) primarily due to the decrease in the number of health check-ups which was a direct result of COVID-19 impacted travel restrictions. We continue to invest in people and technology for the rapid development of GOLD™ medical professional training and the virtual care businesses in Mainland China and mainly the GBA.
Mainland China presents significant growth opportunities and is a point of focus for us as we continue to innovate and develop new business lines.
中國保健業務
ԸІϤุਕᇞٙϗɝ͟27.7ϵຬಥʩಯˇߒ 26.3%Ї20.4 ϵຬಥʩ€ʱගתቖۃdɗ ˴ࠅ͟ΪᏐอۨڿًषݭϾྼ݄༷ٙࣚࠢ ՓdϾ˿ԶٙᏨϣᅰಯˇfҢࡁᘱᚃ ίʕʫή€˴ɢ݊ίɽᝄਜҳ༟ɛʑʿ ߅Ҧ˸પਗGOLDTMږᔼᐕਖ਼ุʿჃ ᔼᐕุਕٙԘ೯࢝fʕɽᘾᔛ̙ᝈٙ ᄣڗዚ༾dɰ݊Ңࡁᘱᚃ௴อձ೯࢝อุਕ ᇞٙࠠᓃהίf
The following table sets out the revenue for our business lines for the six months ended 31 December 2020 and the corresponding period for comparison:
ɨڌ༱ΐҢࡁ࿚Ї2020ϋ12˜31˚˟ʬࡈ˜ ˸ʿᏐಂගุٙਕᇞϗɝ˸Զˢ༰j
Revenue by business lines
按業務線劃分收入
Six months ended 31 December 截至12月31日止六個月
Increase/ (decrease)
2020 | 2019 | ᄣ̋Ŋ | ||
2020年 | 2019ϋ | €ಯˇ | ||
HK$'000 | HK$'000 | |||
千港元 | ɷಥʩ | |||
Hong Kong & Macau Corporate | ࠰ಥʿዦژΆุᔼᐕ | |||
Healthcare Solution Services | ڭ༆Ӕ˙ࣩਕ | 122,275 | 129,914 | (5.9%) |
Hong Kong & Macau Clinical | ࠰ಥʿዦژᑗґᔼᐕ | |||
Healthcare Services | ڭਕ | 213,054 | 201,633 | 5.7% |
PRC Healthcare Business | ʕڭุਕ | 20,406 | 27,697 | (26.3%) |
TOTAL | 合計 | 355,735 | 359,244 | (1.0%) |
(1) | Business lines revenue presented above are before inter-segment sales | (1) | ɪڌהяΐุਕᇞϗɝމආБʱගቖਯתቖ |
elimination. | ۃf |
FINANCIAL REVIEWS
1HFY2021 compared to 1HFY2020
Revenue
During 1HFY2021, we primarily generated revenue from (i) the provision of corporate healthcare solutions to Contract Customers in Hong Kong and Macau; (ii) the provision of clinical healthcare services in Hong Kong and Macau and (iii) the provision of healthcare services in the PRC.
財務回顧 2021財政年度上半年與2020財政年度上 半年比較 收入 2021ৌ݁ϋܓɪ̒ϋdҢࡁٙϗɝ˴ࠅପ ͛І(i)࠰ಥʿዦژΣΥߒ܄˒ԶΆุᔼᐕ ڭ༆Ӕ˙ࣩi(ii)࠰ಥʿዦژԶᑗґᔼ ᐕڭਕʿ(iii)ʕԶᔼᐕڭਕf
Total consolidated revenue decreased by 1.5% from HK$306.8 million in 1HFY2020 to HK$302.1 million in 1HFY2021, primarily due to a decrease in revenue from HK$27.7 million to HK$20.4 million from the PRC Healthcare Business.
ᐼၝΥϗɝ͟2020ৌ݁ϋܓɪ̒ϋ306.8ϵຬ ಥʩಯˇ 1.5%Ї2021 ৌ݁ϋܓɪ̒ϋ 302.1
ϵຬಥʩdɗ˴ࠅ͟ԸІʕڭุਕٙ ϗɝ͟27.7ϵຬಥʩಯˇЇ20.4ϵຬಥʩf
Provision of corporate healthcare solution services to Contract Customers in Hong Kong and Macau
Revenue from the provision of corporate healthcare solution services to Contract Customers in Hong Kong and Macau decreased 5.8% from HK$129.1 million in 1HFY2020 to HK$121.6 million in 1HFY2021.
࠰ಥʿዦژΣΥߒ܄˒ԶΆุᔼᐕڭ ༆Ӕ˙ࣩਕ
ԸІΣ࠰ಥʿዦژٙΥߒ܄˒ԶΆุᔼᐕ ڭ༆Ӕ˙ࣩਕٙϗɝ͟2020ৌ݁ϋܓɪ
̒ϋ 129.1 ϵຬಥʩಯˇ 5.8%Ї2021 ৌ݁ϋ ܓɪ̒ϋ121.6ϵຬಥʩf
• Medical. Revenue generated from the provision of Medical Services to Contract Customers decreased by 5.9% from HK$116.7 million for 1HFY2020 to HK$109.8 million for 1HFY2021, primarily due to a decrease in the number of visits from patients seeking Medical Services.
• 醫療。ΣΥߒ܄˒Զᔼᐕਕٙϗ ɝ͟ 2020 ৌ݁ϋܓɪ̒ϋ 116.7 ϵຬ ಥʩಯˇ5.9%Ї2021ৌ݁ϋܓɪ̒ϋ 109.8ϵຬಥʩdɗ˴ࠅ͟రӋᔼᐕ ਕٙઃ٫ఱൢϣᅰಯˇf
• Dental. Revenue generated from the provision of Dental Services to Contract Customers decreased by 4.8% from HK$12.4 million for 1HFY2020 to HK$11.8 million for 1HFY2021, primarily due to a decrease in the number of visits from the patients seeking Dental Services.
• 牙科。ΣΥߒ܄˒Զ˫߅ਕٙϗ ɝ͟2020ৌ݁ϋܓɪ̒ϋ12.4ϵຬಥ ʩಯˇ 4.8%Ї2021 ৌ݁ϋܓɪ̒ϋ 11.8 ϵຬಥʩdɗ˴ࠅ͟రӋ˫߅ ਕٙઃ٫ఱൢϣᅰಯˇf
Provision of clinical healthcare services in Hong Kong and Macau
• Medical. Revenue generated from the provision of Medical Services to Self-paid Patients increased by 9.2% from HK$121.5 million for 1HFY2020 to HK$132.7 million for 1HFY2021, primarily due to an increase in the average spending per visit.
࠰ಥʿዦژԶᑗґᔼᐕڭਕ
• 醫療。ΣІ൬ઃ٫Զᔼᐕਕٙϗ ɝ͟ 2020 ৌ݁ϋܓɪ̒ϋ 121.5 ϵຬ ಥʩᄣ̋9.2%Ї2021ৌ݁ϋܓɪ̒ϋ 132.7ϵຬಥʩdɗ˴ࠅ͟ϣѩൢ൬ ᄣ̋f
• Dental. Revenue generated from the provision of Dental Services to Self-paid Patients decreased by approximately 3.5% from HK$28.4 million for 1HFY2020 to HK$27.4 million for 1HFY2021 due to the decrease in number of self-paid patient visits.
• 牙科。ΣІ൬ઃ٫Զ˫߅ਕٙϗ ɝ͟2020ৌ݁ϋܓɪ̒ϋ28.4ϵຬಥ ʩಯˇߒ3.5%Ї2021ৌ݁ϋܓɪ̒ϋ 27.4 ϵຬಥʩdɗ˴ࠅ͟І൬ઃ٫ ఱൢϣᅰಯˇf
PRC Healthcare Business
Revenue generated from the PRC Healthcare Business decreased from HK$27.7 million in 1HFY2020 to HK$20.4 million in 1HFY2021, primarily due to a decrease in the number of health check-ups for PRC residents traveling abroad for study or work and health check-ups for corporate employees and insurance scheme members, which was significantly impacted by COVID-19 related travel restrictions.
ʕڭุਕ
ԸІʕڭุਕٙϗɝ͟2020ৌ݁ϋܓɪ ̒ϋ27.7ϵຬಥʩಯЇ2021ৌ݁ϋܓɪ̒ϋ 20.4 ϵຬಥʩdɗ˴ࠅ͟މՑऎ̮वኪא ʈЪٙʕ֢͏ԶٙᏨϣᅰ˸ʿމΆุ ྇ࡰʿڭᎈࠇྌϓࡰԶٙᏨϣᅰաՑอ ۨڿًषݭᗫ̈ɝྤࠢՓٙᜑഹᅂᚤϾಯ ˇf
Other Income and Gains
Other income and gains primarily comprise administrative support fees (including fees derived from providing administrative support to Affiliated Doctors, Affiliated Dentists and Affiliated Auxiliary Services Providers), bank interest income, interest income from financial assets at amortised cost, dividend income from investments at fair value through other comprehensive income and investments at fair value through profit or loss, gain on disposal of subsidiaries and fixed assets, and other income.
其他收入及收益
Չ˼ϗɝʿϗू˴ࠅܼ̍Б݁˕౪൬͜€̍ ܼΣᑌ᙮ᔼ͛eᑌ᙮˫ᔼʿᑌ᙮Ⴞпਕ Զ٫ԶБ݁˕౪הପ͛ٙ൬͜eვБлࢹ ϗɝeܲᛅቖϓ͉ࠇඎٙږፄ༟ପٙлࢹϗ ɝeܲʮʪᄆ࠽ࠇɝՉ˼Όࠦϗɝٙҳ༟˸ ʿܲʮʪᄆ࠽ࠇɝฦूٙҳ༟ʘٰࢹϗɝe ̈ਯڝ᙮ʮ̡ʿո֛༟ପʘϗूd˸ʿՉ˼ ϗɝf
Other income and gains decreased by 65.1% from HK$10.9 million in 1HFY2020 to HK$3.8 million in 1HFY2021. The decrease was primarily due to decrease in dividend income received from an investment at fair value through other comprehensive income.
Չ˼ϗɝʿϗू͟2020ৌ݁ϋܓɪ̒ϋ10.9 ϵຬಥʩಯˇ65.1%Ї2021ৌ݁ϋܓɪ̒ϋ 3.8ϵຬಥʩfՉಯˇ˴ࠅ͟ɓධܲʮʪ ᄆ࠽ࠇɝՉ˼Όࠦϗɝٙҳ༟ϗ՟ٰٙࢹϗ ɝಯˇהߧf
Professional Services Expenses
Professional services expenses primarily comprise fees paid to
Doctors, Dentists and Auxiliary Services Providers for Medical Services, Dental Services and Auxiliary Services rendered within the UMP Network, as well as fees paid to third party laboratories and testing centres for services rendered to the Group.
專業服務費用 ਖ਼ุਕ൬͜˴ࠅܼ̍ఱᔼ͛e˫ᔼʿႾп ਕԶ٫UMPၣഖʫԶٙᔼᐕਕe ˫߅ਕʿႾпਕΣՉ˕˹ٙ൬͜d˸ʿ ఱୋɧ˙ʷ᜕ʿᏨʕːΣ͉ණྠԶٙ ਕϾ˕˹ٙ൬͜f
Professional services expenses decreased by 9.3% from HK$122.2 million for 1HFY2020 to HK$110.8 million for 1HFY2021, primarily due to a decrease in the cost of services rendered by doctors, dentists and other professionals.
ਖ਼ุਕ൬͜͟ 2020 ৌ݁ϋܓɪ̒ϋ 122.2 ϵຬಥʩಯˇ 9.3%Ї2021 ৌ݁ϋܓɪ̒ϋ 110.8ϵຬಥʩd˴ࠅ͟ᔼ͛e˫ᔼʿՉ˼ ਖ਼ุɛɻԶਕٙϓ͉ಯˇf
Property Rental and Related Expenses
Property rental and related expenses decreased by 34.9% from HK$6.3 million for 1HFY2020 to HK$4.1 million for 1HFY2021, primarily due to the rental concessions granted by landlords of various premises.
物業租金及相關開支 يุॡږʿᗫක˕͟2020ৌ݁ϋܓɪ̒ϋ 6.3ϵຬಥʩಯˇ34.9%Ї2021ৌ݁ϋܓɪ̒ ϋ4.1ϵຬಥʩd˴ࠅ͟ʔΝஈהุٙ˴ഗ ʚॡږಯеf
Depreciation and Amortisation
Depreciation and amortisation, which comprises of depreciation of the right-of-use assets and depreciation and amortisation of other non-current assets, increased by 14.1% from HK$35.4 million in 1HFY2020 to HK$40.4 million for 1HFY2021, primarily due to the increase of depreciation because of decoration and acquisitions of plant and equipment.
折舊及攤銷 ұᔚʿᛅቖ€ܼ̍Դ͜ᛆ༟ପұᔚ˸ʿՉ˼ڢ ݴਗ༟ପʘұᔚʿᛅቖ͟ 2020ৌ݁ϋܓɪ ̒ϋٙ 35.4 ϵຬಥʩᄣ̋ 14.1%Ї2021 ৌ݁ ϋܓɪ̒ϋٙ40.4 ϵຬಥʩd˴ࠅ݊͟ༀ ࡌʈ˸ʿᒅໄዚኜʿண௪˿ұᔚᄣ̋f
Other Expenses, net
Other expenses, net primarily comprise provision of impairment loss, warrants expenses and general overhead expenses such as utilities, operation and other administrative expenses such as audit fees, legal fees, repair and maintenance expenses incurred with respect to the Group's offices and medical equipment, printing expenses and bank charges.
其他開支淨額
Չ˼ක˕ଋᕘ˴ࠅܼ̍ಯ࠽ᑦฦᅡ௪eႩٰ ᛆᗇක˕˸ʿ˚੬කቖdԷν˥ཥeᐄʿ Չ˼Б݁ක˕€Էνᄲࣨ൬͜eجܛ൬͜eၾ ͉ණྠ፬ʮ܃ʿᔼᐕண௪ᗫٙၪࡌʿڭቮ ක˕eΙՏ൬ʿვБϗ൬f
Other expenses, net, increased by 403.1% from approximately HK$6.4 million in 1HFY2020 to HK$32.2 million in 1HFY2021, primarily due to an impairment of other assets of HK$4.1 million, an impairment of deposit of HK$4.1 million in 1HFY2021, and a reversal of the non-cash equity-settled share-based payment expense of approximately HK$15.2 million was recorded in 1HFY2020 since the associated terms and conditions for the Second and Third Vesting Milestones had not been met before its expiration on 14 November 2019, which did not recur in 1HFY2021.
Չ˼ක˕ଋᕘ͟2020ৌ݁ϋܓɪ̒ϋٙߒ6.4 ϵຬಥʩᄣ̋403.1%Ї2021ৌ݁ϋܓɪ̒ϋ ٙ32.2 ϵຬಥʩd˴ࠅ͟ 2021ৌ݁ϋܓɪ ̒ϋʫϞՉ˼༟ପʘಯ࠽މ4.1ϵຬʩdܲږ ʘಯ࠽މ4.1ϵຬʩdʿ2020ৌ݁ϋܓɪ̒ϋ ʫᅡΫڢତږ˸ᛆूഐၑٰٙ΅˕˹ක˕ߒ 15.2 ϵຬಥʩdࡡΪމୋɚධʿୋɧධᓥ᙮ ԢʘᗫૢಛʿૢԨೌίՉ2019ϋ 11˜14˚֣တۃ༺ϓdϾϤධͦ2021ৌ݁ ϋܓɪ̒ϋԨೌΎϣ̈ତf
Summary of operational data for 1HFY2021 with comparative figures for 1HFY2020
Revenue by operating segment
2021財政年度上半年的經營數據與2020財政 年度上半年比較數據概要 ܲᐄʱྌʱϗɝ
Six months ended 31 December 截至12月31日止六個月
Increase/ (decrease)
2020 | 2019 | ᄣ̋Ŋ | ||
2020年 | 2019ϋ | €ಯˇ | ||
HK$'000 | HK$'000 | |||
千港元 | ɷಥʩ | |||
(Unaudited) | (Unaudited) | |||
(未經審核) | €͊ᄲࣨ | |||
Provision of corporate | 提供企業醫療保健 | |||
healthcare solution services | 解決方案服務 | 124,523 | 132,418 | (6.0%) |
Medical | ᔼᐕ | 112,723 | 119,962 | (6.0%) |
Dental | ˫߅ | 11,800 | 12,456 | (5.3%) |
Provision of clinical | 提供臨床醫療保健 | |||
healthcare services | 服務 | 177,620 | 174,395 | 1.8% |
Medical | ᔼᐕ | 150,164 | 145,952 | 2.9% |
Dental | ˫߅ | 27,456 | 28,443 | (3.5%) |
TOTAL | 合計 | 302,143 | 306,813 | (1.5%) |
Number of visits by operating segment
ܲᐄʱྌʱఱൢϣᅰ
Six months ended 31 December 截至12月31日止六個月
Increase/ (decrease)
2020 | 2019 | ᄣ̋Ŋ | ||
2020年 | 2019ϋ | €ಯˇ | ||
Provision of corporate | 提供企業醫療保健解決 | |||
healthcare solution services | 方案服務 | 408,427 | 636,819 | (35.9%) |
Medical | ᔼᐕ | 395,260 | 621,427 | (36.4%) |
Dental | ˫߅ | 13,167 | 15,392 | (14.5%) |
Provision of clinical | 提供臨床醫療保健 | |||
healthcare services | 服務 | 119,542 | 144,134 | (17.1%) |
Medical | ᔼᐕ | 105,127 | 124,749 | (15.7%) |
Dental | ˫߅ | 14,415 | 19,385 | (25.6%) |
TOTAL | 合計 | 527,969 | 780,953 | (32.4%) |
主要財務狀況項目 使用權資產 ࣬ኽ࠰ಥৌਕజѓۆୋ16dԴ͜ᛆ༟ପ ॡ༣ක˚ಂᆽႩfԴ͜ᛆ༟ପܲϓ͉ಯ ̘Оଢ଼ࠇұᔚձОಯ࠽ᑦฦܝٙږᕘ ࠇඎdԨఱॡ༣ࠋවٙОࠠอࠇඎආБሜ fԴ͜ᛆ༟ପٙϓ͉ܼ̍ʊᆽႩٙॡ༣ࠋ වږᕘeʊପ͛ٙڋٜટϓ͉˸ʿίක ˚ಂאʘۃʊЪ̈ٙॡ༣˹ಛಯʊϗՑٙ Оॡ༣ᎴfʊᆽႩٙԴ͜ᛆ༟ପ˸ٜᇞج ܲПࠇ̙Դ͜ϋಂձॡಂʘ༰٫ࠇұᔚf
KEY FINANCIAL POSITION ITEMS
Right-of-use assets
Under HKFRS 16, right-of-use assets are recognised at the commencement date of the lease. Right-of-use assets are measured at cost, less any accumulated depreciation and any impairment losses, and adjusted for any remeasurement of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognised, initial direct costs incurred, and lease payments made at or before the commencement date less any lease incentives received. The recognised right-of-use assets are depreciated on a straight-line basis over the shorter of the estimated useful life and the lease term.
As at 31 December 2020, the Group's right-of-use assets amounted to HK$75.5 million (30 June 2020: HK$82.2 million).
2020ϋ12˜31˚d͉ණྠٙԴ͜ᛆ༟ପމ 75.5 ϵຬಥʩ€ 2020ϋ6˜30˚j82.2ϵຬಥ ʩf
Financial Assets at Amortised Cost
Financial assets at amortised cost primarily represent the marketable corporate bonds issued by listed corporations with fixed interest rates from 4.25% to 8.50% per annum. The marketable debt securities which will mature within one year and more than one year are classified as current assets and non-current assets, respectively. The Group receives related interest payments semi-annually and annually.
按攤銷成本計量的金融資產 ܲᛅቖϓ͉ࠇඎٙږፄ༟ପ˴ࠅܸɪ̹ʮ̡ ೯Бٙቇቖʮ̡වՎdܲո֛ϋлଟ 4.25% Ї8.50% ࠇࢹfɓϋʫʿɓϋܝՑಂٙቇ ቖවਕᗇՎʱйʱᗳމݴਗ༟ପʿڢݴਗ༟ ପf͉ණྠӊ̒ϋʿӊϋϗ՟ᗫлࢹ˹ಛf
As at 31 December 2020 and 30 June 2020, the Group's financial assets at amortised cost amounted to HK$50.0 million (of which HK$17.1 million is classified as current assets and HK$32.9 million is classified as non-current assets) and HK$55.8 million (of which HK$35.6 million is classified as current assets and HK$20.2 million is classified as non-current assets), respectively.
2020ϋ12˜31 ˚ʿ 2020ϋ6˜30˚d͉ ණ ྠܲᛅቖϓ͉ࠇඎٙږፄ༟ପʱйމ50.0ϵ ຬಥʩ€Չʕ 17.1 ϵຬಥʩʱᗳމݴਗ༟ପ Ͼ32.9ϵຬಥʩʱᗳމڢݴਗ༟ପʿ55.8ϵ ຬಥʩ€Չʕ35.6ϵຬಥʩʱᗳމݴਗ༟ପϾ 20.2ϵຬಥʩʱᗳމڢݴਗ༟ପf
Lease liabilities
Under HKFRS 16, lease liabilities are recognised at the commencement date of the lease at the present value of lease payments to be made over the lease term. After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made.
租賃負債 ࣬ኽ࠰ಥৌਕజѓۆୋ16dॡ༣ࠋවί ॡ༣ක˚ಂ˸ίॡ༣ಂʫਗ਼Ъ̈ٙॡ༣˹ ಛٙତ࠽ᆽႩfίක˚ಂʘܝdॡ༣ࠋව ٙږᕘʚ˸ɪሜ˸ˀ݈лࢹٙᄣ̋dԨఱʊ Ъ̈ٙॡ༣˹ಛϾಯˇf
As at 31 December 2020 and 30 June 2020, the carrying amount of lease liabilities amounted to HK$83.0 million (of which HK$51.4 million is classified as current liabilities and HK$31.6 million is classified as non-current liabilities) and HK$86.5 million (of which HK$43.4 million is classified as current liabilities and HK$43.1 million is classified as non-current liabilities).
2020ϋ12˜31 ˚ʿ 2020ϋ6˜30˚dॡ ༣ ࠋවٙሪࠦ࠽ʱйމ83.0ϵຬಥʩ€Չʕ51.4 ϵຬಥʩʱᗳމݴਗࠋවϾ31.6ϵຬಥʩʱ ᗳމڢݴਗࠋවʿ 86.5 ϵຬಥʩ€Չʕ 43.4 ϵຬಥʩʱᗳމݴਗࠋවϾ43.1ϵຬಥʩʱ ᗳމڢݴਗࠋවf
LIQUIDITY AND FINANCIAL RESOURCES
The Group has historically funded its operations primarily by cash generated from operating activities. Upon the listing of the shares of the Company on the Hong Kong Stock Exchange, the Group intended to satisfy its liquidity requirements using a combination of cash generated from operating activities and net proceeds from the Global Offering. The Group may also seek to borrow to satisfy liquidity requirements. As of 31 December 2020, the Group had a cash and cash equivalents of HK$235.0 million.
流動資金及財務資源
͉ණྠཀֻ˴ࠅீཀᐄݺਗהତږ˕ܵ Չุਕᐄf͉ʮٰ̡΅࠰ಥᑌʹהɪ̹ ܝd͉ණྠᏝਗ͜ᐄݺਗהତږʿΌଢ ೯ਯהಛධଋᕘԸတԑՉݴਗ༟ږცӋf ͉ණྠ͵̙ঐరӋ࠾ಛԸတԑݴਗ༟ږც Ӌf࿚Ї2020ϋ12˜31˚d͉ණྠܵϞٙତ ږʿତږഃᄆيމ235.0ϵຬಥʩf
As of the date of this report, the Group did not have any bank borrowings or outstanding bank loans and did not enter into any bank loan facilities.
࿚Ї͉జѓ˚ಂd͉ණྠԨೌОვБ࠾ಛ א͊ᎵᒔვБ൲ಛd͵ೌࠈͭОვБ൲ಛ ፄ༟f
Management Discussion and Analysis | |
管理層討論及分析 | |
CAPITAL STRUCTURE | 資本結構 |
There has been no significant change in the capital structure of the | ࿚Ї2020ϋ12˜31˚˟ಂගd͉ʮ̡ٙ༟͉ |
Company during the period ended 31 December 2020. The capital | ഐԨೌࠠɽᜊਗf͉ʮ̡ٙ༟͉ܼ̍౷ஷ |
of the Company comprises ordinary shares and other reserves. | ٰʿՉ˼Ꮇ௪f |
MATERIAL ACQUISITION OR DISPOSAL OF | 重大收購或出售附屬公司 |
SUBSIDIARIES | |
There was no material acquisition or disposal of subsidiaries | ͉ණྠ2021ৌ݁ϋܓɪ̒ϋԨೌࠠɽϗᒅ |
undertaken by the Group during 1HFY2021. | א̈ਯڝ᙮ʮ̡f |
CAPITAL EXPENDITURE | 資本開支 |
The capital expenditure during the period was primarily related | ಂʫ༟͉ක˕˴ࠅϞᗫༀࡌʿމ͉ණྠᔼਕ |
to decoration and the acquisitions of plant and equipment for the | ʕːᒅໄዚኜʿண௪f2021ৌ݁ϋܓɪ̒ |
Group's medical centres. For 1HFY2021, the Group incurred capital | ϋd͉ණྠପ͛༟͉ක˕Υߒ 15.0ϵຬಥ |
expenditure in an aggregate amount of approximately HK$15.0 | ʩ€2020ৌ݁ϋܓɪ̒ϋj17.8 ϵຬಥʩf |
million (1HFY2020: HK$17.8 million). | |
FUTURE PLANS FOR MATERIAL INVESTMENTS | 重大投資或資本資產的未來計劃 |
OR CAPITAL ASSETS | |
The Group continues to strengthen its current business and explore | ͉ණྠᘱᚃ̋੶ତϞุਕʿઞӋʔΝᄣڗዚ |
growth opportunities. The Group did not have any specific future | ༾f͉ණྠ2020ϋ12˜31˚ԨೌОࠠɽ |
plan for material investments or capital assets as of 31 December | ҳ༟א༟͉༟ପٙՈ͊Ըࠇྌf |
2020. | |
INDEBTEDNESS | 債務 |
Contingent Liabilities | 或然負債 |
As at 31 December 2020, the Group did not have any material | 2020ϋ12˜31˚d͉ණྠԨೌОࠠɽ༟ |
off-balance sheet arrangements. | ପࠋවڌ̮τરf |
Capital Commitment | 資本承擔 |
The Group has no material outstanding capital commitment as at 31 | ͉ණྠ2020ϋ12˜31˚Ԩೌࠠɽ͊ᄵБ༟ |
December 2020. | ͉וዄf |
PLEDGE OF ASSETS
As at 31 December 2020, the Group has pledged certain deposits with an aggregate carrying amount of HK$1.0 million (30 June 2020: HK$1.4 million) in connection with a surety bond issued by a bank in favour of an independent third party for potential damages of dental equipment and potential disruption of Medical Services, and a bank guarantee issued by a bank in favour of a landlord for leasing of a medical centre of the Group.
資產抵押
2020ϋ12˜31˚d͉ණྠתץሪࠦ࠽Υ 1.0ϵຬಥʩ€2020ϋ6˜30˚j1.4ϵຬಥʩ ٙ߰ʍπಛdɗϞᗫ͟ɓගვБΣɓΤዹͭ ୋɧ˙ఱᆑί˫߅ண௪ฦᕸʿᔼᐕਕٙᆑ ίʍᓔ೯̈ٙᄵߒڭᗇ˸ʿ͟ɓගვБఱ͉ ණྠॡ༣ɓගᔼਕʕːΣุ˴Ъ̈ٙვБዄ ڭf
EMPLOYEE AND REMUNERATION POLICY
As at 31 December 2020, the Group had a total of 451 (30 June 2020: 452) full-time employees. For 1HFY2021, the staff cost (including Directors' remuneration in the form of salaries and other benefits) was approximately HK$60.0 million (1HFY2020: HK$72.6 million).
The Group ensures that the pay levels of its employees are competitive and employees are rewarded on a performance related basis, together with reference to the profitability of the Group, prevailing remuneration benchmarks in the industry, and market conditions within the general framework of the Group's remuneration system.
僱員及薪酬政策
2020 ϋ 12 ˜ 31 ˚d͉ණྠϞ 451Τ €2020ϋ6˜30˚j452ΤΌᔖ྇ࡰf2021 ৌ݁ϋܓɪ̒ϋdࡰʈϓ͉€ܼ̍˸ᑚږʿ Չ˼၅лҖόٙԫᑚཇߒމ60.0ϵຬಥʩ €2020ৌ݁ϋܓɪ̒ϋj72.6 ϵຬಥʩf ͉ණྠᆽڭՉ྇ࡰٙᑚږ˥̻Ոᘩنɢd྇ ࡰܲʈЪڌତਿᐏᆤᎸd˲ਞϽ͉ණ ྠޮлঐɢeБุʫତБٙᑚཇਿ˸ʿ͉ ණྠᑚཇӻ࣪ݖʫ̹ٙఙًرf
In addition, the Company also adopted the Pre-IPO Share Option Scheme and the Post-IPO Share Option Scheme, where eligible employees and consultants are entitled to subscribe for the Shares for their contribution to the Group. As at 31 December 2020, 27,008,000 options remained outstanding under the Pre-IPO Share Option Scheme and none of the share options under the Pre-IPO Share Option Scheme have been exercised during 1HFY2021.
As at 31 December 2020, 19,270,000 options granted under the Post-IPO Share Option Scheme and none of the share options under the Post-IPO Share Option Scheme have been exercised during 1HFY2021.
The Company has also adopted the Share Award Scheme to provide an incentive and reward to selected participants for their contribution to the Group. Certain Shares have been purchased and no Shares have been granted under the Share Award Scheme during 1HFY2021.
Ϥ̮d͉ʮ̡͵મॶϣʮක೯ਯۃᒅٰ ᛆࠇྌʿϣʮක೯ਯܝᒅٰᛆࠇྌdϾ Υ༟ࣸ྇ࡰʿᚥਪΪ־ഃ࿁͉ණྠЪ্̈ ᘠϾϞᛆႩᒅٰ΅f 2020ϋ12˜31˚d 27,008,000΅ᒅٰᛆ֠͊࣬ኽϣʮක೯ਯ ۃᒅٰᛆࠇྌБԴdԨೌᒅٰᛆʊ2021ৌ ݁ϋܓɪ̒ϋ࣬ኽϣʮක೯ਯۃᒅٰᛆࠇ ྌᐏБԴf2020ϋ12˜31˚d࣬ኽϣʮ ක೯ਯܝᒅٰᛆࠇྌબ̈ٙ19,270,000΅ᒅ ٰᛆ֠͊ᐏБԴdԨೌᒅٰᛆʊ2021ৌ݁ ϋܓɪ̒ϋ࣬ኽϣʮක೯ਯܝᒅٰᛆࠇྌ ᐏБԴf ͉ʮ̡͵મॶٰ΅ᆤᎸࠇྌd˸ఱ፯֛ਞၾ ٫࿁͉ණྠЪ্̈ᘠϾΣ־ഃԶᆤᎸʿΫ జf2021ৌ݁ϋܓɪ̒ϋd͉ʮ̡ʊ࣬ኽ ٰ΅ᆤᎸࠇྌᒅɝ߰ʍٰ΅ϾԨೌબٰ̈΅f
The remuneration packages of the Directors are reviewed by the Remuneration Committee and approved by the Board, according to the relevant Director's experience, responsibility, workload and the time devoted to the Group, the Company's operating results and comparable market statistics.
ԫᑚཇ˙ࣩ͟ᑚཇ։ࡰึᄲቡԨ͟ԫึ ҭࡘdɗ࣬ኽᗫԫ᜕ٙeᔖபeʈЪ ඎʿ͉ණྠҳ׳ٙࣛගe͉ʮ̡ٙᐄุ ᐶʿ̙༟ˢ༰̹ఙᅰኽӔ֛f
INTERIM DIVIDEND
The Board has declared an interim dividend of HK1.00 cent per ordinary share for the six months ended 31 December 2020 (FY2020 interim dividend: HK0.65 cent). The interim dividend will be payable to the shareholders of the Company whose names appear on the register of members of the Company on Thursday, 18 March 2021. It is expected that the interim dividend will be paid on or about Friday, 9 April 2021.
中期股息
ԫึʊ܁ݼ࿚Ї2020ϋ12˜31˚˟ʬࡈ˜ ٙʕಂٰࢹӊٰ౷ஷٰ1.00ಥ̀€2020ৌ݁ϋ ܓ ʕ ಂ ٰ ࢹj0.65ಥ̀fʕಂٰࢹਗ਼ݼ˹ʚ 2021ϋ3˜18 ˚€ಂ̬Τΐ͉ʮٰ̡؇ Τ͉̅ٙʮٰ̡؇fཫಂʕಂٰࢹਗ਼2021 ϋ4˜9 ˚€ಂʞאۃܝݼ˹f
Corporate Governance Highlights 企業管治摘要
COMPLIANCE WITH THE CORPORATE GOVERNANCE PRACTICES
The Company is committed to maintaining high standards of corporate governance and transparency. The Company confirms that it has complied with the code provisions of the Corporate Governance Code contained in Appendix 14 to the Listing Rules during the six months ended 31 December 2020, save for the deviation from code provision A.2.1 as mentioned below.
遵守企業管治常規
͉ʮ̡ߧɢၪܵ৷˥̻ٙΆุ၍طʿீ ܓf͉ʮ̡ᆽႩdৰɨ˖הࠑ࿁Άุ၍ط ςۆୋ A.2.1 ૢʘࠅӋٙᕎ̮dՉ࿚Ї 2020ϋ12˜31˚˟ʬࡈ˜ʊ፭ςɪ̹ۆڝ ɤ̬ה༱ʘΆุ၍طςۆٙςۆૢ˖f
According to code provision A.2.1 of the Corporate Governance Code, the roles of the chairman and chief executive should be separate and should not be performed by the same individual.
Dr. Sun Yiu Kwong, the Chairman of the Board, is also the Chief Executive Officer. The Board believes that vesting the roles of both chairman and chief executive in an experienced and qualified person such as Dr. Sun Yiu Kwong provides the Company with strong and consistent leadership while allowing effective and efficient planning and implementation of business decisions and strategies. The Board considers that this structure will not impair the balance of power and authority between the Board and the management of the Group.
࣬ኽΆุ၍طςۆૢ˖ୋA.2.1ૢd˴ࢩၾБ ݁ ᐼ Ꮠ Ϟ ਜ ʱdԨ ʔ Ꮠ ͟ ɓ ɛ Ν ࣛ ࡒ f ᘴϪᔼ͛މԫึ˴ࢩ͵މБ݁ᐼf ԫึႩމd͟ᘴϪᔼ͛வᅵ᜕ᔮబٙΥ ༟ࣸɛɻዄ˴ࢩࡒБ݁ᐼ̙މ͉ʮ̡ Զ੶ϾϞɢձᖢ֛ٙჯኬdΝࣛᆽڭ࿁ุਕ ӔഄʿഄଫЪ̈Ϟࣖʿ৷ࣖٙྌձྼ݄f ԫึႩމdϤഐʔึᅂᚤ͉ණྠԫึ ၾ၍ଣᄴʘගٙᛆɢʿબᛆ̻ፅf
The Board will review the corporate governance structure and practices from time to time and shall make necessary arrangements when the Board considers appropriate.
ԫึਗ਼ʔࣛᄲቡΆุ၍طݖʿ੬dԨ ՉႩމቇࣛЪ̈̀ࠅτરf
THE BOARD
As of the date of this report, the Board comprised nine Directors, including six executive Directors, namely Dr. Sun Yiu Kwong as Chairman and Chief Executive Officer, Ms. Kwok Cheuk Kwan, Jacquen as Managing Director, Mr. Tsang On Yip, Patrick, Dr. Sun Man Kin, Michael, Mr. Lee Kar Chung, Felix and Dr. Lee Pak Cheung, Patrick; and three independent non-executive Directors, namely Mr. Lee Luen Wai, John BBS JP, Dr. Li Kwok Tung, Donald SBS JP and Mr. Yeung Wing Sun, Mike.
董事會
͉జѓ˚ಂdԫึ͟ɘЗԫଡ଼ϓd̍ ܼʬЗੂБԫdʱйމᘴϪᔼ͛€Ъމ˴ ࢩࡒБ݁ᐼeெՙёɾɻ€Ъމԫᐼ ଣeಀτุ͛e˖ᔼ͛eҽᑋ͛ ʿҽݡୂᔼ͛iʿɧЗዹͭڢੂБԫdʱ йމҽᑌਃ͛€ზഓঠd˄̻ɻeҽಊ ᔼ͛€ვഓঠd˄̻ɻʿเ⮹͛f
Corporate Governance Highlights 企業管治摘要
MODEL CODE FOR SECURITIES TRANSACTIONS
The Company has adopted the Model Code as its own code of conduct for dealing in securities of the Company by the Directors.
Having made specific enquiry with all Directors, the Company confirmed that the Directors have complied with the Model Code during the six months ended 31 December 2020.
Relevant employees who are likely to be in possession of inside information of the Group are also subject to compliance with the Code of Conduct for Securities Transactions by Employees on terms that are no less exacting than those set out in the Model Code.
To the best knowledge of the Company, there was no incident of non-compliance of the Code of Conduct for Securities Transactions by Employees during the six months ended 31 December 2020.
進行證券交易的標準守則
͉ʮ̡ʊમॶᅺςۆЪމԫ൯ር͉ʮ̡ ᗇՎٙБމςۆf ࿁ΌԫЪ̈Ոݟ༔ܝd͉ʮ̡ᆽႩ ԫ࿚Ї2020ϋ12˜31˚˟ʬࡈ˜ʫѩ፭ ςᅺςۆf ̙ঐ͉ණྠʫ࿇ऊࢹٙᗫ྇ࡰ͵፭ ς྇ࡰආБᗇՎʹٙςۆdՉૢಛʔ Ⴥᅺςۆהࠈᅺfఱ͉ʮ̡הٝd࿚ Ї2020ϋ12˜31˚˟ʬࡈ˜Ԩೌ̈ତ༼ˀ྇ ࡰආБᗇՎʹٙςۆٙઋرf
REVIEW OF INTERIM RESULTS
The Audit Committee, which comprises three independent non-executive Directors, namely Mr. Lee Luen Wai, John BBS JP (Chairman), Dr. Li Kwok Tung, Donald SBS JP and Mr. Yeung Wing Sun, Mike, has reviewed, together with the management of the Company, the unaudited interim results of the Group for the six months ended 31 December 2020 and considered that they were prepared in compliance with the relevant accounting standards, the Listing Rules and the applicable legal requirements, and that the Company has made appropriate disclosure thereof.
審閱中期業績
ᄲࣨ։ࡰึ͟ɧΤዹͭڢੂБԫଡ଼ϓdу ҽᑌਃ͛€ზഓঠd˄̻ɻ€˴ࢩeҽ ಊᔼ͛€ვഓঠe˄̻ɻʿเ⮹͛d־ ഃʊၾ͉ʮ̡၍ଣᄴᄲቡ͉ණྠ࿚Ї2020ϋ 12˜31˚˟ʬࡈ˜ٙ͊ᄲࣨʕಂุᐶdԨ Ⴉމ༈ഃʕಂุᐶʊ࣬ኽϞᗫึࠇۆeɪ ̹ۆʿቇ͜جܛ֛ᇜႡd˲͉ʮ̡ʊЪ ̈ቇמᚣf
DIRECTORS' AND CHIEF EXECUTIVE'S INTERESTS AND SHORT POSITIONS IN SHARES, UNDERLYING SHARES AND DEBENTURES
As at 31 December 2020, the interests and short positions of the Directors and Chief Executive of the Company in the shares, underlying shares and/or debentures (as the case may be) of the Company or any of its associated corporations (within the meaning of Part XV of the SFO) which were required to be notified to the Company and the Hong Kong Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which they were taken or deemed to have under such provisions of the SFO) or which were required to be entered into the register required to be kept by the Company under section 352 of the SFO or which were otherwise required to be notified to the Company and the Hong Kong Stock Exchange pursuant to the Model Code were set out below:
董事及最高行政人員於股份、相 關股份及債權證的權益及淡倉
2020ϋ12˜31˚dԫʿ͉ʮ̡௰৷Б݁ ɛࡰ͉ʮ̡אՉОᑌجྠ€່֛ԈᗇՎ ʿಂૢԷୋXV ʘٰ΅eᗫٰ΅ʿŊ אවᛆᗇ€ൖ˷ઋرϾ֛ʕdኹϞ࣬ኽᗇՎ ʿಂૢԷୋXVୋ7ʿୋ8ʱϾٝึ͉ ʮ̡ʿ࠰ಥᑌʹהʘᛆूʿ૱ࡑ€ܼ̍־ഃ࣬ ኽ༈ഃᗇՎʿಂૢԷૢ˖ϾൖЪאЪ ኹϞʘᛆूʿ૱ࡑdא࣬ኽᗇՎʿಂૢԷ ୋ352ૢা͉ʮ̡πໄʘ೮াΤ̅ʫʘ ᛆूʿ૱ࡑdא࣬ኽᅺςۆϾٝึ͉ʮ ̡ʿ࠰ಥᑌʹהʘᛆूʿ૱ࡑνɨj
(I)The Company
(I)
本公司
Name of Director 董事姓名
Long/short position 好倉╱淡倉
Dr. Sun Yiu Kwong ᘴϪᔼ͛
Long position λࡑ
Long position λࡑ
Long position λࡑ
Long position λࡑ
Capacity 身份
Number of Shares/ underlying shares 股份╱相關股份數目
Beneficial owner 17,548,000 ྼूኹϞɛ
Notes 附註
Interest held by his 248,463,278 1 controlled corporations ᛆू͟ՉછՓجྠܵϞ
Beneficial owner ྼूኹϞɛ
Beneficial owner ྼूኹϞɛ
700,000 3
2,300,000 4
Approximate percentage of shareholding 概約持股比例
(%)
269,011,278
35.13
Ms. Kwok Cheuk Kwan, Jacquen ெՙёɾɻ
Long position λࡑ
Long position λࡑ
Long position λࡑ
Long position λࡑ
Beneficial owner ྼूኹϞɛ
Beneficial owner ྼूኹϞɛ
Beneficial owner ྼूኹϞɛ
Beneficial owner ྼूኹϞɛ
17,948,657
11,380,000 2
500,000 3
1,500,000 4
31,328,657
4.09
Name of Director 董事姓名
Long/short position 好倉╱淡倉
Mr. Tsang On Yip, Patrick ಀτุ͛
Long position λࡑ
Long position λࡑ
Long position λࡑ
Long position λࡑ
Capacity 身份
Number of Shares/ underlying shares 股份╱相關股份數目
Beneficial owner 100,000 ྼूኹϞɛ
Notes 附註
Beneficial owner 600,000 2 ྼूኹϞɛ
Beneficial owner 400,000 3 ྼूኹϞɛ
Beneficial owner ྼूኹϞɛ
1,500,000 4
Approximate percentage of shareholding 概約持股比例
(%)
2,600,000
0.34
Dr. Sun Man Kin, Michael ˖ᔼ͛
Long position λࡑ
Long position λࡑ
Long position λࡑ
Beneficial owner ྼूኹϞɛ
Beneficial owner ྼूኹϞɛ
Beneficial owner ྼूኹϞɛ
16,142,000
400,000 3
1,500,000 4
18,042,000
2.36
Mr. Lee Kar Chung, Felix ҽᑋ͛
Long position λࡑ
Long position λࡑ
Long position λࡑ
Long position λࡑ
Beneficial owner ྼूኹϞɛ
Beneficial owner ྼूኹϞɛ
Beneficial owner ྼूኹϞɛ
Beneficial owner ྼूኹϞɛ
1,388,000
10,242,000 2
500,000 3
1,500,000 4
13,630,000
1.78
Dr. Lee Pak Cheung, Patrick ҽݡୂᔼ͛
Long position λࡑ
Long position λࡑ
Long position λࡑ
Beneficial owner ྼूኹϞɛ
Beneficial owner ྼूኹϞɛ
Beneficial owner ྼूኹϞɛ
20,042,959
400,000 3
1,500,000 4
21,942,959
2.87
ApproximateName of Director 董事姓名
Long/short position 好倉╱淡倉
Mr. Lee Luen Wai, John BBS JP ҽᑌਃ͛€ზഓঠd˄̻ɻ
Long position λࡑ
Long position λࡑ
Capacity 身份
Number of Shares/ underlying shares 股份╱相關股份數目
Beneficial owner 220,000 ྼूኹϞɛ
Beneficial owner 300,000 ྼूኹϞɛ
Notes 附註
percentage of shareholding 概約持股比例
(%)
4
520,000
0.07
Dr. Li Kwok Tung, Donald SBS JP ҽಊᔼ͛€ვഓঠd˄̻ɻ
Long position λࡑ
Long position λࡑ
Beneficial owner ྼूኹϞɛ
Beneficial owner ྼूኹϞɛ
328,000
300,000
4
628,000
0.08
Mr. Yeung Wing Sun, Mike เ⮹͛
Long position λࡑ
Long position λࡑ
Beneficial owner ྼूኹϞɛ
Beneficial owner ྼूኹϞɛ
Notes:
(1) Dr. Sun Yiu Kwong was deemed to be interested in the 203,457,278 Shares held by East Majestic Group Limited, being his controlled corporation, and was also deemed to be interested in 45,006,000 Shares held by EM Team Limited, also being his controlled corporation.
(2) These Shares represented the underlying Shares under the options granted by the Company on 18 August 2015 pursuant to the Pre-IPO Share Option Scheme.
(3) These Shares represented the share award granted by the Company on 17 July 2018 pursuant to the Share Award Scheme.
(4) These Shares represented the underlying Shares under the options granted by the Company on 6 November 2018 pursuant to the Post-IPO Share Option Scheme.
20,000
200,000
4
220,000
0.03
ڝൗj
(1) ᘴϪᔼ͛ൖމ־છՓʘجྠ East Majestic Group Limited ܵϞٙ 203,457,278ٰٰ΅ʕኹϞᛆूfᘴϪ ᔼ͛͵ൖމΝᅵމ־છՓʘجྠ EM Team Limited ܵϞٙ 45,006,000 ٰٰ΅ ʕኹϞᛆूf
(2) ༈ഃٰ΅ܸ͉ʮ̡2015ϋ8˜18˚࣬ኽ ϣʮක೯ਯۃᒅٰᛆࠇྌબ̈ٙᒅٰ ᛆධɨٙᗫٰ΅f
(3) ༈ഃٰ΅ܸ͉ʮ̡2018ϋ7˜17˚࣬ኽ ٰ΅ᆤᎸࠇྌબٰ̈ٙ΅ᆤᎸධɨٙ ᗫٰ΅f
(4) ༈ഃٰ΅ܸ͉ʮ̡2018ϋ11˜6˚࣬ኽ ϣʮක೯ਯܝᒅٰᛆࠇྌબ̈ٙᒅٰ ᛆධɨٙᗫٰ΅f
(II) Associated Corporations (within the meaning of the SFO)
Procare Medical Imaging & Laboratory Centre Limited(1)Long/short
(II) 相聯法團(定義見證券及期貨條例)
普康醫學影像及化驗中心有限公司(1)
Name of Director | position | Capacity |
董事姓名 | 好倉╱淡倉 | 身份 |
Dr. Sun Man Kin, Michael | Long position | Beneficial owner |
˖ᔼ͛ | λࡑ | ྼूኹϞɛ |
Causeway Bay MRI Centre Limited(2)
銅鑼灣磁力共振中心有限公司(2)
Long/short
Name of Director | position | Capacity |
董事姓名 | 好倉╱淡倉 | 身份 |
Dr. Sun Man Kin, Michael | Long position | Beneficial owner |
˖ᔼ͛ | λࡑ | ྼूኹϞɛ |
Notes: |
ڝൗj
(1) UMP Medical Centre Limited, a wholly-owned subsidiary of the
Company, holds 62.5% of the entire issued share capital of Procare Medical Imaging & Laboratory Centre Limited.
(2)UMP Medical Centre Limited, a wholly-owned subsidiary of the Company, holds 20% of the entire issued share capital of Causeway Bay MRI Centre Limited.
Number of percentage of shares shareholding 股份數目 概約持股比例
Approximate
(%)
625
6.25
Approximate
Number of percentage of shares shareholding 股份數目 概約持股比例
(%)
95
6.33
(1) ͉ʮ̡ٙΌ༟ڝ᙮ʮ̡ᑌΥᔼਕʕːϞ ࠢʮ̡ܵϞ౷ੰᔼኪᅂ྅ʿʷ᜕ʕːϞ ࠢʮ̡ٙΌʊ೯Бٰ͉ٙ62.5%f
(2) ͉ʮ̡ٙΌ༟ڝ᙮ʮ̡ᑌΥᔼਕʕːϞ ࠢʮ̡ܵϞზᝄှɢࣈʕːϞࠢʮ ̡ٙΌʊ೯Бٰ͉ٙ20%f
Save as disclosed above, as at 31 December 2020, none of | ৰɪ˖המᚣ̮d 2020 ϋ 12 ˜ 31 |
the Directors or Chief Executive of the Company had any | ˚dԫא͉ʮ̡௰৷Б݁ɛࡰ͉ʮ |
interests or short positions in the shares, underlying shares and | ̡ʿՉᑌجྠ€່֛ԈᗇՎʿಂૢ |
debentures of the Company and its associated corporations | ԷୋXV ʘٰ΅eᗫٰ΅ʿවᛆᗇ |
(within the meaning of Part XV of the SFO) which were | ʕd฿ೌኹϞ࣬ኽᗇՎʿಂૢԷୋXV |
required to be notified to the Company and the Hong Kong | ୋ7ʿୋ8ʱϾٝึ͉ʮ̡ʿ࠰ಥ |
Stock Exchange pursuant to Divisions 7 and 8 of Part XV of | ᑌʹהʘᛆूא૱ࡑ€ܼ̍־ഃ࣬ኽ༈ |
the SFO (including interests or short positions which they | ഃᗇՎʿಂૢԷૢ˖ϾൖЪאЪ |
were taken or deemed to have under such provisions of the | ኹϞʘᛆूא૱ࡑdאা࣬ኽ |
SFO), or were required, pursuant to Section 352 of the SFO, to | ᗇՎʿಂૢԷୋ352ૢπໄʘ೮াΤ |
be entered in the register referred to therein, or as otherwise | ̅ʫʘᛆूא૱ࡑdא࣬ኽᅺςۆϾ |
notified to the Company and the Hong Kong Stock Exchange | ٝึ͉ʮ̡ʿ࠰ಥᑌʹהʘᛆूא૱ |
pursuant to the Model Code. | ࡑf |
UPDATE ON DIRECTORS' INFORMATION | 董事資料更新 |
In accordance with Rule 13.51B(1) of the Listing Rules, the changes | ࣬ኽɪ̹ۆୋ 13.51B(1) ૢdІ̊೯͉ʮ |
in information required to be disclosed by Directors pursuant to | ̡2020 ϋϋజ˸Ըdԫ࣬ኽɪ̹ۆୋ |
paragraphs (a) to (e) and (g) of Rule 13.51(2) of the Listing Rules | 13.51(2) ૢୋ (a)Ї(e) ݬʿୋ (g) ݬʚמᚣٙ |
since the publication of the Company's 2020 Annual Report is set | ༟ࣘᜊਗ༱ΐνɨj |
out below: |
Name of Director 董事姓名
Details of Change 變動詳情
Dr. Li Kwok Tung, Donald SBS JP
ҽಊᔼ͛€ვഓঠd˄̻ɻ
Dr. Li was appointed as an independent non-executive director of Sino Biopharmaceutical Limited, a company incorporated in Cayman Islands with limited liability, the shares of which are listed on the main board of Stock Exchange (stock code: 1177), on 31 December 2020. ҽᔼ͛2020ϋ12˜31˚ᐏ։މʕ͛يႡᖹϞࠢʮ̡€ɓකਟ໊ࢥൗ ̅ϓͭٙϞࠢʮ̡dՉٰ΅ᑌʹה˴ؐɪ̹€ٰ΅˾j 1177 ٙዹͭڢੂ Бԫf
SHARE OPTION SCHEMES
The Company has adopted two share option schemes, namely the Pre-IPO Share Option Scheme and the Post-IPO Share Option Scheme.
購股權計劃
͉ʮ̡ʊમॶՇධᒅٰᛆࠇྌdуϣʮක ೯ਯۃᒅٰᛆࠇྌʿϣʮක೯ਯܝᒅٰᛆ ࠇྌf
(A) Pre-IPO Share Option Scheme | (A) | 首次公開發售前購股權計劃 |
The Company adopted the Pre-IPO Share Option Scheme on | ͉ʮ̡ʊ2015ϋ8˜18˚મॶϣʮ | |
18 August 2015 under which the maximum number of Shares | ක೯ਯۃᒅٰᛆࠇྌdהϞ֠͊БԴ | |
to be issued upon full exercise of all outstanding share options | ᒅٰᛆᐏᅰБԴܝdՉධɨ̙೯Б | |
is 27,008,000, being approximately 3.53% of the issued share | ʘٰ΅ᅰͦɪࠢމ27,008,000ٰdу͉ | |
capital of the Company as at 31 December 2020. | ʮ̡ 2020ϋ12˜31 ˚ʊ೯Бٰ͉ߒ | |
3.53%f | ||
Details of the options granted and outstanding under the | ϣʮක೯ਯۃᒅٰᛆࠇྌධɨબ̈ | |
Pre-IPO Share Option Scheme are set out as follows: | ʿ͊БԴٙᒅٰᛆ༉ઋ༱ΐνɨj | |
Number of Shares issuable under the share options | ||
購股權項下可予發行股份數目 |
Granted Exercised Cancelled/ during during Lapsed during the period the period the period 期內已 期內已授出 期內已行使 註銷╱失效
Grantee
承授人
Directors 董事
Ms. Kwok Cheuk Kwan, Jacquen ெՙёɾɻ
Mr. Tsang On Yip, Patrick ಀτุ͛
Mr. Lee Kar Chung, Felix ҽᑋ͛
Employees 僱員
In aggregate
Υ
Other eligible grantees 其他合資格承授人
In aggregate
Υ
Position
Date of grant
職位
授出日期
(dd/mm/yy)
€˚Ŋ˜Ŋϋ
Managing Director and Executive Director ԫᐼଣࡒੂБԫ
18/08/2015
Executive Director
18/08/2015
ੂБԫ
Executive Director
18/08/2015
ੂБԫ
-
18/08/2015
-
18/08/2015
Exercise price per ShareExercise period
每股行使價
行使期
(HK$)
(dd/mm/yy)
€ಥʩ €˚Ŋ˜Ŋϋ
1.2228
18/08/2016-26/11/2022 18/08/2017-26/11/2022
1.2228
18/08/2016-26/11/2022 18/08/2017-26/11/2022
As at 1 July 2020 於2020年 7月1日
1,138,000 - - - 1,138,000
10,242,000
60,000 - - - 60,000
540,000 - - - 540,000
1.2228
18/08/2017-26/11/2022 10,242,000
Sub-total: ʃࠇj
1.2228
18/08/2017-26/11/2022
22,222,000
3,186,000 - - - 3,186,000
Sub-total: ʃࠇj
3,186,000
1.2228
18/08/2016-26/11/2022 160,000
18/08/2017-26/11/2022 1,440,000
Sub-total: ʃࠇjTotal: ᐼࠇj
As at 31 December 2020 於2020年 12月31日
-
-
- 10,242,000
-
-
- 10,242,000
-
-
- 22,222,000
-
-
-
3,186,000
- -
- -
- -
160,000 1,440,000
1,600,000
-
-
-
1,600,000
27,008,000
-
-
-
27,008,000
As at 31 December 2020, 27,008,000 options remained outstanding under the Pre-IPO Share Option Scheme.
2020ϋ12˜31 ˚dϣʮක೯ਯۃ ᒅٰᛆࠇྌධɨϞ27,008,000΅ᒅٰᛆ ֠͊БԴf
(B) Post-IPO Share Option Scheme | 首次公開發售後購股權計劃 |
The Company adopted the Post-IPO Share Option Scheme on | ͉ʮ̡2015ϋ11˜2˚ʊમॶϣʮ |
2 November 2015 under which the maximum number of Share | ක೯ਯܝᒅٰᛆࠇྌdהϞ֠͊БԴ |
to be issued upon full exercise of all outstanding share option | ᒅٰᛆᐏᅰБԴՉධɨ̙೯Бʘٰ΅ |
is 19,270,000 Shares, being approximately 2.52% of the issue | ᅰͦɪࠢމ19,270,000ٰٰ΅dу͉ʮ |
share capital of the Company as at 31 December 2020. | ̡ 2020ϋ12˜31 ˚ʊ೯Бٰ͉ʘߒ |
2.52%f | |
Details of the options granted and outstanding under the | ϣʮක೯ਯܝᒅٰᛆࠇྌධɨʊબ̈ |
Post-IPO Share Option Scheme are set out as follows: | ʿ֠͊БԴʘᒅٰᛆ༉ઋ༱ΐνɨj |
Cancelled/ |
Lapsed during the period 期內已 註銷╱失效
Grantee 承授人
Directors 董事
Dr. Sun Yiu Kwong ᘴϪᔼ͛
Ms. Kwok Cheuk Kwan, Jacquen ெՙёɾɻ
Mr. Tsang On Yip, Patrick ಀτุ͛
Dr. Sun Man Kin, Michael ˖ᔼ͛
Mr. Lee Kar Chung, Felix ҽᑋ͛
Dr. Lee Pak Cheung, Patrick ҽݡୂᔼ͛
Mr. Lee Luen Wai, John BBS JP ҽᑌਃ͛€ზഓঠd˄̻ɻ
Position 職位
Chairman, Chief Executive Officer and Executive Director ˴ࢩeБ݁ᐼࡒ ੂБԫ
Managing Director and Executive Director ԫᐼଣࡒੂБԫ
Executive Director
ੂБԫ
Executive
ੂБԫ
Director
ExecutiveDirector
ੂБԫ
Executive Director
ੂБԫ
Independent
Non-executive Director ዹͭڢੂБԫ
Dr. Li Kwok Tung, Donald SBS JP Independent
ҽಊᔼ͛€ვഓঠd˄̻ɻ
Mr. Yeung Wing Sun, Mike เ⮹͛
Non-executive Director ዹͭڢੂБԫ
Independent
Non-executive Director ዹͭڢੂБԫ
Date of grant 授出日期
Exercise price per Share Exercise period 每股行使價 行使期
(dd/mm/yyyy)
(HK$) dd/mm/yyyy)
€˚Ŋ˜Ŋϋ
€ಥ ʩ €˚Ŋ˜Ŋϋ
(B)
As at 1 July 2020 於2020年 7月1日
Granted during the period 期內已授出
Exercised during the period 期內已行使
As at 31 December 2020 於2020年 12月31日
06/11/2018
2.06 30/06/2019
- 05/11/2023
2,300,000 - - - 2,300,000
06/11/2018
2.06 30/06/2019
- 05/11/2023
1,500,000 - - - 1,500,000
06/11/2018
2.06 30/06/2019
- 05/11/2023
1,500,000 - - - 1,500,000
06/11/2018
2.06 30/06/2019
- 05/11/2023
1,500,000 - - - 1,500,000
06/11/2018
2.06 30/06/2019
- 05/11/2023
1,500,000 - - - 1,500,000
06/11/2018
2.06 30/06/2019
- 05/11/2023
1,500,000 - - - 1,500,000
06/11/2018
2.06 30/06/2019
- 05/11/2023
300,000 - - - 300,000
06/11/2018
2.06 30/06/2019
- 05/11/2023
300,000 - - - 300,000
06/11/2018
2.06 30/06/2019
- 05/11/2023
200,000 - - - 200,000
Sub-total 小計
10,600,000
-
-
-
10,600,000
Cancelled/LapsedAs atGrantee 承授人
Employees 僱員
In aggregate
Υࠇ
Other eligible grantee(s)
其他合資格承授人
In aggregate
Υࠇ
Position 職位
€˚Ŋ˜Ŋϋ
Date of grant 授出日期
(dd/mm/yyyy)
06/11/2018
05/05/2019
05/05/2019
05/05/2019
23/03/2017
23/03/2017
06/11/2018
05/05/2019
05/05/2019
05/05/2019
As at | Granted | Exercised | during | 31 December | ||
Exercise price | 1 July 2020 | during | during | the period | 2020 | |
per Share | Exercise period | 於2020年 | the period | the period | 期內已 | 於2020年 |
每股行使價 | 行使期 | 7月1日 | 期內已授出 | 期內已行使 | 註銷╱失效 | 12月31日 |
(HK$) | dd/mm/yyyy) | |||||
340,000 | - | - | - | 340,000 | ||
330,000 | - | - | - | 330,000 | ||
1,000,000 | - | - | - | 1,000,000 | ||
750,000 | - | - | - | 750,000 | ||
1,500,000 | - | - | - | 1,500,000 | ||
2,250,000 | - | - | - | 2,250,000 | ||
6,170,000 | - | - | - | 6,170,000 | ||
1,000,000 | - | - | - | 1,000,000 | ||
250,000 | - | - | - | 250,000 | ||
500,000 | - | - | - | 500,000 | ||
750,000 | - | - | - | 750,000 | ||
2,500,000 | - | - | - | 2,500,000 | ||
19,270,000 | - | - | - | 19,270,000 |
€ಥ ʩ €˚Ŋ˜Ŋϋ
2.06 30/06/2017
- 29/06/2022
2.06 30/06/2018
- 29/06/2022
2.06 30/06/2019
- 05/11/2023
1.56 04/05/2020
- 03/05/2025
1.56 04/05/2021
- 03/05/2025
1.56 04/05/2022
- 03/05/2025
Sub-total 小計
2.06 30/06/2019
- 05/11/2023
1.56 04/05/2020
- 03/05/2025
1.56 04/05/2021
- 03/05/2025
1.56 04/05/2022
- 03/05/2025
Sub-total 小計
Total 總計
As at 31 December 2020, none of options granted under the Post-IPO Share Option Scheme during the six months ended 31 December 2020.
2020ϋ12˜31 ˚d฿ೌ࣬ኽϣʮ ක೯ਯܝᒅٰᛆࠇྌ࿚Ї2020ϋ12˜ 31˚˟ʬࡈ˜બ̈ᒅٰᛆf
SHARE AWARD SCHEME
The Company has adopted the Share Award Scheme on 30 June 2016 to recognise the contributions of and provide incentives for the key management personnel including Directors and senior management, employed experts and employees of the Group.
Subject to any early termination as may be determined by the Board, pursuant to the trust deed, the Share Award Scheme shall be valid and effective for a term of 10 years commencing on the adoption date. The maximum number of Shares which may be awarded to a selected participant under the Share Award Scheme shall not exceed 1% of the issued share capital of the Company in each year.
The Board shall not make any further award of the awarded Shares which will result in the nominal value of the Shares awarded by the Board under the Share Award Scheme exceeding 2% of the issued share capital of the Company from time to time.
股份獎勵計劃
͉ʮ̡ʊ 2016ϋ6˜30 ˚મॶٰ΅ᆤᎸࠇ ྌdྗᆤʿᆤᎸ˴ࠅ၍ଣɛࡰ€ܼ̍ԫʿ ৷ॴ၍ଣᄴe͉ණྠա྇ਖ਼ʿ྇ࡰהЪ ্ᘠfաԫึ̙ঐᔾ֛ٙОۃ˟ה ࠢd࣬ኽڦৄ۰ኽdٰ΅ᆤᎸࠇྌમॶ˚ ಂৎࠇɤϋಂගϞࣖʿ͛ࣖf࣬ኽٰ΅ᆤᎸ ࠇྌ̙બʚ፯֛ਞၾ٫ٰٙ΅ᅰͦɪࠢʔ ൴ཀ͉ʮ̡ϋʊ೯Бٰ͉ٙ1%fԫึʔ બ̈Оึኬߧԫึ࣬ኽٰ΅ᆤᎸࠇྌ બ̈൴ཀ͉ʮ̡ʔࣛʊ೯Бٰ͉2%ʘٰ΅ࠦ ࠽ٙආɓӉᆤᎸٰ΅f
Details of the share award granted and outstanding under the Share Award Scheme are set out as follows:
ٰ΅ᆤᎸࠇྌධɨʊબ̈ʿ֠͊БԴʘٰ΅ ᆤᎸ༉ઋ༱ΐνɨj
Name or category of participant 參與人姓名或類別
As at 1 July 2020 於2020年7月1日
Granted during the period 期內授出
Vested during the period 期內歸屬
Cancelled/lapsed during the period 期內註銷╱失效
As at 31 December 2020 於2020年12月31日
Directors ԫ
2,900,000
-
-
-
2,900,000 (Note 1) €ڝൗ1
Other eligible grantee(s)
Չ˼Υ༟ࣸוબɛ
In aggregate 總計
400,000
2,330,000
-
-
5,630,000
-
-
-
-
-
-
400,000
(Note 1)
€ڝൗ1
2,330,000
(Note 1)
€ڝൗ1
-
5,630,000
Note:
ڝൗj
1. | These awarded shares were granted on 17 July 2018 with the exercise price | 1. | ϤഃᆤᎸٰ΅݊2018ϋ7˜17˚બ̈dБԴᄆ |
of HK$1.5 per award shares. | މӊٰᆤᎸٰ΅1.5ಥʩf |
Certain Shares have been purchased and no Shares have been granted under the Share Award Scheme during the period and none of shares have been vested during the period up to 31 December 2020.
ಂʫʊ࣬ኽٰ΅ᆤᎸࠇྌᒅ൯߰ʍٰ΅ʿԨ ೌબٰ̈΅dٜЇ2020ϋ12˜31˚˟ಂගԨ ೌٰ΅ᓥ᙮f
SUBSTANTIAL SHAREHOLDERS' INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES OF THE COMPANY
As at 31 December 2020, so far as was known to the Directors of the Company, the following persons/entities (other than the Directors or Chief Executive of the Company) had, or were deemed to have, interests or short positions in the Shares or underlying shares of the Company which would fall to be disclosed to the Company and the Hong Kong Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO, or which were recorded in the register required to be kept by the Company under Section 336 of the SFO:
主要股東於本公司股份及相關股 份的權益及淡倉
2020ϋ12˜31˚dኽ͉ʮ̡ԫהٝd˸ ɨɛɻŊྼ€ԫא͉ʮ̡௰৷Б݁ɛࡰৰ ̮͉ʮ̡ʘٰ΅אᗫٰ΅ʕኹϞאൖ މኹϞ˸ɨᛆूא૱ࡑϾ࣬ኽᗇՎʿಂ ૢԷୋXVୋ2ʿ3ʱૢ˖Σ͉ʮ̡ʿ࠰ ಥᑌʹהמᚣdאা͉ʮ̡࣬ኽᗇՎ ʿಂૢԷୋ336ૢπໄʘ೮াΤ̅ʫj
Name of substantial shareholder
主要股東姓名╱名稱
East Majestic Group LimitedEM Team Limited
Cheng Yu Tung Family
(Holdings II) LimitedCheng Yu Tung Family
(Holdings) Limited
Chow Tai Fook Capital LimitedChow Tai Fook (Holding) Limited մɽ၅€છٰϞࠢʮ̡
Chow Tai Fook Enterprises Limited մɽ၅ΆุϞࠢʮ̡
Healthcare Ventures
China Resources Company Limited ʕശᆗϞࠢʮ̡
Long/short position
好倉╱淡倉
Capacity
身份
Long position λࡑ
Beneficial owner ྼूኹϞɛ
Long position λࡑ
Beneficial owner ྼूኹϞɛ
Long position λࡑ
Interest held by its controlled corporations ᛆू͟ՉછՓجྠܵϞ
Long position λࡑ
Interest held by its controlled corporations ᛆू͟ՉછՓجྠܵϞ
Long position λࡑ
Interest held by its controlled corporation ᛆू͟ՉછՓجྠܵϞ
Long position λࡑ
Interest held by its controlled corporations ᛆू͟ՉછՓجྠܵϞ
Long position λࡑ
Interest held by its controlled corporation ᛆू͟ՉછՓجྠܵϞ
Long position λࡑ
Beneficial owner ྼूኹϞɛ
Long position λࡑ
Interest held by its controlled corporations ᛆू͟ՉછՓجྠܵϞ
CR Medical ശᆗᔼᐕ
Long position λࡑ
Interest held by its controlled corporations ᛆू͟ՉછՓجྠܵϞ
Number of Shares/ underlying shares
股份╱相關股份數目
Interests under equity derivatives 股本衍生工具 項下之權益
NotesApproximate percentage of shareholding
附註
概約持股比例
(%)
203,457,278 - 1 26.57
45,006,000 - 1 5.88
112,687,939 - 2 14.72
112,687,939 - 2 14.72
112,687,939 - 2 14.72
112,687,939 - 2 14.72
112,687,939 - 2 14.72
112,687,939 - 2 14.72
91,803,000 - 3 11.99
91,803,000 - 3 11.99
Notes:
1. Dr. Sun Yiu Kwong was deemed to be interested in the 203,457,278 Shares held by East Majestic Group Limited, being his controlled corporation, and was also deemed to be interested in the 45,006,000 Shares held by EM Team Limited, also being his controlled corporation. Dr. Sun's interests in Shares are disclosed in this interim report in the section headed "Directors' and Chief Executive interests and Short Positions in Shares, Underlying Shares and Debentures".
2. Healthcare Ventures was wholly owned by Chow Tai Fook Enterprises Limited ("CTFE"), which was wholly owned by Chow Tai Fook (Holding) Limited ("CTFH"). So far as the Company is aware, CTFH was held as to 81.03% by Chow Tai Fook Capital Limited ("CTFC"), which was in turn held as to 48.98% by Cheng Yu Tung Family (Holdings) Limited ("CYTF") and as to 46.65% by Cheng Yu Tung Family (Holdings II) Limited ("CYTFII"). By virtue of the SFO, CTFE, CTFH, CTFC, CYTF and CYTFII were deemed to be interested in the same parcel of Shares in which Healthcare Ventures was interested.
3. Pinyu Limited was the beneficial owner of the Shares. Pinyu Limited was wholly owned by Unison Champ Premium Limited, which was wholly owned by CR Medical. CR Medical was held as to 35.76% by CRH (Medical) Limited and as to 0.82% by Commotra Company Limited. CRH (Medical) Limited was wholly owned by China Resources Healthcare Group Limited, which was wholly owned by CRH (Healthcare) Limited. Both CRH (Healthcare) Limited and Commotra Company Limited were wholly owned by China Resources (Holdings) Company Limited, which was wholly owned by CRC Bluesky Limited. CRC Bluesky Limited was wholly owned by China Resources INC, which was wholly owned by China Resources Company Limited. By virtue of the SFO, Unison Champ Premium Limited, CR Medical, CRH (Medical) Limited, China Resources Healthcare Group Limited, CRH (Healthcare) Limited, China Resources INC, China Resources (Holdings) Company Limited, CRC Bluesky Limited and China Resources Company Limited were deemed to be interested in the same parcel of Shares in which Pinyu Limited was interested.
ڝൗj
1. ᘴϪᔼ͛ൖމ־છՓʘجྠ East Majestic Group LimitedܵϞٙ203,457,278ٰٰ΅ʕኹ Ϟᛆूfᔼ͛͵ൖމΝᅵ͟־છՓʘج ྠ EM Team LimitedܵϞٙ45,006,000ٰٰ΅ʕ ኹϞᛆूfᔼٰ͛΅ʘᛆूʊ͉ʕಂజ ѓ˜ԫʿ௰৷Б݁ɛࡰٰ΅eᗫٰ΅ʿව ᛆᗇٙᛆूʿ૱ࡑ™ɓືמᚣf
2. ᔼᐕ௴ุછٰ͟մɽ၅ΆุϞࠢʮ̡€˜մɽ၅ Άุ™Ό༟ኹϞdϾմɽ၅Άุ͟մɽ၅€છ ٰϞ ࠢ ʮ ̡€˜ CTFH ™Ό༟ኹϞfఱ͉ʮ̡ הٝdCTFH͟Chow Tai Fook Capital Limited €˜ CTFC ™ܵ Ϟ81.03% ٰٙᛆdϾ CTFC ʱй ͟Cheng Yu Tung Family (Holdings) Limited €˜CYTF™ʿCheng Yu Tung Family (Holdings
II) Limited€˜ CYTFII ™ܵ Ϟ48.98%ʿ46.65% ٰٙᛆf࣬ኽᗇՎʿಂૢԷdմɽ၅Άุe CTFHeCTFCeCYTFʿCYTFIIൖމᔼᐕ௴ ุછٰኹϞᛆूٙΝɓҭٰ΅ʕኹϞᛆूf
3. ۜ༃Ϟࠢʮ̡މٰ΅ʘྼूኹϞɛfۜ༃Ϟ ࠢʮ̡͟ Unison Champ Premium LimitedΌ ༟ኹϞdϾUnison Champ Premium Limited͟ ശᆗᔼᐕΌ༟ኹϞfശᆗᔼᐕ͟ശᆗණྠ€ᔼ ᐕϞࠢʮ̡ኹϞ 35.76%˸ʿ͟Υ൱Ϟࠢʮ̡ ኹϞ0.82% fശᆗණྠ€ᔼᐕϞࠢʮ̡͟ശᆗ ੰණྠϞࠢʮ̡Ό༟ኹϞdϾശᆗੰණྠ Ϟࠢʮ̡͟ശᆗණྠ€ੰϞࠢʮ̡Ό༟ኹ Ϟfശᆗණྠ€ੰϞࠢʮ̡ʿΥ൱Ϟࠢʮ ̡ѩ͟ശᆗ€ණྠϞࠢʮ̡Ό༟ኹϞdϾശ ᆗ€ණྠϞࠢʮ̡͟ CRC Bluesky LimitedΌ ༟ኹϞfCRC Bluesky Limited͟ശᆗٰ΅Ϟࠢ ʮ̡Ό༟ኹϞdϾശᆗٰ΅Ϟࠢʮ̡͟ʕശ ᆗϞࠢʮ̡Ό༟ኹϞf࣬ኽᗇՎʿಂૢԷd Unison Champ Premium Limitedeശᆗᔼᐕe ശᆗණྠ€ᔼᐕϞࠢʮ̡eശᆗੰණྠϞࠢ ʮ̡eശᆗණྠ€ੰϞࠢʮ̡eശᆗٰ΅Ϟ ࠢʮ̡eശᆗ€ණྠϞࠢʮ̡e CRC Bluesky LimitedʿʕശᆗϞࠢʮ̡ൖމۜ༃Ϟࠢ ʮ̡ኹϞᛆूٙΝɓҭٰ΅ʕኹϞᛆूf
According to disclosure of interest filings available on the Stock Exchange website, Snow Lake China Master Fund, Ltd. ("SLCMF") and Snow Lake China Master Long Fund, Ltd. ("SLCMLF") beneficially owned 100,000,000 and 20,640,000 Shares respectively. Snow Lake Capital (HK) Limited ("SLCHKL"), which was wholly controlled by Mr. Ma Sean, was the investment manager to both SLCMF and SLCMLF respectively. Accordingly, Mr. Ma Sean and SLCHKL were deemed to be interested in aggregate holding of 120,640,000 Shares owned by SLCMF and SLCMLF pursuant to the SFO, representing, for illustrative purpose, 15.75% of the total issued share capital of the Company as at 31 December 2020. Out of these 120,640,000 Shares, 86,984,000 Shares (representing, for illustrative purpose, 11.36% of the total issued share capital of the Company as at 31 December 2020) are interests in cash-settled equity derivatives.
Other than as disclosed above, as at 31 December 2020, the Directors have not been notified by any person (other than the Directors or Chief Executive of the Company) who had interests or short positions in the Shares or underlying shares of the Company as recorded in the register required to be kept pursuant to Section 336 of the SFO.
࣬ኽᑌʹהၣ१̙ٙᛆूמᚣ༟ࣘdSnow Lake China Master Fund, Ltd€. ˜SLCMF™ʿ Snow Lake China Master Long Fund, Ltd. €˜ SLCMLF ™ʱйྼूኹϞ 100,000,000 ٰʿ 20,640,000 ٰٰ΅f͟৵Іთ͛Ό ༟છՓٙ Snow Lake Capital (HK) Limited €˜SLCHKL™މSLCMFʿSLCMLFʘҳ༟၍ଣ ɛfΪϤd࣬ኽᗇՎʿಂૢԷd৵Іთ ͛ʿSLCHKLൖމSLCMFʿSLCMLFΥ ܵϞʘ120,640,000 ٰٰ΅ʕኹϞᛆू€සԶ Ⴍ͜d2020ϋ12˜31˚͉ʮ̡ʊ ೯Бٰ͉ᐼᕘ15.75%)f༈120,640,000ٰ ٰ΅ʕd86,984,000ٰٰ΅€සԶႭ͜d 2020ϋ12˜31˚͉ʮ̡ʊ೯Бٰ͉ᐼ ᕘ11.36%މ˸ତږഐၑٰᛆࠃ͛ʈՈʘ ᛆूf ৰɪ˖מᚣ̮d2020ϋ12˜31˚dԫԨ ೌٝОɛɻ€ԫא͉ʮ̡௰৷Б݁ɛࡰ ৰ̮͉ʮٰ̡΅אᗫٰ΅ʕኹϞ࣬ኽᗇ ՎʿಂૢԷୋ336ૢπໄٙ೮াΤ̅הা ٙᛆूא૱ࡑf
INTERIM DIVIDEND
The Board declared an interim dividend of HK1.00 cent (the corresponding period in 2019: HK0.65 cent) per Share for the six months ended 31 December 2020.
中期股息
ԫึݼ˹࿚Ї2020ϋ12˜31˚˟ʬࡈ˜ٙ ʕಂٰࢹӊٰ1.00ಥ̀€2019ϋΝಂj0.65ಥ ̀f
The interim dividend will be payable to the shareholders of the Company whose names appear on the register of members of the Company on Thursday, 18 March 2021. It is expected that the interim dividend will be paid on or about Friday, 9 April 2021.
ʕಂٰࢹਗ਼ݼ˹ʚ 2021ϋ3˜18˚€ ಂ ̬Τΐ͉ʮٰ̡؇Τ̅ɪʘ͉ʮٰ̡؇fཫ ಂʕಂٰࢹਗ਼2021ϋ4˜9˚€ಂʞאۃ ܝݼ˹f
CLOSURE OF REGISTER OF MEMBERS
Book close dates
(both days inclusive)
Latest time to lodge transfer with share registrar
: Tuesday, 16 March 2021 to Thursday, 18 March 2021
: 4:30 p.m. on Monday,
15 March 2021
暫停辦理股份過戶手續
ᅲ৾፬ଣٰ΅ཀ˒
j
2021ϋ3˜16˚€ ಂ ɚЇ
೮া˚ಂ€҈
2021ϋ3˜18˚€ ಂ ̬
Շ˂ܼ̍ίʫ
ٰ΅ཀ˒೮া࿚˟
j
2021ϋ3˜15˚€ ಂ ɓd
፬ଣٰ΅ཀ˒
ɨʹ̬ࣛɧɤʱ
ٰ΅ཀ˒೮াήᓃ j ࠰ಥٰ΅ཀ˒೮াʱஈ
ՙԳᗇՎ೮াϞࠢʮ̡
࠰ಥ
ެΧɽ༸؇183
Υձʕː54ᅽ
PURCHASE, SALE OR REDEMPTION OF THE
購買、出售或贖回本公司上市證
COMPANY'S LISTED SECURITIES
券
During the six months ended 31 December 2020, neither the
࿚Ї2020ϋ12˜31˚˟ʬࡈ˜d͉ʮ̡ʿ͉
Company nor any of its subsidiaries has purchased, sold or
ʮ̡Оڝ᙮ʮ̡฿ೌᒅ൯ëਯאᛙΫ͉
redeemed any of the Company's listed securities.
ʮ̡Оɪ̹ᗇՎf
SUFFICIENCY OF THE PUBLIC FLOAT
足夠公眾持股量
Based on the information publicly available to the Company and
ఱ͉ʮ̡הʘʮක༟ࣘהͪdԨኽԫה
to the best knowledge, information and belief of the Directors, the
ଉٝeהʿהڦdԫᆽႩ࿚Ї2020ϋ12
Directors confirm that the Company had maintained a sufficient
˜31˚˟ʬࡈ˜͉ʮ̡ʊၪܵɪ̹ۆה
public float as required under the Listing Rules during the six months
֛ʘ̂ԑʮٰܵඎf
ended 31 December 2020.
On behalf of the Board
˾ڌԫึ
Dr. Sun Yiu Kwong
孫耀江醫生
Chairman and Chief Executive Officer
˴ࢩࡒБ݁ᐼ
Hong Kong, 25 February 2021
࠰ಥd2021ϋ2˜25˚
Address of share registrar
: Hong Kong Branch Share Registrar Tricor Investor Services Limited Level 54, Hopewell Centre 183 Queen's Road East
Hong Kong
Condensed Consolidated Statement of Profit or Loss 簡明綜合損益表
Six months ended 31 December 2020
࿚Ї2020 ϋ 12 ˜ 31˚˟ʬࡈ˜
Six months ended 31 December 截至12月31日止六個月
2020 | 2019 | |||
2020年 | 2019ϋ | |||
Notes | HK$'000 | HK$'000 | ||
ڝൗ | 千港元 | ɷಥʩ | ||
(Unaudited) | (Unaudited) | |||
(未經審核) | €͊ᄲࣨ | |||
REVENUE | 收入 | 5 | 302,143 | 306,813 |
Other income and gains | Չ˼ϗɝʿϗू | 5 | 3,827 | 10,922 |
Professional services expenses | ਖ਼ุਕ൬͜ | (110,765) | (122,181) | |
Employee benefit expense | ࡰʈ၅лක˕ | (60,045) | (72,585) | |
Property rental and related expenses | يุॡږʿᗫක˕ | (4,129) | (6,270) | |
Cost of inventories consumed | ʊঃπϓ͉ | (15,006) | (15,455) | |
Depreciation and amortisation | ұᔚʿᛅቖ | (40,432) | (35,392) | |
Other expenses, net | Չ˼˕̈ଋᕘ | (32,233) | (6,378) | |
Finance cost | ፄ༟ϓ͉ | (1,975) | (1,968) | |
Share of profits and losses of: | ʱЦлᆗʿᑦฦj | |||
Joint ventures | Υ༟ʮ̡ | - | (169) | |
Associates | ᑌᐄʮ̡ | 1,182 | 967 | |
PROFIT BEFORE TAX | 除稅前利潤 | 6 | 42,567 | 58,304 |
Income tax expense | ה൬͜ | 7 | (9,993) | (9,138) |
PROFIT FOR THE PERIOD | 期內利潤 | 32,574 | 49,166 | |
Attributable to: | ˸ɨ˙ᏐЦj | |||
Owners of the Company | ͉ʮ̡ኹϞɛ | 31,079 | 45,551 | |
Non-controlling interests | ڢછٰᛆू | 1,495 | 3,615 | |
32,574 | 49,166 | |||
EARNINGS PER SHARE | 本公司普通權益持有人應佔 | |||
ATTRIBUTABLE TO ORDINARY EQUITY | 每股盈利 | |||
HOLDERS OF THE COMPANY | 9 | |||
Basic | ਿ͉ | HK4.105 cents港仙 | HK6.046 centsಥ̀ | |
Diluted | ᛅᑛ | HK4.105 cents港仙 | HK5.990 centsಥ̀ |
Condensed Consolidated Statement of Comprehensive Income 簡明綜合全面收入表
Six months ended 31 December 2020 ࿚Ї2020 ϋ 12 ˜ 31˚˟ʬࡈ˜
PROFIT FOR THE PERIOD
期內利潤
Six months ended 31 December 截至12月31日止六個月
2020 2020年 HK$'000 千港元
(Unaudited)
(未經審核)
2019 2019ϋ HK$'000 ɷಥʩ
(Unaudited)
€͊ᄲࣨ
49,166
OTHER COMPREHENSIVE INCOME/(LOSS)
Other comprehensive income/(loss) that may be reclassified to profit or loss in subsequent periods:
Exchange differences on translation of foreign operations
Share of other comprehensive loss of an associate
Reclassification adjustments for amount transferred to profit or loss on disposal of a subsidiary
其他全面收入╱(虧損)
Չܝಂග̙ঐࠠอʱᗳЇฦू
ٙՉ˼ΌࠦϗɝŊ€ᑦฦj ұၑऎุ̮ਕٙිгࢨᕘ ʱЦɓගᑌᐄʮ̡ٙՉ˼Όࠦ ᑦฦ ̈ਯɓගڝ᙮ʮ̡ࣛࠠอʱᗳ ሜᔷɝЇฦूʘږᕘ
Net other comprehensive income/(loss) that may Չܝಂග̙ঐࠠอʱᗳЇฦूٙ
be reclassified to profit or loss in subsequent periods
Չ˼ΌࠦϗɝŊ€ᑦฦଋᕘ
2,494 (587)
- (18)
-
(605)Other comprehensive loss that will not be reclassified to profit or loss in subsequent periods:
Changes in fair value of equity investments designated at fair value through other comprehensive income
ՉܝಂගʔึࠠอʱᗳЇฦू
ٙՉ˼Όࠦᑦฦj ܸ֛މܲʮʪᄆ࠽ࠇɝՉ˼
Όࠦϗɝʘٰ͉ҳ༟ٙ ʮʪᄆ࠽ᜊਗ
(2,411) (11,376)
OTHER COMPREHENSIVE INCOME/(LOSS)
FOR THE PERIOD, NET OF TAX
期內其他全面收入╱(虧損),
扣除稅項
1,362 (11,981)
TOTAL COMPREHENSIVE INCOME
FOR THE PERIOD
期內全面收入總額
37,185
Attributable to:
Owners of the Company Non-controlling interests
˸ɨ˙ᏐЦj ͉ʮ̡ኹϞɛ ڢછٰᛆू
32,441 33,570
1,495 3,615
37,185
31 December 2020 2020 ϋ 12 ˜ 31˚
31 December | 30 June | |||
2020 | 2020 | |||
2020年 | 2020ϋ | |||
12月31日 | 6˜30˚ | |||
Notes | HK$'000 | HK$'000 | ||
ڝൗ | 千港元 | ɷಥʩ | ||
(Unaudited) | (Audited) | |||
(未經審核) | €ᄲࣨ | |||
NON-CURRENT ASSETS | 非流動資產 | |||
Property, plant and equipment | يุeᅀגʿண௪ | 10 | 99,081 | 96,424 |
Right-of-use assets | Դ͜ᛆ༟ପ | 75,455 | 82,152 | |
Goodwill | ਠᚑ | 11 | 171,264 | 171,264 |
Other intangible assets | Չ˼ೌҖ༟ପ | 75,769 | 76,972 | |
Investments in associates | ᑌᐄʮ̡ٙҳ༟ | 9,729 | 8,546 | |
Financial assets at amortised cost | ܲᛅቖϓ͉ࠇඎٙږፄ༟ପ | 12 | 32,878 | 20,206 |
Investments at fair value through other | ܲʮʪᄆ࠽ࠇɝՉ˼Όࠦϗɝ | |||
comprehensive income | ٙҳ༟ | 13 | 21,814 | 23,187 |
Deferred tax assets | ַධ༟ପ | 1,865 | 1,691 | |
Deposits | 43,116 | 21,977 | ||
Total non-current assets | ڢݴਗ༟ପᐼᕘ | 530,971 | 502,419 | |
CURRENT ASSETS | 流動資產 | |||
Inventories | π | 12,492 | 9,083 | |
Trade receivables | ൱Ꮠϗಛධ | 14 | 85,067 | 74,354 |
Prepayments, other receivables and | ཫ˹ಛධeՉ˼Ꮠϗಛධʿ | |||
other assets | Չ˼༟ପ | 36,609 | 32,423 | |
Financial assets at fair value through | ܲʮʪᄆ࠽ࠇɝฦूٙ | |||
profit or loss | ږፄ༟ପ | 14,522 | 1,723 | |
Financial assets at amortised cost | ܲᛅቖϓ͉ࠇඎٙږፄ༟ପ | 12 | 17,120 | 35,646 |
Due from associates | Ꮠϗᑌᐄʮ̡ಛධ | 3,100 | 2,204 | |
Due from related companies | Ꮠϗᗫᑌʮ̡ಛධ | 1,186 | 1,220 | |
Tax recoverable | ̙ϗΫධ | 356 | 210 | |
Pledged deposits | תץπಛ | 1,029 | 1,354 | |
Cash and cash equivalents | ତږʿତږഃᄆي | 235,016 | 230,671 | |
Total current assets | ݴਗ༟ପᐼᕘ | 406,497 | 388,888 |
ڭᗇږ
31 December 2020 2020 ϋ 12 ˜ 31˚
31 December | 30 June | |||
2020 | 2020 | |||
2020年 | 2020ϋ | |||
12月31日 | 6˜30˚ | |||
Notes | HK$'000 | HK$'000 | ||
ڝൗ | 千港元 | ɷಥʩ | ||
(Unaudited) | (Audited) | |||
(未經審核) | €ᄲࣨ | |||
CURRENT LIABILITIES | 流動負債 | |||
Trade payables | ൱Ꮠ˹ಛධ | 15 | 40,997 | 36,370 |
Other payables and accruals | Չ˼Ꮠ˹ಛධʿᏐࠇ൬͜ | 88,709 | 62,584 | |
Due to associates | Ꮠ˹ᑌᐄʮ̡ಛධ | 18 | 184 | |
Due to related companies | Ꮠ˹ᗫᑌʮ̡ಛධ | 4,491 | 2,020 | |
Due to a joint venture | Ꮠ˹ɓගΥ༟ʮ̡ಛධ | 34 | 203 | |
Lease liabilities | ॡ༣ࠋව | 51,391 | 43,420 | |
Tax payable | Ꮠ˹ධ | 18,566 | 14,994 | |
Total current liabilities | ݴਗࠋවᐼᕘ | 204,206 | 159,775 | |
NET CURRENT ASSETS | 流動資產淨額 | 202,291 | 229,113 | |
TOTAL ASSETS LESS CURRENT | 總資產減流動負債 | |||
LIABILITIES | 733,262 | 731,532 | ||
NON-CURRENT LIABILITIES | 非流動負債 | |||
Lease liabilities | ॡ༣ࠋව | 31,646 | 43,145 | |
Deferred tax liabilities | ַධࠋව | 14,242 | 14,572 | |
Provision | ᅡ௪ | 3,360 | 3,308 | |
Total non-current liabilities | ڢݴਗࠋවᐼᕘ | 49,248 | 61,025 | |
Net assets | ༟ପଋᕘ | 684,014 | 670,507 | |
EQUITY | 權益 | |||
Equity attributable to owners of the | 本公司擁有人應佔權益 | |||
Company | ||||
Issued capital | ʊ೯Бٰ͉ | 16 | 766 | 766 |
Reserves | Ꮇ௪ | 623,767 | 611,080 | |
624,533 | 611,846 | |||
Non-controlling interests | ڢછٰᛆू | 59,481 | 58,661 | |
Total equity | ᛆूᐼᕘ | 684,014 | 670,507 | |
2020/2021 INTERIM REPORT |
Condensed Consolidated Statement of Changes in Equity 簡明綜合權益變動表
Six months ended 31 December 2020
࿚Ї2020 ϋ 12 ˜ 31˚˟ʬࡈ˜
Attributable to owners of the Company 本公司擁有人應佔
Shares held for theShareCapitalIssued capitalpremium contributionaccountreserve
award scheme 就股份 獎勵計劃 持有的 股份
share Share-basedpayment reserve 以股份 為基礎 支付的 儲備
Fair value reserveLegal reserve
Exchange fluctuation reserveRetained profitsTotalNon-controlling interests
Total equity
已發行 股本
股份 溢價賬
出資 儲備
公允 價值儲備
法定儲備
匯兌波動 儲備
留存 利潤
合計
非控股 權益
權益 總額
Notes ڝൗ
HK$'000 ɷಥʩ
HK$'000 ɷಥʩ
HK$'000 ɷಥʩ
HK$'000 ɷಥʩ
HK$'000 ɷಥʩ
HK$'000 ɷಥʩ
HK$'000 ɷಥʩ
HK$'000 ɷಥʩ
HK$'000 ɷಥʩ
HK$'000 ɷಥʩ
HK$'000 ɷಥʩ
HK$'000 ɷಥʩ
At 1 July 2019
ಂʫлᆗ
(unaudited and restated) Profit for the period
Other comprehensive income/(loss) ಂʫՉ˼ΌࠦϗɝŊfor the period:
Changes in fair value of equityinvestments at fair value through ɝʘٰ͉ҳ༟ٙʮʪᄆ࠽
other comprehensive incomeExchange differences on translation ұၑऎุ̮ਕٙිгࢨᕘ of foreign operations
Share of other comprehensive loss of an associate
ಂʫΌࠦϗɝŊ€ᑦฦ
Total comprehensive income/(loss)for the period
˸ᛆूഐၑʘτર
Equity-settled arrangementsDividends paid/payable to non-controlling interests Purchase of shares for the share award scheme
Acquisition of non-controlling interest
Disposal of a subsidiary Transfer to legal reserveAt 31 December 2019 (unaudited) 2019ϋ12˜31˚ €͊ᄲࣨ
2020ϋ6˜30 ˚€ᄲࣨ397,612*(13,430)*(22,301)*169,409*670,507
ಂʫлᆗ
At 30 June 2020 (audited) Profit for the period
Other comprehensive income/(loss) for the period: Changes in fair value of equityinvestments at fair value through ɝʘٰ͉ҳ༟ٙʮʪᄆ࠽
other comprehensive incomeExchange differences on translation ұၑऎุ̮ਕٙිгࢨᕘ of foreign operations
ಂʫΌࠦϗɝŊ€ᑦฦ
Reclassification adjustments for amount transferred to profit or loss on disposal of a subsidiary Total comprehensive income/(loss)for the period
˸ᛆूഐၑʘτર Dividends paid to non-controlling ʊ˹ڢછٰᛆूٙ
Equity-settled arrangementsinterests
Purchase of shares for the share award scheme
Final 2020 dividend Transfer to legal reserve At 31 December 2020 (unaudited)
*These reserve accounts comprise the consolidated reserves of HK$623,767,000 (30 June 2020: HK$611,080,000) in the condensed consolidated statement of financial position.
*
༈ഃᎷ௪ሪܼ̍ᔊၝΥৌਕًرڌʫʘ ၝΥᎷ௪ 623,767,000 ಥ ʩ€ 2020ϋ6˜30˚j 611,080,000ಥ ʩf
Condensed Consolidated Statement of Cash Flows 簡明綜合現金流量表
Six months ended 31 December 2020 ࿚Ї2020 ϋ 12 ˜ 31˚˟ʬࡈ˜
Six months ended 31 December 截至12月31日止六個月
2020 | 2019 | |||
2020年 | 2019ϋ | |||
Notes | HK$'000 | HK$'000 | ||
ڝൗ | 千港元 | ɷಥʩ | ||
(Unaudited) | (Unaudited) | |||
(未經審核) | €͊ᄲࣨ | |||
CASH FLOWS FROM OPERATING | 經營活動的現金流量 | |||
ACTIVITIES | ||||
Profit before tax | ৰۃлᆗ | 42,567 | 58,304 | |
Total non-cash adjustments | ڢତږሜᐼᕘ | 47,928 | (57,987) | |
Total working capital adjustments | ᐄ༶༟ږሜᐼᕘ | (37,455) | 106,986 | |
Cash generated from operations | 經營業務產生的現金 | 53,040 | 107,303 | |
Interest received | ʊϗлࢹ | 84 | 902 | |
Hong Kong profits tax paid | ʊ˹࠰ಥл | (7,071) | (356) | |
Overseas taxes paid | ʊ˹ऎ̮ධ | - | (2,578) | |
Net cash flows from operating activities | 經營活動產生的現金流量淨額 | 46,053 | 105,271 | |
CASH FLOWS FROM INVESTING | 投資活動的現金流量 | |||
ACTIVITIES | ||||
Acquisition of a subsidiary/a business | ϗᒅڝ᙮ʮ̡Ŋุਕ | 17 | - | (8,932) |
Purchases of items of property, plant | ᒅ൯يุeᅀגʿண௪ධͦ | |||
and equipment | (14,978) | (17,763) | ||
Proceeds from disposal of a subsidiary | ̈ਯڝ᙮ʮ̡ٙהಛධ | - | 1,422 | |
Purchases of debt investments at fair value | ᒅ൯ܲʮʪᄆ࠽ࠇɝՉ˼Όࠦ | |||
through other comprehensive income | ϗɝٙවਕҳ༟ | (494) | - | |
Proceeds from redemption of | ᛙΫܲᛅቖϓ͉ࠇඎ | |||
financial assets at amortised cost | ٙږፄ༟ପהಛධ | 18,843 | 12,471 | |
Purchase of investments at fair value | ᒅ൯ܲʮʪᄆ࠽ࠇɝ | |||
through profit or loss | ฦूٙҳ༟ | (12,602) | - | |
Purchase of financial assets | ᒅ൯ܲᛅቖϓ͉ࠇඎ | |||
at amortised cost | ٙږፄ༟ପ | (12,989) | (15,317) | |
Other investing activities | Չ˼ҳ༟ݺਗ | 2,093 | 5,694 |
Condensed Consolidated Statement of Cash Flows 簡明綜合現金流量表
Six months ended 31 December 2020
࿚Ї2020 ϋ 12 ˜ 31˚˟ʬࡈ˜
Six months ended 31 December 截至12月31日止六個月
Net cash used in investing activities | 投資活動使用的現金淨額 |
CASH FLOWS FROM FINANCING | 融資活動的現金流量 |
ACTIVITIES | |
Principal portion of lease payments | ॡ༣˹ಛ͉ٙږʱ |
Other financing activities | Չ˼ፄ༟ݺਗ |
Net cash flows used in financing activities | 融資活動使用的 |
現金流量淨額 | |
NET INCREASE IN CASH | 現金及現金等價物增加淨額 |
AND CASH EQUIVALENTS | |
Effect of foreign exchange rate changes, net | ̮ිිଟᜊਗʘᅂᚤ€ଋᕘ |
Cash and cash equivalents at beginning of | ಂڋତږʿତږഃᄆي |
period | |
CASH AND CASH EQUIVALENTS AT END | 期末現金及現金等價物 |
OF PERIOD | |
ANALYSIS OF BALANCES OF CASH AND | 現金及現金等價物結餘分析 |
CASH EQUIVALENTS | |
Cash and bank balances | ତږʿვБπಛ |
Cash and cash equivalents as stated in the | ᔊၝΥତږݴඎڌʫΐʘ |
condensed consolidated statement of cash | ତږʿତږഃᄆي |
flows |
2020 | 2019 | |
2020年 | 2019ϋ | |
Notes | HK$'000 | HK$'000 |
ڝൗ | 千港元 | ɷಥʩ |
(Unaudited) | (Unaudited) | |
(未經審核) | €͊ᄲࣨ | |
(20,127) | (22,425) | |
(21,612) | (22,849) | |
(844) | (26,184) | |
(22,456) | (49,033) | |
3,470 | 33,813 | |
875 | 346 | |
230,671 | 207,644 | |
235,016 | 241,803 | |
235,016 | 241,803 | |
235,016 | 241,803 |
1. CORPORATE AND GROUP INFORMATION | 1. | 公司及集團資料 |
UMP Healthcare Holdings Limited is a limited liability | ᑌΥᔼਕණྠϞࠢʮ̡މίකਟ໊ࢥൗ | |
company incorporated in the Cayman Islands. The principal | ̅ϓͭٙϞࠢபʮ̡f͉ʮ̡˴ࠅᐄ | |
place of business of the Company is located at Room 1404- | ุήᓃމ࠰ಥᅃႾ༸ʕ71͑τණྠɽ | |
1408, 14/F., Wing On House, 71 Des Voeux Road Central, | ข14ᅽ1404-1408܃f | |
Hong Kong. | ||
During the period, the Group was principally engaged in the | ͉ಂගd͉ණྠٙ˴ࠅุਕމԶᔼ | |
provision of healthcare services which include: | ᐕڭਕdܼ̍j | |
2. |
"Listing").
• corporate healthcare solution services;
• medical and dental services;
• medical imaging and laboratory services;
• other auxiliary medical services; and
• healthcare management services.
The shares of the Company were listed on the Main Board of the Hong Kong Stock Exchange on 27 November 2015 (the
2. BASIS OF PREPARATION
The unaudited condensed consolidated financial statements of the Group for the six months ended 31 December 2020 have been prepared in accordance with the Hong Kong Accounting Standard ("HKAS") 34 "Interim Financial Reporting" issued by the Hong Kong Institute of Certified Public Accountants ("HKICPA"). They have been prepared under the historical cost convention, except for equity investments, debt investments and a contingent consideration receivable which have been measured at fair value. The unaudited condensed consolidated financial statements are presented in Hong Kong dollars and all values are rounded to the nearest thousand except when otherwise indicated.
• Άุᔼᐕڭ༆Ӕ˙ࣩਕi
• ᔼᐕʿ˫߅ਕi
• ᔼኪᅂ྅ʿʷ᜕ਕi
• Չ˼Ⴞпᔼᐕਕiʿ
• ᔼᐕڭ၍ଣਕf ͉ʮٰ̡΅ 2015ϋ11˜27 ˚ί࠰ಥ ᑌʹה˴ؐɪ̹€˜ɪ̹™f
編製基準
͉ණྠ࿚Ї 2020ϋ12˜31 ˚˟ʬࡈ˜ ʘ͊ᄲࣨᔊၝΥৌਕజڌɗ࣬ኽ࠰ ಥึࠇࢪʮึ€˜࠰ಥึࠇࢪʮึ™б ٙ࠰ಥึࠇۆ€˜࠰ಥึࠇۆ™ୋ34 ˜ʕಂৌਕజѓ™ϾᇜႡfৰ˸ʮʪᄆ ࠽ࠇඎٰ͉ٙҳ༟eවਕҳ༟˸ʿᏐϗ אϞ˾ᄆ̮d͊ᄲࣨᔊၝΥৌਕజ ڌʊ࣬ኽዝ̦ϓ͉جᇜႡf͊ᄲࣨᔊ ၝΥৌਕజڌ˸ಥʩяΐd˲ৰ̤Ϟ ܸ٫̮dהϞږᕘѩ̬વʞɝЇ௰ટ ڐٙɷЗᅰf
The unaudited condensed consolidated financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual consolidated financial statements for the year ended 30 June 2020.
͊ᄲࣨᔊၝΥৌਕజڌԨʔܼ̍ϋ ܓৌਕజڌהცٙהϞ༟ࣘʿמᚣdԨ Ꮠၾ͉ණྠ࿚Ї2020ϋ6˜30˚˟ϋܓ ʘϋܓၝΥৌਕజڌɓԻቡᛘf
CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES
3. 會計政策及披露變動
The accounting policies adopted in the preparation of the unaudited condensed consolidated financial statements of the Group for the six months ended 31 December 2020 are consistent with those followed in the preparation of the Group's annual consolidated financial statements for the year ended 30 June 2020, except for the adoption of the following new and revised Hong Kong Financial Reporting Standards ("HKFRSs"), which are effective for the Group's annual period beginning on 1 July 2020.
ᇜႡ͉ණྠ࿚Ї 2020ϋ12˜31 ˚˟ʬ ࡈ˜ʘ͊ᄲࣨᔊၝΥৌਕజڌהમ ٙ͜ึࠇ݁ഄၾᇜႡ͉ණྠ࿚Ї 2020 ϋ6˜30˚˟ϋܓʘϋܓၝΥৌਕజڌ הમ͜٫ɓߧdઓમॶ˸ɨ͉ණྠ 2020ϋ7˜1˚කʘϋܓಂග͛ࣖʘอ ࠈʿࡌࠈ࠰ಥৌਕజѓۆ€˜࠰ಥৌ ਕజѓۆ™ৰ̮f
• Amendments to HKFRS 3, Definition of a Business
• ࠰ಥৌਕజѓۆୋ3 ʘ ࡌ ࠈุ ਕʘ່֛
• Amendment to HKFRS 16, Covid-19-Related Rent Concessions
• ࠰ಥৌਕజѓۆୋ16ʘࡌࠈ อۨڿًषݭषʘᗫॡږಯе
The Group has not applied any new standard or interpretation | ͉ණྠԨೌᏐ͜О͉ึࠇಂග֠͊ |
that is not yet effective for the current accounting period. | ͛ࣖٙอۆא༕ᙑfમॶࡌࠈ࠰ಥ |
Impacts of the adoption of the amended HKFRSs are discussed | ৌਕజѓۆٙᅂᚤীሞνɨj |
below: | |
Amendment to HKFRS 16, Covid-19-Related Rent Concessions | ࠰ಥৌਕజѓۆୋ16ʘࡌࠈอۨڿ |
ًषݭषʘᗫॡږಯе | |
The amendment provides a practical expedient that allows | ϞᗫࡌࠈԶྼਕᛆ֝τરdʪוॡ |
a lessee to by-pass the need to evaluate whether certain | ɛˡ൙ПݔԬΪอۨڿًषݭषɽݴ |
qualifying rent concessions occurring as a direct consequence | БٜટˏߧٙୌΥૢٙॡږಯе€˜อ |
of the COVID-19 pandemic ("COVID-19-related rent | ۨڿًषݭषʘᗫॡږಯе™݊щ᙮ |
concessions") are lease modifications and, instead, account for | ॡ༣ࡌࠈdϾ݊ਗ਼ϞᗫॡږಯеЪމڢ |
those rent concessions as if they were not lease modifications. | ॡ༣ࡌࠈɝሪf |
Rent concessions received have been accounted for as | ʊϗՑٙॡږಯеʊЪމᙃ೯༈ഃ˹ಛ |
negative variable lease payments recognised in profit or loss in | ٙԫאૢ೯͛ಂගٙࠋओਗॡ༣˹ |
the period in which the event or condition that triggers those | ಛίฦूʕɝሪf࿁2020ϋ7˜1˚ٙಂ |
payments occurred. There is no impact on the opening balance | ڋᛆूഐቱԨೌᅂᚤf |
of equity at 1 July 2020. |
4. OPERATING SEGMENT INFORMATION | 4. | 經營分部資料 |
For management purposes, the Group is organised into | ఱ၍ଣϾԊd͉ණྠਿՉପۜʿਕ | |
business units based on their products and services and has | ଡ଼ᔌุਕఊЗ༶ᐄd˲ϞνɨՇࡈ̙я | |
two reportable operating segments as follows: | జᐄʱj |
(a) Corporate healthcare solution services ("Corporate Healthcare Solution Services to Contract Customers") segment engages in the provision of corporate healthcare solutions to contract customers; and
(a) Άุᔼᐕڭ༆Ӕ˙ࣩਕ€˜Σ Υߒ܄˒ԶΆุᔼᐕڭ༆Ӕ ˙ࣩਕ™ʱމΥߒ܄˒Զ Άุᔼᐕڭ༆Ӕ˙ࣩiʿ
(b) Clinical healthcare services ("Clinical Healthcare Services") segment engages in the provision of medical and dental services, health check-up and other auxiliary services.
(b) ᑗґᔼᐕڭਕ€˜ᑗґᔼᐕڭ ਕ™ܼ̍Զᔼᐕʿ˫߅ ਕeੰᏨݟʿՉ˼Ⴞпਕf
Management monitors the results of the Group's operating | ၍ଣᄴʱй္છ͉ණྠᐄʱุٙ |
segments separately for the purpose of facilitating | ᐶd˸лک༟๕ʱৣʿุᐶ൙ПٙӔഄ |
decision-making process of resources allocation and | ݴfʱุᐶਿ̙яజʱлᆗŊ |
performance assessment. Segment performance is evaluated | ᑦฦ൙Пdމሜৰۃлᆗٙࠇඎ |
based on reportable segment profit/loss, which is a | ˙جfሜৰۃлᆗܲၾ͉ණྠৰ |
measurement of adjusted profit before tax. The adjusted profit | ۃлᆗɓߧٙ˙όࠇඎdʕʔܼ̍ |
before tax is measured consistently with the Group's profit | лࢹϗɝeՉ˼ϗɝʿϗूeʱЦΥ༟ |
before tax excluding interest income, other income and gains, | ʮ̡ʿᑌᐄʮ̡ฦू˸ʿᐼ፬ԫஈʿʮ |
and share of profits and losses of joint ventures and associates | ̡ක˕f |
as well as head office and corporate expenses. | |
Inter-segment sales and transfers are transacted with reference | ʱගቖਯʿᔷᜫɗਞϽܲࣛତБ̹ |
to the selling prices used for sales made to third parties at the | ᄆΣୋɧ˙ቖਯٙਯᄆஈଣf |
then prevailing market prices. |
OPERATING SEGMENT INFORMATION
(Continued)
(a) Revenue and results
Six months ended 31
December 2020 (unaudited)
Segment revenue (note 5):
External sales Inter-segment sales
Reconciliation:
Elimination of inter-segment sales
Revenue
Segment results Reconciliation: Interest income
Other income and gains Share of profits and losses of:
Joint ventures
Associates Corporate and other unallocated expenses, net Profit before tax
4. 經營分部資料€ᚃ
(a) 收入及業績
Corporate Healthcare
Solution
Services to
Contract Customers 向合約客戶 提供企業 醫療保健 解決方案服務
HK$'000 千港元
Clinical Healthcare
Services
臨床醫療 保健服務
HK$'000 千港元
Total
合計
HK$'000 千港元
4. OPERATING SEGMENT INFORMATION
(Continued)
(a) Revenue and results (Continued)
Six months ended 31
December 2019 (unaudited)
截至2019年12月31日止 六個月(未經審核)
4. 經營分部資料€ᚃ
(a) 收入及業績€ᚃ
Corporate
Healthcare
Solution
Services to
Contract Customers
ΣΥߒ܄˒
ԶΆุ ᔼᐕڭ ༆Ӕ˙ࣩਕ
HK$'000 ɷಥʩ
Clinical Healthcare
Services
ᑗґᔼᐕ ڭਕ
HK$'000 ɷಥʩ
Total
Υࠇ
HK$'000 ɷಥʩ
Segment revenue (note 5):
External sales Inter-segment sales
分部收入(附註 5): ̮ቖਯ ʱගቖਯ
Reconciliation:
Elimination of inter-segment sales
Revenue
Segment results Reconciliation: Interest income
Other income and gains Share of profits and losses of:
Joint ventures
Associates Corporate and other unallocated expenses, net Profit before tax
ሜືj ʱගቖਯתቖ
132,418 174,395 306,813
791 133,209
51,640 52,431 226,035 359,244
ϗɝ
(52,431) 306,813
分部業績 ሜືj
21,927
30,902 52,829
лࢹϗɝ 3,054
Չ˼ϗɝʿϗू 7,868 ʱЦлᆗʿᑦฦj
Υ༟ʮ̡ (169)
ᑌᐄʮ̡ 967 ʮ̡ʿՉ˼͊ʱৣ
ක˕ଋᕘ ৰۃлᆗ
(6,245) 58,304
4. OPERATING SEGMENT INFORMATION
(Continued)
(b) Information about major customers
Revenue from a major customer which accounted for
10% or more of the Group's revenue from the Corporate
Healthcare Solution Services to Contract Customers
segment is set out below:
Customer A
4. 經營分部資料€ᚃ
(b) 主要客戶資料
ԸІɓΤ˴ࠅ܄˒€Ц͉ණྠԸІ ΣΥߒ܄˒ԶΆุᔼᐕڭ༆ Ӕ˙ࣩਕʱٙϗɝٙ10%א˸ ɪٙ܄˒ٙϗɝ༱ΐνɨj
Six months ended 31 December 截至12月31日止六個月
܄˒A
2020
2019
2020年
2019ϋ
HK$'000
HK$'000
千港元
ɷಥʩ
(Unaudited)
(Unaudited)
(未經審核)
€͊ᄲࣨ
20,654
22,095
5. REVENUE, OTHER INCOME AND GAINS
An analysis of revenue is as follows:
Revenue from contracts with customers
Provision of corporate healthcare solution services:
Medical services Dental services
Provision of clinical healthcare services:
Medical services
Dental services
5. 收入、其他收入及收益
ϗɝʘʱؓνɨj
Six months ended 31 December 截至12月31日止六個月
2020 2020年 HK$'000 千港元
(Unaudited)
(未經審核)
2019 2019ϋ HK$'000 ɷಥʩ
(Unaudited)
€͊ᄲࣨ
5. REVENUE, OTHER INCOME AND GAINS | 收入、其他收入及收益€ᚃ |
(Continued) | |
Disaggregated revenue information | 經分拆之收入資料 |
Six months ended 31 December 2020 | 截至2020年12月31日止六個月 |
Corporate |
Healthcare
SegmentsType of services
Medical services Dental services
Total revenue from contracts with customers
Geographical markets
Hong Kong and Macau PRC
Total revenue from contracts with customers
分部
Contract Customers 向合約客戶 提供企業 醫療保健 解決方案服務
5.
Solution Services to
HK$'000 千港元
Clinical Healthcare
Services
臨床醫療 保健服務
HK$'000 千港元
Total
合計
HK$'000 千港元
5. | REVENUE, OTHER INCOME AND GAINS | 收入、其他收入及收益€ᚃ |
(Continued) | ||
Disaggregated revenue information (Continued) | 經分拆之收入資料€ᚃ | |
Six months ended 31 December 2019 | ࿚Ї2019ϋ12˜31˚˟ʬࡈ˜ | |
Corporate |
Healthcare
Segments
ʱ
Type of services
Medical services
Dental services
Total revenue from contracts with customers
服務類型 ᔼᐕਕ ˫߅ਕ ܄˒Υߒϗɝᐼᕘ
Geographical markets
Hong Kong and Macau
PRC
Total revenue from contracts with customers
地理市場 ࠰ಥʿዦژ ʕ ܄˒Υߒϗɝᐼᕘ
5.
Solution Services to
Contract Customers
ΣΥߒ܄˒
ԶΆุ ᔼᐕڭ ༆Ӕ˙ࣩਕ
HK$'000 ɷಥʩ
119,962 12,456
132,418
129,123 3,295
132,418
Clinical Healthcare
Services
ᑗґᔼᐕ ڭਕ
HK$'000 ɷಥʩ
Total
Υࠇ
HK$'000 ɷಥʩ
145,952 265,914 28,443 40,899
174,395
306,813
149,993 279,116 24,402 27,697
174,395
306,813
5. REVENUE, OTHER INCOME AND GAINS | 5. | 收入、其他收入及收益€ᚃ |
(Continued) | ||
An analysis of other income and gains is as follows: | Չ˼ϗɝʿϗूٙʱؓνɨj | |
Six months ended 31 December | ||
截至12月31日止六個月 |
2020 | 2019 | ||
2020年 | 2019ϋ | ||
HK$'000 | HK$'000 | ||
千港元 | ɷಥʩ | ||
(Unaudited) | (Unaudited) | ||
(未經審核) | €͊ᄲࣨ | ||
Other income and gains | 其他收入及收益 | ||
Administrative support fees | Б݁˕౪൬͜ | 341 | 663 |
Bank interest income | ვБлࢹϗɝ | 84 | 902 |
Interest income on financial assets at | ܲᛅቖϓ͉ࠇඎٙږፄ༟ପٙ | ||
amortised cost | лࢹϗɝ | 1,345 | 1,962 |
Interest income on investments at fair value | ܲʮʪᄆ࠽ࠇɝՉ˼Όࠦ | ||
through other comprehensive income | ϗɝٙҳ༟ٙлࢹϗɝ | 189 | 190 |
Dividend income from investments at fair | ܲʮʪᄆ࠽ࠇɝՉ˼Όࠦ | ||
value through other comprehensive | ϗɝٙҳ༟ٰٙࢹϗɝ | ||
income | - | 4,447 | |
Dividend income from financial assets at | ܲʮʪᄆ࠽ࠇɝฦूʘږፄ | ||
fair value through profit or loss | ༟ପٰٙࢹϗɝ | 61 | 66 |
Gain on disposal of subsidiaries | ̈ਯڝ᙮ʮ̡ٙϗू | - | 1,162 |
Others | Չ˼ | 1,807 | 1,530 |
3,827 | 10,922 |
PROFIT BEFORE TAX
The Group's profit before tax is arrived at after charging/ (crediting):
6. 除稅前利潤
͉ණྠٙৰۃлᆗɗϔৰŊ€ࠇɝɨ
ΐධܝ̈j
Six months ended 31 December 截至12月31日止六個月
2020 | 2019 | ||
2020年 | 2019ϋ | ||
HK$'000 | HK$'000 | ||
千港元 | ɷಥʩ | ||
(Unaudited) | (Unaudited) | ||
(未經審核) | €͊ᄲࣨ | ||
Amortisation of intangible assets | ೌҖ༟ପᛅቖ | 1,203 | 1,203 |
Depreciation of property, plant | يุeᅀגʿண௪ұᔚ | ||
and equipment | 12,096 | 10,897 | |
Depreciation of right-of-use assets | Դ͜ᛆ༟ପұᔚ | 27,133 | 23,292 |
Equity-settled share-based payment | ˸ᛆूഐၑ˸ٰ΅މਿᓾٙ | ||
expense (including employees and | ˹ಛක˕€ܼ̍྇ࡰʿਖ਼ุ | ||
professional consultants) | ᚥਪ | 709 | 2,714 |
Reversal of equity-settled share-based | ᅡΫ˸ᛆूഐၑ˸ٰ΅މ | ||
payment expense | ਿᓾٙ˹ಛක˕ | - | (15,150) |
Fair value (gain)/loss on financial assets | ܲʮʪᄆ࠽ࠇɝฦूʘږፄ | ||
at fair value through profit or loss | ༟ପٙʮʪᄆ࠽€ϗूŊᑦฦ | (197) | 81 |
Foreign exchange differences, net | ිгࢨᕘଋ࠽ | (103) | (16) |
Gain on disposal of subsidiaries | ̈ਯڝ᙮ʮ̡ٙϗू | - | (1,162) |
Loss on disposal of a subsidiary | ̈ਯڝ᙮ʮ̡ٙᑦฦ | 1,279* | - |
Write-off of items of property, plant | ቖيุeᅀגʿண௪ධͦ | ||
and equipment | - | 153 | |
Impairment of other assets | Չ˼༟ପʘಯ࠽ | 4,082 | - |
Impairment of deposit | ܲږʘಯ࠽ | 4,146 | - |
* | The loss on disposal of a subsidiary above is excluded in note 5 | ɪΐٙ̈ਯڝ᙮ʮ̡ٙᑦฦԨʔܼ̍ί |
"Revenue, other income and gains". | ڝൗ5 ˜ϗɝeՉ˼ϗɝʿϗू™ʘʫf |
*
7. INCOME TAX | 7. | 所得稅 |
Hong Kong profits tax has been provided at the rate of | ࠰ಥлʊಂʫ࿁࠰ಥପ͛ٙПࠇ | |
16.5% (six months ended 31 December 2019: 16.5%) on | Ꮠሙлᆗܲ16.5% €࿚Ї2019ϋ12˜ | |
the estimated assessable profits arising in Hong Kong during | 31 ˚˟ʬࡈ˜j 16.5% ٙଟࠇᅡ | |
the period. Taxes on profits assessable elsewhere have been | ௪fՉ˼ήਜᏐሙлᆗٙධ͉ܲණ | |
calculated at the rates of tax prevailing in the countries/ | ྠุਕהίŊ̡جᛆਜٙତБଟ | |
jurisdictions in which the Group operates. | ࠇၑf | |
Six months ended 31 December | ||
截至12月31日止六個月 |
2019 2019ϋ HK$'000 ɷಥʩ
Current - Hong Kong
Charge for the period
Current - Mainland China/Macau
Charge for the period
Deferred
Total tax charge for the period
2020 2020年 HK$'000 千港元
(Unaudited)
(未經審核)
(Unaudited)
€͊ᄲࣨ
DIVIDENDS
The proposed interim dividend of HK1.00 cent per ordinary share in respect of the year ending 30 June 2021 was approved by the board of directors on 25 February 2021. The interim dividend of HK0.65 cent per ordinary share in respect of the year ended 30 June 2020 was approved by the board of directors on 26 February 2020.
8. 股息
Six months ended 31 December 截至12月31日止六個月
2020 | 2019 |
2020年 | 2019ϋ |
HK$'000 | HK$'000 |
千港元 | ɷಥʩ |
(Unaudited) | (Unaudited) |
(未經審核) | €͊ᄲࣨ |
Dividend recognised as distribution during the period: ಂʫᆽႩމʱݼʘٰࢹj Final dividend for the year ended 30 June 2020: HK2.65 cents (year ended 30 June 2019: HK2.55 cents) per ordinary share ࿚Ї2020ϋ6˜30˚˟ϋܓʘ ͋ಂٰࢹj ӊٰ౷ஷٰ2.65 ಥ̀€࿚Ї 2019ϋ6˜30˚˟ϋܓj 2.55ಥ̀ | 20,293 | 19,324 |
Dividend proposed after the end of the జѓಂ͋ܝᏝݼٰࢹjreporting period: Interim dividend for the six months ended 31 December 2020: HK1.00 cent (six months ended 31 December 2019: HK0.65 cent) per ordinary share ࿚Ї2020ϋ12˜31˚˟ ʬࡈ˜ʘʕಂٰࢹj ӊٰ౷ஷٰ1.00ಥ̀ €࿚Ї2019ϋ12˜31˚˟ ʬࡈ˜j0.65ಥ̀ | 7,754 | 4,926 |
Ϟᗫ࿚Ї2021ϋ6˜30˚˟ϋܓʘᏝݼ ʕಂٰࢹӊٰ౷ஷٰ1.00ಥ̀2021ϋ 2˜25˚ᐏԫึҭࡘfϞᗫ࿚Ї2020 ϋ6˜30˚˟ϋܓʘʕಂٰࢹӊٰ౷ஷ ٰ0.65 ಥ̀ 2020ϋ2˜26 ˚ᐏԫึ ҭࡘf
The final dividend of HK2.65 cents per ordinary share, with a scrip dividend alternative, in respect of the year ended 30 June 2020 was approved by the Company's shareholders at the annual general meeting held on 20 November 2020. The final dividend of HK2.55 cents per ordinary share in respect of year ended 30 June 2019 was approved by the Company's shareholders at the annual general meeting held on 20
November 2019.
Ϟᗫ࿚Ї2020ϋ6˜30˚˟ϋܓʘ͋ಂ ٰࢹӊٰ౷ஷٰ2.65 ಥ̀€ஹΝ˸ٰ˾ ࢹ፯ධ 2020ϋ11˜20˚ᑘБʘٰ؇ ϋɽึɪᐏ͉ʮٰ̡؇ҭࡘfϞᗫ࿚ Ї2019ϋ6˜30˚˟ϋܓʘ͋ಂٰࢹӊ ٰ౷ஷٰ 2.55 ಥ̀ 2019ϋ11˜20˚ ᑘБʘٰ؇ϋɽึɪᐏ͉ʮٰ̡؇ҭ ࡘf
9.
EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE COMPANY
The calculation of the basic earnings per share amount is based on the unaudited consolidated profit for the six months ended 31 December 2020 attributable to ordinary equity holders of the Company of HK$31,079,000, and the weighted average number of ordinary shares of 757,019,355 in issue during the period. The calculation of the basic earnings per share amount for the six months ended 31 December 2019 was based on the unaudited consolidated profit of HK$45,551,000, and the weighted average number of ordinary shares of 753,422,467 in issue which have excluded the shares held under the share award scheme during the period.
9. 本公司普通權益持有人應佔每 股盈利
࿚Ї 2020 ϋ 12 ˜ 31 ˚˟ʬࡈ˜ʘӊ ٰਿ͉ޮлږᕘɗਿಂʫ͉ʮ̡౷ ஷᛆूܵϞɛᏐЦ͊ᄲࣨၝΥлᆗ 31,079,000ಥʩʿಂʫʊ೯Б౷ஷٰ̋ ᛆ̻ѩٰᅰ 757,019,355 ٰࠇၑf࿚Ї 2019ϋ12˜31 ˚˟ʬࡈ˜ʘӊٰਿ͉ ޮлږᕘɗਿಂʫ͊ᄲࣨၝΥлᆗ 45,551,000ಥʩʿಂʫʊ೯Б౷ஷٰ̋ ᛆ̻ѩٰᅰ753,422,467ٰ€ϤԨʔܼ̍ ٰ΅ᆤᎸࠇྌධɨཫवٰٙ΅ࠇၑf
The calculation of the diluted earnings per share amount is based on the unaudited consolidated profit for the six months ended 31 December 2020 attributable to ordinary equity holders of the Company of HK$31,079,000. The weighted average number of ordinary shares used in the calculation is the number of ordinary shares of 757,019,355 in issue during the period and excluded the shares held under the share award scheme, as used in the basic earnings per share calculation, and the weighted average number of ordinary shares of 102,542 assumed to have been issued at no consideration on the deemed exercise of all share options and shares under the share award scheme into ordinary shares.
࿚Ї 2020 ϋ 12 ˜ 31 ˚˟ʬࡈ˜ʘӊ ٰᛅᑛޮлږᕘɗਿಂʫ͉ʮ̡౷ ஷᛆूܵϞɛᏐЦ͊ᄲࣨၝΥлᆗ 31,079,000ಥʩfࠇၑהٙ͜౷ஷٰ̋ ᛆ̻ѩٰᅰމࠇၑӊٰਿ͉ޮлהٙ͜ ಂʫʊ೯Б 757,019,355 ٰ౷ஷٰdԨ ʔٰܼ̍΅ᆤᎸࠇྌධɨཫवٰٙ΅d ˸ʿணהϞᒅٰᛆʿٰ΅ᆤᎸࠇྌ ධɨٰ΅ൖމʊБԴމ౷ஷٰࣛdܲ ೌᎵ˙ό೯Бٙ౷ஷٰ̋ᛆ̻ѩٰᅰ 102,542ٰf
The calculation of the diluted earnings per share amount is based on the unaudited consolidated profit for the six months ended 31 December 2019 attributable to ordinary equity holders of the Company of HK$45,551,000. The weighted average number of ordinary shares used in the calculation is the number of ordinary shares of 753,422,467 in issue during the period and excluded the shares held under the share award scheme, as used in the basic earnings per share calculation, and the weighted average number of ordinary shares of 7,053,638 assumed to have been issued at no consideration on the deemed exercise of all share options and shares under the share award scheme into ordinary shares.
࿚Ї 2019 ϋ 12 ˜ 31 ˚˟ʬࡈ˜ʘӊ ٰᛅᑛޮлږᕘɗਿಂʫ͉ʮ̡౷ ஷᛆूܵϞɛᏐЦ͊ᄲࣨၝΥлᆗ 45,551,000ಥʩfࠇၑהٙ͜౷ஷٰ̋ ᛆ̻ѩٰᅰމࠇၑӊٰਿ͉ޮлהٙ͜ ಂʫʊ೯Б 753,422,467 ٰ౷ஷٰdԨ ʔٰܼ̍΅ᆤᎸࠇྌධɨཫवٰٙ΅d ˸ʿணהϞᒅٰᛆʿٰ΅ᆤᎸࠇྌ ධɨٰ΅ൖމʊБԴމ౷ஷٰࣛdܲ ೌᎵ˙ό೯Бٙ౷ஷٰ̋ᛆ̻ѩٰᅰ 7,053,638ٰf
10. PROPERTY, PLANT AND EQUIPMENT
During the six months ended 31 December 2020, additions of property, plant and equipment amounted to HK$14,978,000 (six months ended 31 December 2019: HK$17,768,000).
10. 物業、廠房及設備
࿚Ї 2020 ϋ 12 ˜ 31 ˚˟ʬࡈ˜ಂ ගdໄيุeᅀגʿண௪ධͦމ 14,978,000 ಥʩ€࿚Ї 2019ϋ12˜31˚ ˟ʬࡈ˜j17,768,000ಥ ʩf
11. GOODWILL
11. 商譽
31 December
30 June
2020 2020
2020年 2020ϋ
12月31日 6˜30˚
HK$'000 千港元
(Unaudited)
(未經審核)
At beginning of period/year Acquisitions of subsidiaries/businesses
(note 17)
At end of period/year
HK$'000 ɷಥʩ
(Audited)
€ᄲࣨ
12. FINANCIAL ASSETS AT AMORTISED COST
12. 按攤銷成本計量的金融資產
31 December | 30 June |
2020 | 2020 |
2020年 | 2020ϋ |
12月31日 | 6˜30˚ |
HK$'000 | HK$'000 |
千港元 | ɷಥʩ |
(Unaudited) | (Audited) |
(未經審核) | €ᄲࣨ |
Financial assets at amortised cost | 金融資產,按攤銷成本計量 | 49,998 | 55,852 |
Analysed into: | ʱؓЪj | ||
Non-current portion | ڢуಂʱ | 32,878 | 20,206 |
Current portion | уಂʱ | 17,120 | 35,646 |
49,998 | 55,852 |
As at 31 December 2020, the Group's financial assets at amortised cost have fixed maturity dates between 2021 and 2023 and fixed interest rates ranging from 4.25% to 8.50% per annum (30 June 2020: 4.25% to 8.50% per annum).
2020ϋ12˜31 ˚d͉ණྠܲᛅቖϓ ͉ࠇඎٙږፄ༟ପՈϞί 2021 ϋЇ 2023ϋʘගٙո֛Ցಂ˚d֛ࢹϋлଟ ʧ˷4.25%Ї8.50%€2020ϋ6˜30˚j ϋлଟʧ˷4.25%Ї8.50%f
13. INVESTMENTS AT FAIR VALUE THROUGH
OTHER COMPREHENSIVE INCOME
13. 按公允價值計入其他全面收入 的投資
31 December
30 June
2020 2020
2020年 2020ϋ
12月31日 6˜30˚
HK$'000 千港元
(Unaudited)
(未經審核)
Investments at fair value through other comprehensive income
Unlisted equity investments, at fair value
Listed equity investments, at fair value
Listed debt investments, at fair valueHK$'000 ɷಥʩ
(Audited)
€ᄲࣨ
The above investments were designated at fair value through | ˸ɪҳ༟ʊܸ֛މܲʮʪᄆ࠽ࠇɝՉ˼ |
other comprehensive income as the Group considers these | ΌࠦϗɝdΪމ͉ණྠႩމϤഃҳ༟ί |
investments to be strategic in nature. | ሯɪ᙮ഄଫҳ༟f |
During the period, the Group received dividends in the | ಂʫd͉ණྠɓධڢɪٰ̹͉ҳ༟ |
approximate amounts of nil (30 June 2020: HK$4,200,000) | ʿɓධɪٰ̹͉ҳ༟ϗ՟ږᕘʱйߒމ |
and HK$61,000 (30 June 2020: HK$547,000) from an unlisted | ཧಥʩ€ 2020ϋ6˜30˚j4,200,000ಥ |
equity investment and a listed equity investment, respectively. | ʩʿ61,000 ಥʩ€ 2020ϋ6˜30˚j |
547,000 ಥʩٰٙࢹf |
14. TRADE RECEIVABLES | 14. 貿易應收款項 |
31 December | 30 June |
2020 | 2020 |
2020年 | 2020ϋ |
12月31日 | 6˜30˚ |
HK$'000 | HK$'000 |
千港元 | ɷಥʩ |
(Unaudited) | (Audited) |
(未經審核) | €ᄲࣨ |
൱Ꮠϗಛධ
Trade receivables
85,067
74,354
The Group's trading terms with its contract customers are | ͉ණྠၾՉΥߒ܄˒ʘ൱ૢಛ˴ࠅ˸ |
mainly on credit. The credit period is generally one month, | ڦ൲˙όආБfڦ൲ಂɓছމ 1 ࡈ˜d |
extending up to two months for major customers. Each | ࿁˴ࠅ܄˒ַ̙ڗЇ2 ࡈ˜fӊΤΥߒ |
contract customer has a maximum credit limit. The Group | ܄˒ѩணϞ௰৷ڦ͜ᕘܓf͉ණྠɢӋ |
seeks to maintain strict control over its outstanding receivables | ࿁͊ᎵᒔᏐϗಛධၪܵᘌࣸછՓdԨண |
and has a designated policy to monitor and minimise credit | Ϟܸ֛݁ഄd˸္Ԩਗ਼ڦ൲ࠬᎈಯЇ |
risk. Overdue balances are reviewed regularly by senior | ௰Эfགྷಂഐቱ͟৷ॴ၍ଣᄴ֛ಂᄲ |
management. The Group does not hold any collateral or other | ቡf͉ණྠԨೌఱ༈ഃ൱Ꮠϗಛධቱ |
credit enhancements over its trade receivable balances. Trade | ᕘܵϞОתץۜאՉ˼ڦ൲ʺڭ |
receivables are non-interest-bearing. | ღf൱Ꮠϗಛධʔࠇࢹf |
An aging analysis of the trade receivables as at the end of the | జѓಂ͋ٙ൱Ꮠϗಛධܲ೯ୃ˚ಂ |
reporting period, based on the invoice date and net of loss | ʿϔৰᑦฦᅡ௪ٙሪᙧʱؓνɨj |
allowance, is as follows: |
31 December | 30 June |
2020 | 2020 |
2020年 | 2020ϋ |
12月31日 | 6˜30˚ |
HK$'000 | HK$'000 |
千港元 | ɷಥʩ |
(Unaudited) | (Audited) |
(未經審核) | €ᄲࣨ |
Within 1 month | 1ࡈ˜ʫ | 72,281 | 54,404 |
1 to 2 months | 1Ї2ࡈ˜ | 9,239 | 6,235 |
2 to 3 months | 2Ї3ࡈ˜ | 1,269 | 6,861 |
Over 3 months | 3ࡈ˜˸ɪ | 2,278 | 6,854 |
85,067 | 74,354 | ||
UMP HEALTHCARE HOLDINGS LIMITED | | | 2020/2021 INTERIM REPORT |
15. TRADE PAYABLES | 15. 貿易應付款項 |
An aging analysis of the trade payables as at the end of the | జѓಂ͋ٙ൱Ꮠ˹ಛධܲ೯ୃ˚ಂ |
reporting period, based on the invoice date, is as follows: | ٙሪᙧʱؓνɨj |
31 December | 30 June |
2020 | 2020 |
2020年 | 2020ϋ |
12月31日 | 6˜30˚ |
HK$'000 | HK$'000 |
千港元 | ɷಥʩ |
(Unaudited) | (Audited) |
(未經審核) | €ᄲࣨ |
Within 1 month | 1ࡈ˜ʫ | 21,653 | 23,861 |
1 to 3 months | 1Ї3ࡈ˜ | 16,812 | 11,392 |
Over 3 months | 3ࡈ˜˸ɪ | 2,532 | 1,117 |
40,997 | 36,370 |
The trade payables are non-interest-bearing and are normally | ൱Ꮠ˹ಛධމеࢹ˲ɓছ30˂Ї90 |
settled on terms of ranging from 30 to 90 days. | ˂ʫഐၑf |
16. SHARE CAPITAL | 16. 股本 |
31 December | 30 June |
2020 | 2020 |
2020年 | 2020ϋ |
12月31日 | 6˜30˚ |
HK$'000 | HK$'000 |
千港元 | ɷಥʩ |
(Unaudited) | (Audited) |
(未經審核) | €ᄲࣨ |
Authorised: 5,000,000,000 (30 June 2020: 5,000,000,000) ordinary shares of HK$0.001 (30 June 2020: HK$0.001) each ج֛j 5,000,000,000ٰ€2020ϋ6˜30˚j 5,000,000,000ٰӊٰࠦ࠽ 0.001ಥʩ€2020ϋ6˜30˚j 0.001ಥʩٙ౷ஷٰ | 5,000 | 5,000 |
Issued and fully paid: 765,759,953 (30 June 2020: 765,759,953) ordinary shares of HK$0.001 (30 June 2020: HK$0.001) each ʊ೯Бʿᖮԑj 765,759,953ٰ€2020ϋ6˜30˚j 765,759,953ٰӊٰࠦ࠽ 0.001ಥʩ€2020ϋ6˜30˚j 0.001ಥʩٙ౷ஷٰ | 766 | 766 |
16. SHARE CAPITAL (Continued) | 16. 股本€ᚃ |
The movements in the Company's authorised and issued share | 2019ϋ7˜1 ˚Ї 2020ϋ12˜31 ˚ಂ |
capital during the period from 1 July 2019 to 31 December | ගd͉ʮ̡ٙج֛ʿʊ೯Бٰ͉ᜊਗν |
2020 are as follows: | ɨj |
Authorised:
At 1 July 2019, at 31 December 2019, at 30 June 2020, at
1 July 2020 and at 31 December 2020
ج֛j
2019ϋ7˜1˚e2019ϋ
12˜31˚e2020ϋ
6˜30˚e2020ϋ7˜
Issued and fully paid:
At 1 July 2019
Shares issued in lieu of cash dividend
1˚ʿ2020ϋ12˜31˚ ʊ೯Бʿᅰᖮԑj
2019ϋ7˜1˚ ೯Бٰ΅˸˾ಁତږٰࢹ
At 30 June 2020, at 1 July 2020, and at 31 December 2020
2020ϋ6˜30˚e 2020ϋ7˜1˚ʿ 2020ϋ12˜31˚
Number of ordinary shares 普通股數目
Note ڝൗ
Nominalvalue of ordinary shares 普通股面值
HK$'000 ɷಥʩ
5,000,000,000
5,000
757,818,000 758
(a)
7,941,953 8
765,759,953
766
(a)On 20 November 2019, the Company's shareholders approved at the annual general meeting a final dividend of HK2.55 cents per ordinary share payable in cash with a scrip dividend alternative ("the Scrip Dividend Scheme") for the year ended 30 June 2019 (the "2019 Final Dividend"). During the year ended 30 June 2020, 7,941,953 new shares were issued by the Company at a deemed price of HK$1.32 per ordinary share, credited as fully paid, to shareholders of the Company who had elected to receive scrip shares in lieu of cash to settle the 2019 Final Dividend of HK$10,483,000. The remaining balance of the 2019 Final Dividend of HK$8,841,000 was satisfied by cash. Further details of the Scrip Dividend Scheme are set out in the Company's circular dated 20 December 2019.
(a)
2019ϋ11˜20 ˚d͉ʮٰ̡؇ ٰ؇ϋɽึɪҭࡘݼ೯࿚Ї 2019ϋ6˜30˚˟ϋܓٙ͋ಂٰࢹ ӊٰ౷ஷٰ2.55ಥ̀dϞᗫٰࢹ˸ ତږ˕˹ԨڝϞ˸ٰ˾ࢹ௪፯˙ ࣩ€˜˸ ٰ ˾ ࢹ ࠇ ྌ™€˜ 2019ϋ͋ ಂٰࢹ™f࿚Ї2020ϋ6˜30˚˟ ϋܓd͉ʮ̡ܲӊٰ౷ஷٰ 1.32 ಥʩٙൖЪᄆࣸΣ፯ϗ՟˾ࢹ ٰ΅˸˾ಁତږ͉ٙʮٰ̡؇೯ Б7,941,953ٰɝሪΐЪᖮԑʘอ ٰ΅d˸˕˹ 10,483,000 ಥʩٙ 2019 ϋ͋ಂٰࢹf 2019ϋ͋ಂٰ ࢹٙቱᕘ8,841,000ಥʩʊ˸ତ ږ˕˹f˸ٰ˾ࢹࠇྌٙආɓӉ༉ ઋ༱˚ಂމ2019ϋ12˜20˚ٙ ͉ʮ̡ஷՌf
17. BUSINESS COMBINATION | 17. 業務合併 |
In order to increase the range of healthcare services offered | މᓒɽᔼᐕڭਕᇍఖd˸ʿᘱᚃމ |
and to continually provide comprehensive and integrated | ઃ٫ԶၝΥϾҁഛٙᔼᐕڭਕd |
healthcare services for the benefit of the patients, on 1 | 2019ϋ11˜1 ˚d͉ණྠၾᅰΤዹͭ |
November 2019, the Group acquired 100% equity interest | ୋɧ˙ࠈͭ൯ርᙄd˸12.5ϵຬಥʩ |
in Axon Scanning Centre Limited ("Axon") from several | ʘ˾ᄆϗᒅτڦᔼኪધʕːϞࠢʮ |
independent third parties for a consideration of HK$12.5 | ̡€˜τ ڦ™ʘ100% ٰᛆfτڦί࠰ಥ |
million. Axon is engaged in the provision of magnetic | ԫԶှɢࣈϓ྅eધʿʷ᜕ |
resonance imaging, scanning and laboratory service in Hong | ਕf |
Kong. | |
The fair values of the identifiable assets and liabilities of Axon | τڦʘ̙ᗆй༟ପʿࠋවϗᒅ˚ಂʘ |
as at the date of acquisition were as follows: | ʮʪᄆ࠽νɨj |
Fair value recognised on business combinations 因業務合併 而確認的 公允價值
Notes ڝൗ
HK$'000 ɷಥʩ
Property, plant and equipment Right-of-use assets
Trade receivables
Prepayment, deposits and other receivables Tax recoverable
Cash and bank balances Other payables and accruals Lease liabilities
Deferred tax liabilities Provision
يุeᅀגʿண௪ 2,596
Դ͜ᛆ༟ପ 3,324
൱Ꮠϗಛධ 950
ཫ˹ಛධeڭᗇږʿՉ˼Ꮠϗಛධ 2,139
̙ϗΫධ 66
ତږʿვБഐቱ 568
Չ˼Ꮠ˹ಛධʿᏐࠇ൬͜ (715)
ॡ༣ࠋව (3,350)
ַධࠋව (422)
ᅡ௪ (200)
Total identifiable net assets at fair value Goodwill on acquisition
ܲʮʪᄆ࠽ΐሪ̙ٙᗆйଋ༟ପᐼᕘ 4,956
ϗᒅପ͛ٙਠᚑ
Satisfied by:
Cash consideration Other payables
˸ɨΐධᎵ˹j
ତږ˾ᄆ 9,500
Չ˼Ꮠ˹ಛධ 3,009
11 7,553 12,509
12,509
17. BUSINESS COMBINATION (Continued) | 17. 業務合併€ᚃ |
Goodwill arose from the acquisition of Axon represented the | ϗᒅτڦପ͛ٙਠᚑܸఱཫಂΥԻτ |
premium paid for the benefits of expected synergies from | ڦʿ͉ණྠމઃ٫ԶၝΥʿɓʷ |
combining operation of Axon and the Group to provide | ਕٙᐄ༶੭ԸٙΝࣖᏐٙࣖूה˕˹ |
comprehensive and integrated services for the patients. None | ٙ๐ᄆf฿ೌʊᆽႩਠᚑཫಂ̙Ъϔ |
of the goodwill recognised is expected to be deductible for tax | ʘ͜f |
purposes. | |
An analysis of the cash flows in respect of the combination of | ၾτڦΥԻϞᗫʘତږݴඎʱؓνɨj |
Axon is as follows: | |
HK$'000 | |
ɷಥʩ |
Cash consideration | ତږ˾ᄆ | (9,500) |
Cash and bank balances acquired | הϗᒅତږʿვБഐቱ | 568 |
Net outflow of cash and cash | ࠇɝҳ༟ݺਗה͜ତږ | |
equivalents included in cash flows | ݴඎʫٙତږʿତږ | |
used in investing activities | ഃᄆيݴ̈ଋᕘ | (8,932) |
18. COMMITMENTS
The Group had the following capital commitments at the end
of the reporting period:
Contracted, but not provided for:
18. 承擔
జѓಂ͋d͉ණྠٙ༟͉וዄνɨj
31 December | 30 June |
2020 | 2020 |
2020年 | 2020ϋ |
12月31日 | 6˜30˚ |
HK$'000 | HK$'000 |
千港元 | ɷಥʩ |
(Unaudited) | (Audited) |
(未經審核) | €ᄲࣨ |
Leasehold improvements | ॡ༣يุༀࡌ | 125 | 21 |
Fixtures and office equipment | ༀໄʿ፬ʮ܃ண௪ | 31 | 44 |
Medical equipment | ᔼᐕண௪ | 364 | 16,276 |
Computer equipment and software | ཥ໘ண௪ʿழ | 2,083 | 115 |
2,603 | 16,456 |
19. RELATED PARTY TRANSACTIONS
(a)
In addition to the transactions, arrangements and balances detailed elsewhere in these unaudited condensed consolidated interim financial statements, the Group had the following material transactions with related parties during the period:
Associates:
Administrative support fee income
Professional services expense Healthcare services income
19. 關聯方交易
(a)
Notes ڝൗ
ᑌᐄʮ̡j
Б݁˕౪൬ϗɝ (i)
ਖ਼ุਕ൬͜ (ii)
ᔼᐕڭਕϗɝ (iii)
ৰ༈ഃ͊ᄲࣨᔊၝΥʕಂৌ ਕజڌՉ˼ධͦ༉ࠑٙʹeτર ʿഐቱ̮d͉ණྠಂʫၾᗫᑌ˙ Ϟ˸ɨࠠɽʹj
Six months ended 31 December 截至12月31日止六個月
2020 2020年 HK$'000 千港元
(Unaudited)
(未經審核)
198 187
1,632 1,526
170 126
Joint ventures:
Administrative support fee income
Professional services expense
Υ༟ʮ̡j
Б݁˕౪൬ϗɝ (i)
ਖ਼ุਕ൬͜ (ii)
Related companies*:
Administrative support fee
ᗫᑌʮ̡*j
Б݁˕౪൬ϗɝ (i)
income - 82
Professional services expense Healthcare services income Lease payments/property rental and related expenses Contract healthcare solution services income Management fee income
ਖ਼ุਕ൬͜ (ii) - 2,051
ᔼᐕڭਕϗɝ (iii) - 142
ॡ༣˹ಛŊيุॡږʿ (iv)
ᗫක˕
Υߒᔼᐕڭ༆Ӕ˙ࣩ (v)
ਕϗɝ
၍ଣ൬ϗɝ (vi)
*Certain directors and/or beneficial shareholders of the Company are also directors and/or beneficial shareholders of these related companies.
*
͉ʮ̡߰ʍԫʿŊאྼूٰ؇ ͵މ༈ഃᗫᑌʮ̡ٙԫʿŊא ྼूٰ؇f
2019 2019ϋ HK$'000 ɷಥʩ
(Unaudited)
€͊ᄲࣨ
60 70
256 434
3,257 3,607
10,475 10,373
- 3,321
19. RELATED PARTY TRANSACTIONS (Continued)
19. 關聯方交易€ᚃ
(a) | (Continued) | (a) €ᚃ |
Notes: | ڝൗj |
(i) The administrative support fee income was related to administrative support services, such as payroll services, rendered by the Group and was charged at terms mutually agreed between the relevant parties.
(ii) The professional services expense was related to healthcare services rendered by associates, joint ventures and the related companies and was charged at terms mutually agreed between the relevant parties.
(iii) The healthcare services income was related to medical services rendered by the Group and was charged at terms mutually agreed between the relevant parties.
(iv) The lease payments/property rental and related expenses were related to the leasing of certain medical centres or premises for the Group's operation and were charged at terms stipulated in the respective tenancy agreements.
(v) Contract healthcare solution services income was related to the provision of healthcare services to the employees of related companies and was charged at terms mutually agreed between the relevant parties.
(vi) The management fee income was related to the administrative and management services rendered by the Group and was charged at terms stipulated in the respective service agreements.
(i) Б݁˕౪൬ϗɝၾ͉ණྠԶԨ ܲၾᗫ˙ʝ֛ʘૢಛϗ൬ ٙᑚཇਕഃБ݁˕౪ਕϞᗫf
(ii) ਖ਼ุਕ൬͜ၾᑌᐄʮ̡eΥ༟ʮ ̡ʿᗫᑌʮ̡Զٙᔼᐕڭ ਕᗫԨ˸ၾᗫ˙ʝߒ֛ٙ ૢಛϗ൬f
(iii) ᔼᐕڭਕϗɝၾ͉ණྠԶ Ԩܲၾᗫ˙ʝ֛ʘૢಛϗ ൬ٙᔼᐕਕϞᗫf
(iv) ॡ༣˹ಛŊيุॡږʿᗫක˕ ၾఱ͉ණྠᐄ༶ॡ༣߰ʍᔼਕʕ ːאᐄ༶ఙהԨܲॡ༣ᙄ ֛ʘૢಛϗ൬Ϟᗫf
(v) Υߒᔼᐕڭ༆Ӕ˙ࣩਕϗɝ ၾΣᗫᑌʮ̡ٙ྇ࡰԶԨܲၾ ᗫ˙ʝ֛ʘૢಛϗ൬ٙᔼ ᐕڭਕϞᗫf
(vi) ၍ଣ൬͜ϗɝၾ͉ණྠԶٙБ ݁ʿ၍ଣਕᗫԨ࣬ኽϞᗫ ਕᙄה֛ૢಛϗ൬f
(b) Other transactions with related parties | 其他關聯方交易 |
Professional services fees paid to the executive directors | Σ͉ʮ̡ੂБԫ˕˹ϞᗫΣ͉ |
of the Company in relation to the rendering of healthcare | ණྠԶᔼᐕڭਕٙਖ਼ุ |
services to the Group are as follows: | ਕ൬νɨj |
Six months ended 31 December | |
截至12月31日止六個月 |
2019 2019ϋ HK$'000 ɷಥʩ
Executive directors (note (i))
ੂБԫ€ڝൗ (i)
(b)
2020 2020年 HK$'000 千港元
(Unaudited)
(未經審核)
(Unaudited)
€͊ᄲࣨ
3,377
3,069
Note:
ڝൗj
(i) | The professional services fee related to healthcare services | ਖ਼ุਕ൬ၾ͉ʮ̡ੂБԫ |
rendered by Dr. Sun Man Kin Michael and Dr. Lee Pak | ˖ᔼ͛ʿҽݡୂᔼ͛Զٙᔼ | |
Cheung Patrick, executive directors of the Company. | ᐕڭਕϞᗫf |
(i)
19. RELATED PARTY TRANSACTIONS (Continued)
(c)Compensation of key management personnel of the Group:
19. 關聯方交易€ᚃ
(c) 本集團主要管理人員薪酬:
Six months ended 31 December 截至12月31日止六個月
2020 | 2019 |
2020年 | 2019ϋ |
HK$'000 | HK$'000 |
千港元 | ɷಥʩ |
(Unaudited) | (Unaudited) |
(未經審核) | €͊ᄲࣨ |
Short term employee benefits | ಂ྇ࡰ၅л | 9,302 | 7,710 |
Post-employment benefits | ᕎᔖܝ၅л | 34 | 40 |
Total compensation paid to key | ˕˹ʚ˴ࠅ၍ଣɛࡰٙ | ||
management personnel | ᑚཇᐼᕘ | 9,336 | 7,750 |
20. FAIR VALUE AND FAIR VALUE HIERARCHY | 20. 金融工具的公允價值及公允價 |
OF FINANCIAL INSTRUMENTS | 值等級 |
Management has assessed that the fair values of cash and | ၍ଣᄴ൙Пdତږʿତږഃᄆيeʊ |
cash equivalents, pledged deposits, trade receivables, trade | תץπಛe൱Ꮠϗಛධe൱Ꮠ˹ಛ |
payables, the current portion of financial assets included in | ධeࠇɝཫ˹ಛධeՉ˼ᏐϗಛධʿՉ |
prepayments, other receivables and other assets, financial | ˼༟ପٙږፄ༟ପٙݴਗʱeࠇɝՉ |
liabilities included in other payables and accruals, lease | ˼Ꮠ˹ಛධʿᏐࠇ൬ٙ͜ږፄࠋවeॡ |
liabilities, balances with a joint venture, related companies | ༣ࠋවeၾɓගΥ༟ʮ̡eᗫᑌʮ̡ʿ |
and associates approximate to their carrying amounts largely | ᑌᐄʮ̡ഐቱٙʮʪᄆ࠽ၾሪࠦ࠽ |
due to the short term maturities/no fixed terms of repayments | ߰d˴ࠅΪ༈ഃʈՈʘՑಂࣛග༰Ŋ |
of these instruments or the effect of discounting is not material. | ೌո֛Ꮅᒔಂࠢא൨ତᅂᚤԨʔࠠɽf |
The fair values of the financial assets and liabilities are | ږፄ༟ପʿࠋවٙʮʪᄆ࠽ܲІᗴʹ |
included at the amount at which the instrument could be | ˙€Ͼڢ੶ࠗאᆵቖਯۃʹʕ |
exchanged in a current transaction between willing parties, | ʹ౬༈ʈՈٙږᕘɝሪf |
other than in a forced or liquidation sale. | |
The fair values of the non-current portion of lease liabilities | ॡ༣ࠋවڢݴਗʱٙʮʪᄆ࠽ɗમ͜ |
have been calculated by discounting the expected future | ତ̙ࣛϋಂeڦ൲ࠬᎈʿ௵ቱಂࠢᗳ |
cash flows using rates currently available for instruments with | ЧٙʈՈٙࢹଟ൨ତཫಂ͊Ըତږݴඎ |
similar terms, credit risk and remaining maturities. | Ͼࠇၑf |
The fair values of listed equity and debt investments are based | ɪឈٰᛆʿවਕҳ༟ٙʮʪᄆ࠽ਿʮ |
on quoted market prices. | කឈఙజᄆᔾ֛f |
20. FAIR VALUE AND FAIR VALUE HIERARCHY | 20. 金融工具的公允價值及公允價 |
OF FINANCIAL INSTRUMENTS (Continued) | 值等級€ᚃ |
The fair values of unlisted equity investments, a contingent | ڢɪٰ̹͉ҳ༟eɓධאϞᏐϗಛධʿ |
receivable and derivative financial instrument have been | ࠃ͛ږፄʈՈٙʮʪᄆ࠽ܲʊ൨ତତږ |
estimated using either valuation techniques based on | ݴඎ˙جאܲ௰ڐ̹ఙʹᄆࣸٙП࠽ |
discounted cashflow method or based on recent market | جПࠇf |
transaction prices. | |
Fair value hierarchy | 公允價值等級 |
The following tables illustrate the fair value measurement | ɨڌ༱ΐ͉ණྠږፄʈՈٙʮʪᄆ࠽ࠇ |
hierarchy of the Group's financial instruments: | ඎഃॴj |
Assets measured at fair value: | 按公允價值計量的資產: |
As at 31 December 2020 (unaudited) | 於2020年12月31 日(未經審核) |
Fair value measurement using | |
公允價值計量採用的基準 |
Quoted prices in active markets
Investments at fair value through other comprehensive income:
- Unlisted equity investments
- Listed equity investments
- Listed debt investments
Financial assets at fair value through profit or loss Other assets
(Level 1)
活躍市場報價
(第一級)
HK$'000 千港元
Significant observable inputs
(Level 2)
重大可觀察 輸入數據 (第二級)
HK$'000 千港元
Significant unobservable inputs
(Level 3)
重大不可觀察 輸入數據 (第三級)
HK$'000 千港元
Total
總計
HK$'000 千港元
20. FAIR VALUE AND FAIR VALUE HIERARCHY | 20. 金融工具的公允價值及公允價 |
OF FINANCIAL INSTRUMENTS (Continued) | 值等級€ᚃ |
Assets measured at fair value: (Continued) | 按公允價值計量的資產:€ᚃ |
As at 30 June 2020 (audited) | 2020ϋ6˜30˚€ ᄲ ࣨ |
Fair value measurement using | |
ʮʪᄆ࠽ࠇඎમٙ͜ਿ |
Investments at fair value through other comprehensive income:
- Unlisted equity investments
- Listed equity investments
- Listed debt investments
Financial assets at fair value through profit or loss Other assets
ܲʮʪᄆ࠽ࠇɝՉ˼
Όࠦϗɝٙҳ༟j Ñڢɪٰ̹͉ҳ༟ Ñɪٰ̹͉ҳ༟ Ñɪ̹වਕҳ༟ ܲʮʪᄆ࠽ࠇɝฦूٙ ږፄ༟ପ Չ˼༟ପ
12,948 - - 12,948
-
1,723 - - 1,723
Quoted prices in active markets (Level 1)Significant observable inputs
(Level 2)
ݺᚔ̹ఙ జᄆ €ୋɓᄴ
Significant unobservable inputs
(Level 3)
ࠠɽ̙ᝈ࿀ ፩ɝᅰኽ €ୋɚᄴ
HK$'000 ɷಥʩ
ࠠɽʔ̙ᝈ࿀ ፩ɝᅰኽ €ୋɧᄴ
HK$'000 ɷಥʩ
Total
Υࠇ
HK$'000 ɷಥʩ
HK$'000 ɷಥʩ
-
-
4,745 4,745
5,494 - 5,494
- 14,671
- 5,494
9,589 9,589
14,334
34,499
During the period, there were no transfers of fair value | ಂʫdږፄ༟ପʿږፄࠋවୋɓᄴၾ |
measurements between Level 1 and Level 2 and no transfers | ୋɚᄴʘගԨೌʮʪᄆ࠽ࠇඎᔷᅡd͵ |
into or out of Level 3 for financial assets and financial | ೌᔷЇאᔷ̈ୋɧᄴ€࿚Ї 2019ϋ12˜ |
liabilities (six months ended 31 December 2019: Nil). | 31 ˚˟ʬࡈ˜jೌf |
21. APPROVAL OF THE UNAUDITED | 21. 批准未經審核簡明綜合中期財 |
CONDENSED CONSOLIDATED INTERIM | 務報表 |
FINANCIAL STATEMENTS | |
The unaudited condensed consolidated interim financial | ͊ᄲࣨᔊၝΥʕಂৌਕజڌʊ |
statements were approved and authorised for issue by the | 2021ϋ2˜25˚ᐏԫึҭࡘʿબᛆ̊ |
Board on 25 February 2021. | ೯f |
Glossary 詞彙
"1HFY2020" | six months ended 31 December 2019; |
˜2020ৌ݁ϋܓɪ̒ϋ™ | ࿚Ї2019ϋ12˜31˚˟ʬࡈ˜i |
"1HFY2021" | six months ended 31 December 2020; |
˜2021ৌ݁ϋܓɪ̒ϋ™ | ࿚Ї2020ϋ12˜31˚˟ʬࡈ˜i |
"Affiliated Clinic(s)" | clinic(s) which is/are not operated by the Group but which has entered or will |
enter into an agreement directly with the Group to offer Medical Services, | |
Dental Services and/or Auxiliary Services to the Plan Members; | |
˜ᑌ᙮ൢה™ | Ԩڢ͉͟ණྠᐄШʊאਗ਼ٜટၾ͉ණྠࠈͭᙄٙൢהdኽϤΣࠇྌϓࡰ |
Զᔼᐕਕe˫߅ਕʿŊאႾпਕi | |
"Affiliated Doctor(s)", "Affiliated | doctor(s)/dentist(s)/auxiliary services provider(s) who has entered or will enter |
Dentist(s)" or "Affiliated Auxiliary | into an agreement directly with the Group to provide services to Plan Members |
Services Provider(s)" | and who, in accordance with the terms of such agreement, has received or |
will receive an amount from the Group based on the volume of Plan Members | |
treated; | |
˜ᑌ᙮ᔼ͛™e˜ᑌ᙮˫ᔼ™א | ʊאਗ਼ٜટၾ͉ණྠࠈͭᙄԶਕʚࠇྌϓࡰٙᔼ͛Ŋ˫ᔼŊႾпਕ |
˜ᑌ᙮ႾпਕԶ٫™ | Զ٫d࣬ኽ༈ഃᙄૢಛd־ഃʊאਗ਼ܲટൢٙࠇྌϓࡰᅰͦΣ͉ණྠϗ |
՟ಛධi | |
"Audit Committee" | the audit committee of the Board; |
˜ᄲࣨ։ࡰึ™ | ԫึᒍɨᄲࣨ։ࡰึi |
"Auxiliary Services" | includes imaging and laboratory services, physiotherapy, traditional Chinese |
medicine, vision care and optometry and child health assessment; | |
˜Ⴞпਕ™ | ܼ̍ᔼኪᅂ྅ʿʷ᜕ਕeيଣطᐕeʕᔼe߅ᚐଣʿ᜕Έ˸ʿՅഁੰ೯ |
࢝൙Пi | |
"Auxiliary Services Provider(s)" | auxiliary services provider(s) who is/are or will be engaged directly by the |
Group as a consultant to provide Auxiliary Services in the UMP Medical | |
Centres in accordance with the terms of a consultancy agreement with the | |
Group, and the Affiliated Auxiliary Service Providers; | |
˜ႾпਕԶ٫™ | ʊאਗ਼ٜટա͉ණྠ։໌މᚥਪ˸࣬ኽၾ͉ණྠᖦࠈٙᚥਪᙄٙૢಛίᑌ |
ΥᔼਕʕːʫԶႾпਕٙႾпਕԶ٫d˸ʿᑌ᙮ႾпਕԶ٫i | |
"Board" | the board of Directors of the Company; |
˜ԫึ™ | ͉ʮ̡ԫึi |
˜྇ࡰආБᗇՎʹٙςۆ™
"Code of Conduct for Securities
Transactions by Employees"
the Code of Conduct for Securities Transactions by Employees as adopted by the Company; ͉ʮ̡הમॶ྇ࡰආБᗇՎʹٙςۆi
"Company" or "UMP"
˜͉ʮ̡™א˜ᑌΥᔼਕ™
UMP Healthcare Holdings Limited, a company incorporated under the laws of the Cayman Islands with limited liability, the shares of which are listed on the main board of the Hong Kong Stock Exchange (stock code: 722);
ᑌΥᔼਕණྠϞࠢʮ̡dɓග࣬ኽකਟ໊ࢥجܛൗ̅ϓͭٙϞࠢʮ̡dՉٰ΅ ࠰ಥᑌʹה˴ؐɪ̹€ٰ΅˾j 722i
˜Υߒ܄˒™
"Contract Customers"
collectively, insurance companies and corporations which have entered or will enter into corporate plans with the Group for healthcare benefits for Plan Members; ఱࠇྌϓࡰᔼᐕڭ၅лʊאਗ਼ၾ͉ණྠࠈͭΆุࠇྌٙڭᎈʮ̡ʿΆุٙ ୕၈i
˜Άุ၍طςۆ™
"Corporate Governance Code"
the Corporate Governance Code as set out in Appendix 14 to the Listing Rules; ɪ̹ۆڝɤ̬ה༱Άุ၍طςۆi
˜อۨڿًषݭ™
"COVID-19"
means coronavirus disease 2019, a disease caused by a novel virus designated as severe acute respiratory syndrome coronavirus 2; 2019ڿًषݭशषdɓ၇͟၈މᘌࠠܢխіӻ୕ၝΥसڿًषݭ2ٙอۨ षݭˏৎٙशषi
"CR Medical"
˜ശᆗᔼᐕ™
China Resources Medical Holdings Company Limited, a company incorporated in the Cayman Islands with limited liability and listed on the Main Board of the Hong Kong Stock Exchange (stock code: 1515);
ശᆗᔼᐕછٰϞࠢʮ̡dɓගίකਟ໊ࢥൗ̅ϓͭԨί࠰ಥᑌʹה˴ؐɪ̹ٙ ʮ̡€ٰ΅˾j 1515i
˜˫߅ਕ™
"Dental Services"
include primary dental services such as scaling and polishing and secondary dental services such as crown and bridge, orthodontics, implants and whitening; ܼ̍ਿ͉˫߅ਕ€νݹ˫ʿסΈ˸ʿୋɚᄴ˫߅ਕ€ν˫ڿʿ˫eɹഢ ͍ຆeಔʿ˫ߕͣi
˜˫ᔼ™
"Dentist(s)"
dentist(s) who is/are or will be engaged directly by the Group as a consultant to provide Dental Services in the UMP Medical Centres in accordance with the terms of a consultancy agreement with the Group, and the Affiliated Dentists; ʊאਗ਼ٜટա͉ණྠ։໌މᚥਪ˸࣬ኽၾ͉ණྠᖦࠈٙᚥਪᙄٙૢಛίᑌ ΥᔼਕʕːʫԶਕٙ˫ᔼd˸ʿᑌ᙮˫ᔼi
˜ԫ™
"Director(s)"
the director(s) of the Company; ͉ʮ̡ԫi
Glossary | |
詞彙 | |
"Doctor(s)" | doctor(s) who is/are or will be engaged directly by the Group as a consultant to |
provide Medical Services in the UMP Medical Centres in accordance with the | |
terms of a consultancy agreement with the Group, and the Affiliated Doctors; | |
˜ᔼ͛™ | ʊאਗ਼ٜટա͉ණྠ։໌މᚥਪ˸࣬ኽၾ͉ණྠᖦࠈٙᚥਪᙄٙૢಛίᑌ |
ΥᔼਕʕːʫԶਕٙᔼ͛d˸ʿᑌ᙮ᔼ͛i | |
"FY2020" | the year ended 30 June 2020; |
˜2020ৌ݁ϋܓ™ | ࿚Ї2020ϋ6˜30˚˟ϋܓi |
"GBA" | city cluster cross the Guangdong-Hong Kong-Macau region, consisting of Hong |
Kong, Macau and nine cities in Guangdong Province, namely, Dongguan, | |
Foshan, Guangzhou, Huizhou, Jiangmen, Shenzhen, Zhaoqing, Zhongshan and | |
Zhuhai; | |
˜ɽᝄਜ™ | ᄿ؇{࠰ಥ{ዦژ€ຽಥዦήਜ໊̹ٙ۬dܼ̍࠰ಥeዦژʿᄿ؇ٙɘࡈ۬ |
̹dу؇୷eНʆeᄿψeψeϪژeଉέeၴᅅeʕʆʿमऎi | |
"general practitioner" or "general | doctors trained in general practice and best suited to act as first point of |
practice" | contact for patients, having the required knowledge to refer patients to the |
appropriate specialists or services as required; | |
˜Ό߅ᔼ͛™א˜Ό߅ᔼᐕ™ | ટաΌ߅ᇖٙᔼ͛d௰ቇΥމઃ٫ԶϣൢᓙdʊՈ௪ܲცࠅᔷʧઃ٫Ї |
ቇΥਖ਼߅אਕהცٙٝᗆi | |
"Global Offering" | the offer of the shares of the Company to the public in Hong Kong and outside |
the United States of America in offshore transactions in reliance on Regulation | |
S, the details of which are set out in "Structure of the Global Offering" of the | |
Prospectus; | |
˜Όଢ೯ਯ™ | ͉ʮ̡Σ࠰ಥʮɛɻʿԱኽSԷίߕྤ̮ٙᕎ֦ʹʕ೯ਯٰ΅d༉ઋ |
༱םٰ˜Όଢ೯ਯٙݖ™i | |
"Group", "we", "our" or "us" | the Company and its subsidiaries; |
˜͉ණྠ™א˜Ңࡁ™ | ͉ʮ̡ʿՉڝ᙮ʮ̡i |
"Healthcare Ventures" | Healthcare Ventures Holdings Limited, a company incorporated under the |
laws of British Virgin Islands with limited liability, which is a substantial | |
shareholder of the Company and wholly-owned subsidiary of Chow Tai Fook | |
Enterprises Limited; | |
˜ᔼᐕ௴ุછٰ™ | ᔼᐕ௴ุછٰϞࠢʮ̡dɓග࣬ኽߵ᙮ஈɾ໊ࢥجܛൗ̅ϓͭٙϞࠢʮ̡dމ |
͉ʮ̡ٙ˴ࠅٰ؇ʿմɽ၅ΆุϞࠢʮ̡ٙΌ༟ڝ᙮ʮ̡i | |
"HK$" | Hong Kong dollars, the lawful currency of Hong Kong; |
˜ಥʩ™ | ࠰ಥج֛࿆ಥʩi |
"Hong Kong" | Hong Kong Special Administrative Region of the PRC; |
˜࠰ಥ™ | ʕ࠰ಥतйБ݁ਜi |
"Hong Kong & Macau Clinical | provision of clinical healthcare services to Self-paid Patients as described in | |
Healthcare Services" | "Business Overview and Outlook" of this report; | |
˜࠰ಥʿዦژᑗґᔼᐕڭਕ™ | ΣІ൬ઃ٫Զᑗґᔼᐕڭਕdν͉జѓ˜ุਕΫᚥʿ࢝ૐ™הࠑi | |
"Hong Kong & Macau Corporate | provision of corporate healthcare solutions as described in "Business Overview | |
Healthcare Solution Services" | and Outlook" of this report; | |
˜࠰ಥʿዦژΆุᔼᐕڭ༆Ӕ | ԶΆุᔼᐕڭ༆Ӕ˙ࣩdν͉జѓ˜ุਕΫᚥʿ࢝ૐ™הࠑi | |
˙ࣩਕ™ | ||
"Hong Kong Stock Exchange" or | The Stock Exchange of Hong Kong Limited; | |
"Stock Exchange" | ||
˜࠰ಥᑌʹה™א˜ᑌʹה™ | ࠰ಥᑌΥʹהϞࠢʮ̡i | |
"Listing Rules" | the Rules Governing the Listing of Securities on the Hong Kong Stock Exchange; | |
˜ɪ̹ۆ™ | ࠰ಥᑌʹהᗇՎɪ̹ۆi | |
"Macau" | the Macau Special Administrative Region of the PRC; | |
˜ዦژ™ | ʕዦژतйБ݁ਜi | |
"Medical" or "Medical Services" | includes general practice and specialist practice; | |
˜ᔼᐕ™א˜ᔼᐕਕ™ | ܼ̍Ό߅ᔼᐕʿਖ਼߅ᔼᐕi | |
"Model Code" | the Model Code for Securities Transactions by Directors of Listed Issuers as set | |
out in Appendix 10 to the Listing Rules; | ||
˜ᅺςۆ™ | ɪ̹ۆڝ10ה༱ɪ̹೯БɛԫආБᗇՎʹٙᅺςۆi | |
"Plan Members" | members of the Group's corporate healthcare benefits plans, who typically | |
include group medical insurance policyholders and employees of corporations | ||
and/or their dependants; | ||
˜ࠇྌϓࡰ™ | ͉ණྠΆุᔼᐕڭ၅лࠇྌϓࡰdɓছܼ̍ණྠᔼᐕڭᎈڭఊܵϞɛʿዚ | |
ٙ྇ࡰʿŊא־ഃʘաቮɛi | ||
"Post-IPO Share Option Scheme" | the post-IPO share option scheme approved and adopted by the Board on 2 | |
November 2015; | ||
˜ϣʮක೯ਯܝᒅٰᛆࠇྌ™ | ԫึ2015ϋ11˜2˚ҭࡘʿમॶٙϣʮක೯ਯܝᒅٰᛆࠇྌi | |
"PPP" | Public-Private Partnership; | |
˜PPP™ | ʮӷᐄΥЪi | |
"PRC" | the People's Republic of China (excluding, for the purpose of this report, Hong | |
Kong, Macau and Taiwan); | ||
˜ʕ™ | ʕശɛ͏ձ€ఱ͉జѓϾԊdʔܼ̍࠰ಥeዦژʿ̨ᝄi | |
UMP HEALTHCARE HOLDINGS LIMITED | | | 2020/2021 INTERIM REPORT |
Glossary | |
詞彙 | |
"PRC Healthcare Business" | consists of (i) health check-up business; (ii) corporate healthcare solutions |
business; (iii) selected outpatient services such as family medicine within | |
the clinics we own and operate and (iv) provision of professional training to | |
doctors and nurses under our GOLD™ training programme etc.; | |
˜ʕڭุਕ™ | ܼ̍(i)Ꮸุਕi(ii)Άุᔼᐕڭ༆Ӕ˙ุࣩਕi(iii)ίҢࡁኹϞʿᐄ༶ٙൢה |
ʫԶ፯֛ژൢਕ€νࢬᔼኪiʿ(iv)࣬ኽҢࡁٙGOLD™ږሙΣ | |
ᔼ͛ʿᚐɻԶਖ਼ุഃi | |
"Pre-IPO Share Option Scheme" | the pre-IPO share option scheme approved and adopted by the Board on 18 |
August 2015; | |
˜ϣʮක೯ਯۃᒅٰᛆࠇྌ™ | ԫึ2015ϋ8˜18˚ҭࡘʿમॶٙϣʮක೯ਯۃᒅٰᛆࠇྌi |
"Prospectus" | the prospectus of the Company dated 17 November 2015; |
˜םٰ™ | ˚ಂމ2015ϋ11˜17˚͉ٙʮ̡םٰi |
"Remuneration Committee" | the remuneration committee of the Board; |
˜ᑚཇ։ࡰึ™ | ԫึᑚཇ։ࡰึi |
"Self-paid Patients" | patients who visit a UMP Medical Centre operated by the Group and pay for |
services using cash or credit card; | |
˜І൬ઃ٫™ | Ց͉ණྠᐄٙᑌΥᔼਕʕːఱൢԨԴ͜ତږאڦ̔͜˕˹ਕ൬ٙ͜ઃ٫i |
"SFO" | the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), |
as amended and supplemented from time to time; | |
˜ᗇՎʿಂૢԷ™ | ࠰ಥجԷୋ571 ᗇՎʿಂૢԷ'dʔࣛࡌࠈʿ̂i |
"Share(s)" | ordinary share(s) with a nominal value of HK$0.001 each in the share capital |
of the Company; | |
˜ٰ΅™ | ͉ʮٰ̡͉ʕӊٰࠦ࠽0.001ಥʩʘ౷ஷٰi |
"Share Award Scheme" | the share award scheme approved and adopted by the Board on 30 June 2016; |
˜ٰ΅ᆤᎸࠇྌ™ | ԫึ2016ϋ6˜30˚הҭࡘʿમॶٰٙ΅ᆤᎸࠇྌi |
"specialist practice" or | a range of specialist practice, including Family Medicine, Internal Medicine, |
"specialist services" | Surgery, Paediatrics, Cardiology, Dermatology, Otorhinolaryngology, |
Orthopaedics, Ophthalmology, Urology, Gastroenterology and Hepatology, | |
Radiology, Endocrinology and Diabetes. Please seewww.ump.com.hkfor the | |
updated list of specialist practices; | |
˜ਖ਼߅ᔼᐕ™א˜ਖ਼߅ਕ™ | ɓӻΐਖ਼߅ᔼᐕdܼ̍ࢬᔼኪ߅eʫ߅e̮߅eՅ߅eːᛔ߅eͤᇮ߅eЀ |
ᄀఓ߅e৶߅e߅eؤ҇߅e໑ߞӿᛔ߅e׳࢛߅eʫʱؤʿጟ҇߅ഃfਖ਼ | |
߅ᔼᐕʘһอఊሗਞቡwww.ump.com.hki |
"UMP Medical Centre(s)"
˜ᑌΥᔼਕʕː™
medical centre(s) offering Medical Services, Dental Services and/or Auxiliary Services which is operated by the Group;
Զᔼᐕਕe˫߅ਕʿŊאႾпਕٙᔼਕʕːd͉͟ණྠᐄi
˜UMPၣഖ™
"UMP Network"
consists of (i) UMP Medical Centres which are operated by the Group and (ii) Affiliated Clinics which are clinics not operated by the Group but which has entered into an agreement with the Group to offer Medical Services, Dental Services and/or Auxiliary Services to Plan Members; and ܼ̍(i)͉ණྠᐄٙᑌΥᔼਕʕːʿ(ii) ᑌ᙮ൢה€Ԩڢ͉͟ණྠᐄٙൢהd Шʊၾ͉ණྠࠈͭᙄΣࠇྌϓࡰԶᔼᐕਕe˫߅ਕʿŊאႾпਕi ʿ
˜Ⴉٰᛆᗇ™
"Warrants"
an aggregate of 110,411,000 warrants of the Company issued by the Company on 6 December 2018, and that are exercisable, subject to certain conditions, onto a total of 110,411,000 new Shares of the Company. Please refer to the announcements of the Company dated 27 July 2018, 30 August 2018 and 6 December 2018 and the circular of the Company dated 29 October 2018 for details. ͉ʮ̡2018ϋ12˜6˚೯БʘΥ110,411,000΅͉ʮ̡ႩٰᛆᗇdϞᗫႩٰ ᛆᗇ̙БԴ€ୌΥ߰ʍૢϓމΥ 110,411,000ٰ͉ʮ̡อٰ΅f༉ઋሗ ਞቡ˚ಂʱйމ2018ϋ7˜27˚e2018ϋ8˜30˚ʿ2018ϋ12˜6˚ʘ͉ʮ̡ʮ ѓ˸ʿ˚ಂމ2018ϋ10˜29˚ʘ͉ʮ̡ஷՌf
Attachments
- Original document
- Permalink
Disclaimer
UMP Healthcare Holdings Ltd. published this content on 25 March 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 March 2021 09:12:05 UTC.